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 Short Summary 
The research presented in this thesis has highlighted the complementary and consistent 
links between in vitro and in vivo chronopharmacology findings, as shown for the 
anticancer drug candidate FY26. The use of 24-hour temperature schedules as an 
effective synchroniser of circadian clocks in vitro and that of core body temperature 
rhythm as a circadian biomarker in vivo has enabled the precise determination of the 
endogenous circadian times of best tolerability. This was achieved, as physiologica l 
rhythm had been introduced into cell culture conditions. Should these results be 
applicable to humans, least FY26 toxicity could occur at night, shortly after the 
physiological nadir in core body temperature. More generally, the synchronisation of 
healthy and cancer cells with 24-h periodic temperature schedules mimick ing 
physiological cycles could have a high potential to identify optimal drug timing 
options and underlying chronopharmacokinetics and chronopharmacodymics 
mechanisms, whilst reducing and replacing animal experiments, as illustrated here. 
This could indeed encourage the integration of chronotherapy concepts into drug 
development strategies. In such context, the objectives of animal chronotherapy 
studies might hence become mostly confirmatory. Thus, the use of core body 
temperature circadian cycle appears not only as crucial for the determination of the 
circadian timing resulting in best drug tolerability, antitumour efficacy, and quality of 
life, but it is also in agreement with the principles of the 3 R’s (reduction, refinement 







 Extended Summary 
Due to earth rotation, 24 h cycles with days and nights are generated on earth. In turn, 
the periodic availability of light resets endogenous circadian rhythm in plants, insects 
and mammals. Such rhythms are for example the daily changes of the sleep-wake 
cycle and core body temperature rhythms in mammals generated through a circadian 
timing system (CTS) which is synchronised by the day and night cycle. 
The CTS consists of a central pacemaker in the suprachiasmatic nuclei coordinating 
rhythms in peripheral clocks through neuro-anatomic pathways and diffusible factors 
involving for example hormones and growth factors. Thus, many cellular functions, 
including metabolism, cell proliferation and death, display circadian rhythms. Targets 
of pharmacological agents are also regulated by the CTS. The identification of such 
targets form the basis of chronopharmacodynamics, which enable, together with 
chronopharmakokinetics, to determine the optimal time of drug application with the 
aim to increase efficacy and to decrease adverse effects. This has been especially 
applied to anticancer drugs. The platinum complex cisplatin for example is best 
tolerated following dosing near the middle of the active phase in mice and in patients. 
Nevertheless, cisplatin tumour resistance still remains an issue. To address this 
problem, a new generation of osmium complexes has been developed and has been 
proven to overcome platinum resistance in some preclinical models. A main 
representative of this family is FY26. The research conducted here sought to link in 
vitro and in vivo chronopharmacology and chronotoxicity of FY26 in preclinica l 
models. For such purpose, the physiological core body temperature rhythm was taken 
as a circadian biomarker for referring the time points corresponding to best FY26 
tolerability. 
This research question was addressed first using murine hepatocarcinoma cells 
(Hepa1-6 Per2-luc) with or without silenced Bmal1, and a human colon cancer cell 
line (HCT116 Per2-luc). Cell cultures were synchronised with 24-h temperature 
cycles mimicking the physiological rhythmic variations. Time dependencies were 
sought for FY26 cytotoxicity, cellular uptake, proliferation, cell cycle phase 
distribution, apoptosis and autophagy. Towards this goal, FY26 was administered at 4 





In vitro and in vivo experiments aimed to determine the best tolerated and therapeutic 
FY26 doses. These doses were further used to assess the circadian tolerability profile 
and the difference in antitumor efficacy, when given at the respective time point of 
highest and lowest tolerability. According to the results of the in vitro chronotoxic ity 
study, FY26 was best tolerated at T22, referring to the 2 h before the programmed 
temperature rise from 36 to 37°C. The in vivo chronotoxicity study identified FY26 to 
be best tolerated at ZT06. This time point referred to the middle of the inactive phase 
of mice at which core body temperature was 35.8 ± 0.3°C. In order to determine 
possible time dependent differences in tumour growth inhibition by FY26, the drug 
was injected in 5 repetitive i.p. injections every other day at ZT06 or at ZT18. FY26 
showed the highest tumour growth inhibition at ZT18, the time point of least 
tolerability. Those studies were followed by in vitro chronopharmacokinetics and 
chronopharmacodynamics studies in order to help explain the circadian rhythm in 
FY26 toxicity. 
In vitro pharmacokinetics studies demonstrated maximum and minimum intracellula r 
FY26 uptake at T02 and at T14 respectively. Under continued FY26 exposure for 72 h, 
the doubling time of Hepa1-6 Per2-luc cells was twice as long following FY26 
addition at T18 as compared to that at T10 or T14. Monitoring Per2-luc 
bioluminescence revealed that the inhibition of Per2-luc bioluminescence was highest 
following drug addition at T22. Such finding was coherent with the prolonged 
doubling time resulting from FY26 exposure starting at T18. Flow cytometry analys is 
revealed an accumulation of FY26-treated cells in S-phase. Such S-phase arrest was 
larger following FY26 addition at T16 as compared to T04. Taken together the results 
suggested that FY26 tolerability was best after drug exposure onset at T22, because a 
higher number of cells transiently accumulated in S-phase, but did not undergo 
apoptosis. Thus drug addition at T04 resulted in a higher count of apoptotic cells 
referring to the time point of least FY26 tolerability. FY26 further increased apoptotic 
cell counts in the shBmal1-silenced clone, accounting for a higher FY26 sensitivity. 
The measurement of the autophagy gene LC3B confirmed the higher sensitivity of the 
shBmal1-silenced cell line as compared to Hepa1-6 Per2-luc as shown with higher 





Finally, in vitro and in vivo experiments were performed in order to determine possible 
effects of FY26 on the circadian clock itself, and their temporal relations with core 
body temperature rhythm as a CTS biomarker. Standard statistics, Spectrum 
resampling, and Cosinor Analyses were applied to the longitudinal time series data in 
order to determine circadian parameters and to validate intergroup differences. The 
administration of FY26 at T04, T010, T16 and T22 markedly reduced 
bioluminescence over the 2.5 to 5 days following drug addition, with significant time -
dependency. FY26 did not ablate Per2-luc circadian oscillation yet it dampened its 
amplitude with the highest bioluminescence inhibiting at T22. However, the mRNA 
expressions of clock genes Per2, Bmal1 and Rev-erbα were minimally altered by 
FY26 dosing at T04 or at T22 in synchronised Hepa1-6 Per2-luc cells. This suggested 
that FY26 effects could rather take place at posttranscriptional levels. The in vivo 
relevance of these in vitro findings was investigated through the real-time continuous 
recording of PER2::LUC bioluminescence in transgenic PER2::LUC mice kept in 
constant darkness. In these conditions, the circadian period of PER2::LUC 
bioluminescence averaged 22.5 h, so that the real average endogenous circadian times 
of FY26 dosing were CT24 (range, CT22.5 to CT01.5) and CT12 (CT11.5 to CT13.5). 
FY26 markedly reduced and altered bioluminescence rhythms for up to 48 hours after 
injection, with largest amplitude reduction in the mice dosed at CT24. Simultaneous ly, 
FY26 altered core body temperature rhythm, an effect which was confirmed in 
LD12:12 synchronised mice. FY26 injection sharply decreased core body temperature 
and transiently disrupted its circadian pattern for ~ 24 h following dosing at ZT18. No 
rhythm alteration was observed at ZT06. The results hence confirm that FY26 can 
alter the Circadian Timing System, which more susceptible following was dosing at 
the time of highest systemic toxicity, and least at that of best tolerability.  
In conclusion, the research presented in this thesis has highlighted the complementa ry 
and consistent links between in vitro and in vivo chronopharmacology findings, as 
shown for the anticancer drug candidate FY26. The use of 24-hour temperature 
schedules as an effective synchroniser of circadian clocks in vitro and that of core 
body temperature rhythm as a circadian biomarker in vivo has enabled the precise 





achieved, as physiological rhythm had been introduced into cell culture conditions. 
Should these results be applicable to humans, least FY26 toxicity could occur at night, 
shortly after the physiological nadir in core body temperature. More generally, the 
synchronisation of healthy and cancer cells with 24-h periodic temperature schedules 
mimicking physiological cycles could have a high potential to identify optimal drug 
timing options and underlying chronopharmacokinetics and chronopharmacodymics 
mechanisms, whilst reducing and replacing animal experiments, as illustrated here. 
This could indeed encourage the integration of chronotherapy concepts into drug 
development strategies. In such context, the objectives of animal chronotherapy 
studies might hence become mostly confirmatory. Thus, the use of core body 
temperature circadian cycle appears not only as crucial for the determination of the 
circadian timing resulting in best drug tolerability, antitumour efficacy, and quality of 
life, but it is also in agreement with the principles of the 3 R’s (reduction, refinement 
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1 A screenshot of the public perception of circadian rhythm 
“Google, what is circadian rhythm?” 
“A circadian rhythm is any biological process that displays an endogenous, 
entrainable oscillation about 24 hours” 
This answer is the first definition of circadian rhythm google presents. It was also 
probably the first answer many people read after researching the meaning of circadian 
rhythm following the announcement that Jeffrey C. Hall, Michael Rosbash and 
Michael W. Young were awarded with the Nobel Prize in Physiology or Medicine on 
the 2nd October 2017.  
 
Figure I-1:Screenshot of the results of the worldwide Google Trend search “circadian 
rhythm” during the past 12 months (source: Google Trends).  
As shown in Figure I-1 the public interest in circadian rhythm was high but short. 
Nevertheless, this announcement had a huge impact on medical research as it triggered 
high interest in the possible relevance of circadian rhythm for sleep disorders, and 
mental health, as well as neurodegenerative, metabolic and malignant diseases.  
Further, it motivated non-circadian researchers to implement the circadian clock into 
their field of interest. Unfortunately, less attention has been paid to the impact of the 
circadian rhythm for pharmacology and drug development. Hence, this thesis can be 
understood as a contribution to the integration of the circadian rhythm into 





2 Circadian rhythm 
The word circadian arises from the Latin words circa and diem and means 
approximately a day (Halberg, 1969). Circadian rhythms are biological variations 
which recur approximately every 24 h, and whose regulation is reset to 24-h by the 
regular alternation of natural light and darkness. Rhythms with different oscillato ry 
lengths or periods have been described. For example cyclic adenosine monophospha te 
(cAMP) is released in a pulsatile manner triggering the release of hormones. 
Hormones like insulin, gonadotropin releasing hormone (GnRH), growth hormone 
(GH) are released every 13 min, every hour and every 3 to 5 h. Hence, two kinds of 
biological rhythms have been distinguished: the pulsatile and the circadian rhythms 
(Goldbeter, 2002). Regardless of the length of an oscillation, the parameters period, 
mesor, amplitude and acrophase have been commonly used to describe biologica l 
rhythms. The period is the time needed to complete one oscillation. The mesor 
represents the mean of the fitted cosine function, the amplitude measures the 
difference between the mesor and the maximum value of the oscillation, and the 
acrophase is the timing of the maximum. The cosinor and other spectral methods 
provide these parameters with their confidence limits (Reinberg, 1992; Vitaterna et 
al., 2001).  
In physiology, circadian rhythms can be found in sleep and wake pattern, as well as 
e.g. body temperature (Dibner et al., 2010). In mammals, physiological circadian 
rhythms are endogenous, entrainable, self-sustained and temperature compensated. 
They are moreover generated by circadian clocks (Vitaterna et al., 2001). 
3 The circadian timing system 
Circadian clocks are conserved amongst different tissues such as liver, kidney, heart, 
hypothalamus and fibroblasts (Plikus et al., 2015; Zhang et al., 2014). They are 
organised in a hierarchical network structure resulting in the Circadian Timing System 
(CTS) (Figure I-2). Exogenous or environmental signals such as light or social cues,  
serve as Zeitgeber (German word for “time giver”) through resetting the central clock 
in the suprachiasmatic nuclei (SCN). The SCN generates output signals coordinating 





be e.g. hormones and body temperature (Lévi et al., 2010). Melatonin, a sleep 
hormone, peaks near 04:00 in humans and is involved in the regulation of the sleep-
and wake cycle (Cajochen et al., 1999; Cajochen et al., 2003). Corticosterone in 
rodents and cortisol in humans are rhythmically secreted by the adrenal gland, with 
peaks near the start of the activity phase of the rest-activity cycle in both species. The 
glucocorticoid rhythms participate in the circadian regulation of metabolic function 
and adaptive stress response (Son et al., 2008). 
Core body temperature follows a circadian rhythm with highest values at night in 
rodents and during daytime in humans (Cajochen et al., 2003). Daily changes of core 
body temperature entrain cell-autonomous peripheral clocks in vivo. The SCN of 
rodents remains unaffected by external temperature cycles, which however do entrain 
peripheral clocks in lungs and pituitary tissues, among others. This demonstrates that 
the rhythm in core body temperature, generated by the SCN, is important to entrain 
peripheral clocks without affecting the SCN (Buhr et al., 2010). A comparison 
between the synchronisation properties of light-dark cycles with external temperature 
cycles in mice, identified temperature cycles as Zeitgeber with weak synchronisat ion 
properties (Refinetti, 2010). Nevertheless, temperature cycles mimicking core body 
temperature were shown to maintain autonomous and self-sustained oscillations in 
cultured mouse fibroblasts (Brown et al., 2002; Nagoshi et al., 2004; Saini et al., 
2012). Several internal time cues provided by the rhythms in core body temperature, 
circulating melatonin and cortisol levels, are important as they contribute to the 
coordination of the peripheral clocks machinery. This machinery rhythmica lly 







Figure I-2: Schematic representation of the CTS and its interaction with external time cues 
and other critical cellular functions (Lévi et al., 2010). 
4 Photoperiodic Entrainment of the SCN in Mammals 
The translation of the photoperiod in chemical signals is partly mediated by 
melanopsin located in the retinal ganglion cells (RGC) (Hattar et al., 2002; Ruby et 
al., 2002). Melanopsin and glutamate are both stored in the pituitary adenylate cyclase -
activating polypeptide-containing RGC (Hannibal et al., 2002; Hannibal et al., 2000). 
Retinal ganglion cells innervate the SCN through the retinohypothalamic tract (RHT) 
(Berson et al., 2002; Moore et al., 1995). Voltage dependent Ca2+ channels are 
activated by membrane potentials triggering synaptic glutamate release in the RHT. 
The glutamate further initiates the release of postsynaptic Ca2+ and protein kinases A 
in the neurons of the SCN (Irwin & Allen, 2007). In the presence of calcium, 
calmodulin and the calcium/modulin kinase 2α is activated leading to the 
phosphorylation of the cyclin AMP responsive element binding protein (CREB) at 
Ser133 and Ser142 (Gau et al., 2002). The clock genes Per1 and Per2 (further 
described in the next paragraph), host the cAMP-responsive element (CREs) to which 
CREB binds promoting the expression of PER1 and PER2 which regulate the 





Bendova et al., 2002). Despite Ca2+ regulating the clock function, the protein kinase 
C α (PRKCA) interacts with PER2 and hence stabilises PER2. This interplay is 
dependent on the availability of light (Jakubcakova et al., 2007).  
5 The wheels of the circadian clock 
The discovery of the biological machinery of mammalian clocks was initiated as clock 
gene Per was first discovered in 1971 by Konopka and Benzer (Konopka & Benzer, 
1971). Thirteen years later, Per was identified to be essential for the entrainment of 
Drosophila to light-dark cycles (Bargiello et al., 1984; Zehring et al., 1984). Intensive 
research led to the description of the molecular circadian clock in mammals being 
constituted with interconnected negative and positive transcription/translat ion 
feedback loops (Figure I-3). The molecular clock involves approximately 15 genes. 
Bmal1 (brain and muscle Arnt-like protein) and Clock (circadian locomotor output 
cycles kaput) are core genes whose transcriptional activity governs the positive limb 
of the clock and triggers the transcription of clock genes (e.g., Clock, Bmal1, Per1, 
Per2, Per3, Cry1, Cry2, Reverbα and Reverbβ). In the nucleus, the bHLH-PAS 
proteins BMAL1 and CLOCK/NPAS2 heterodimerise. The heterodimers such as 
CLOCK:BMAL1 bind to E-box elements being short DNA sequences (5’-CACGTG-
3’/ 5’-CACGTT-3’) in the promotor region of the target gene. Once the 
CLOCK:BMAL1 heterodimer is linked to the specific sequence, transcription of the 
targeted clock genes is activated (Gekakis et al., 1998; King et al., 1997). Those clock 
genes are for instance Per (Period) and Cry (Cryptochrome). They form a negative 
limb as their proteins, PER and CRY, feedback to Bmal1 and Clock/Npas2 inhibit ing 
their transcriptional activity. Consequently, PER and CRY are responsible for the 
down regulation of their own transcription (Kume et al., 1999; Sangoram et al., 1998). 
Per and Cry consist of Per1, Per2, Per3 and Cry1 and Cry2 genes. Their proteins 
display different repressor activities on the positive limb. It has been shown in Per3 
knock out mice, that the rhythmic expressions of Per1, Per2, Cry1 and Bmal1 were 
similar to those found in Per3 wildtype (Shearman et al., 2000). The study then 
suggested that Per3 was not essential for maintaining circadian rhythmicity, whereas 
Per1, Per2, Cry1 and Cry2 were indeed as their silencing disrupted the transcriptiona l-





1999). Another feedback loop is generated through the transcription of the clock genes 
Rev-erbα/β and Rorα/β.γ, which are activated by the CLOCK:BMAL1 complex. 
REV-ERBα/β represses the activation of Clock and Bmal1 presenting a second 
negative feedback loop. In the meantime, RORα/β competes with REV-ERBα/β 
targeting the same binding side. Consequently, RORα/β dampens the repressing effect 
of REV-ERBα/β on Clock/Npas2 and Bmal1 transcription (Guillaumond et al., 2005). 
This interacting dynamic molecular system of activating and inhibiting loops forms 
the basis of circadian gene expression. 
 
Figure I-3: Molecular makeup of the circadian clock (Dallmann et al., 2014). 
This interplay between negative and positive transcription and translational feedback 
loop regulates the circadian expression of so-called clock-controlled genes and 
proteins through transcription factors. Transcription factors DBP, TEF and HFL have 
a PAR-domain basic leucine zipper (PAR bZip) and regulate the circadian expression 
of metabolic genes such as Cyp2a5 and Cyp2c50. The P450 oxidoreductase (POR) 
exhibits a strong circadian rhythm which is suppressed in PAR bZip knock out mice 
(Gachon et al., 2006). The heat shock factor 1 (HSF1) is a further transcription factor 
regulating the expression of HSP1 at the onset of darkness by binding to the heat shock 
element (HSE) (Reinke et al., 2008). The release of hematopoietic stem cells (HSC) 





system (SNS) which is governed by the central clock. Noradrenalin down regulates 
Cxcl12 through the inhibition of the Sp transcription factor (Méndez-Ferrer et al., 
2008). The circadian clock further regulates protein expression indirectly through the 
regulation of protein degradation processes. One example is the rapamycin target 
mTOR. It is shown that the rhythmic expression of mTOR is regulated by Fbxw7 
(F-box and WD-40 domain protein 7) whose expression is further regulated by the 
clock output gene Dbp. Consequently, FBXW7 was found the exhibit a circadian 
pattern which are in antiphase to that of the mTOR expression. This suggested that the 
ubiquitination of mTOR rather than its mRNA expression, was clock-controlled 
(Okazaki et al., 2014).  
6 Implementation of circadian clocks in pharmacology 
As demonstrated for mTOR, the circadian clock in involved in the regulation of the 
circadian expression in many genes and proteins. In this context, it is reported that 
43% of the protein-coding genome in mice is rhythmic (Ptitsyn & Gimble, 2011; 
Zhang et al., 2014). A further study identified that 25% of phosphopeptides in the liver 
presents with diurnal rhythms (Robles et al., 2017). The identification of the circadian 
expression of such proteins is crucial as they often represent targets for  
pharmacological agents, e.g. .everolimus targets mTOR, forming the base of 
chronopharmacology (Okazaki et al., 2014).  
Chronopharmacology is the science whose subject it is to determine and describe the 
time dependent drug effects, taking into account the circadian clocks. This includes 
studies on circadian changes in pharmacokinetics and pharmacodynamics. 
Pharmacokinetics describes the properties of drug absorption, distribution, 
metabolism and elimination (ADME), whereas pharmacodynamics defines the effect 
of agents with e.g. molecular and cellular targets. 
7 Circadian Pharmacokinetics 
Gastric pH and motility influence drug absorption thus, determine the speed and 
quantity of drug uptake. The rhythmicity of gastric pH has been reviewed previous ly 
pointing out its importance for drug ionization and hydrophobicity. Additiona lly, 





(Dallmann et al., 2014; Ohdo, 2010). The peptide ghrelin governing gastric motility 
is regulated by clock gene Bmal1. Ghrelin mRNA expression is highest at circadian 
time 4 (CT4, beginning of rest span) in wildtype mice kept in DD. This rhythm is 
ablated in Bmal1 knock out mice (Laermans et al., 2015). A study on 16 heathy male 
subjects confirmed that the mean emptying half-time is on average 30 min faster in 
the morning at 08:00 as compared to evening at 20:00 (Goo et al., 1987). The intestina l 
H+ -coupled peptide transporter (PEPT1) mediates the cellular uptake of active drugs 
such as β-lactam antibiotics or angiotensin-converting enzyme (ACE) inhibitors. The 
expression of PEPT1 is regulated by clock output gene and transcription factor Dbp 
with a peak at ZT08 in mice (Saito et al., 2008).  
The distribution of pharmacological agents is dependent on blood flow, cardiac 
output and plasma proteins. Blood flow as well as heart rate exhibit a circadian rhythm 
with a peak during the late afternoon (Kaneko et al., 1968). The vascular function is 
clock regulated. A reduced endothelium relaxation and an increase in the expression 
of cyclooxygenase-1 (COX1) was observed in the aortic ring of Per2 mutant mice but 
not in wild type mice (Viswambharan et al., 2007). The response of α–adrenoreceptors 
to phenylephrine and the baroreflex sensitivity are higher during the night in mice. 
Those rhythms, however, were depleted in Cry1 and Cry2 knockout mice (Masuki et 
al., 2005). Further, the hepatic blood flow was shown to exhibit a circadian pattern 
with a peak at 04:00 in the morning (Lemmer & Nold, 1991). The rhythms of hepatic 
blood flow is influenced by drugs as nifedipine or propranolol as well as food (Feely, 
1984; Olanoff et al., 1986). The availability of plasma albumin follows a circadian 
pattern. The highest plasma concentration of albumin was determined at ZT15 to ZT18 
in mice (Mauvoisin et al., 2014) and near 16:00 to 20:00 in human subjects (Jubiz et 
al., 1972). 
Drug metabolism involves phase I and phase II enzymes and phase III transporters. 
Proteins belonging to phase I enzymes are oxidases, reductases and hydrolases as part 
of the microsomal cytochrome P450 (CYP450) (Ferrell & Chiang, 2015). They 
activate or inactivate drugs before undergoing phase II metabolism. In phase II, the 
hydrophilicity of drugs is increased by their conjugation through UDP-
glucuronosyltransferases, N-acetyltransferases, glutathione S-transferases, or 





multiple families, including the ABC transporter P-glycoprotein (P-gp) and multid rug 
resistance-associated proteins (MRP) as well as the organic anion transporting 
polypeptide 2 (OATP2) (Xu et al., 2005).  
Transcription factors like aryl hydrocarbon receptor (AhR), constitutive androstane 
receptor (CAR), pregnane X receptor (PXR) or proliferator-activated receptor-α 
(PPARα) exhibite circadian patterns thus generate and propagate circadian changes in 
the mRNA expression of Cyp genes. PPARα activates the rhythmic transcription of 
Cyp4a10 and Cyp4a14. Comparing the transcription levels of Cyp genes in male and 
female mice liver, revealed a higher expression of Cyp genes in female compared to 
male mice. Female mice exhibited a 20-fold higher RNA expression of Cyp4a14 as 
compared to male mice (Lu et al., 2013). In the hepatocellular carcinoma cells, 
HepG2, the transcription factor Dbp (Yamaguchi et al., 2000) shows a simila r 
circadian oscillating pattern as that in Cyp3A4. Increased DBP levels, mediats the 
expression of Cyp3A4 in HepG2 cells (Takiguchi et al., 2007). Contrary to Cyp3A4 
activation, the circadian expression of the transcription factor PPARα which activates 
enzymes of the Cyp4 family, is governed by the CLOCK:BMAL1 heterodimer. 
Circadian rhythms are also found for the transcription of enzymes in the Cyp4 family 
(Lu et al., 2013; Oishi et al., 2005). As a result, the metabolism of the analgesic and 
antipyretic drug acetaminophen (APAP) also known as paracetamol, is an example for 
a drug whose toxicity is affected by the rhythmic expression of metabolising enzymes.  
Due to higher alanine and aspartate transferase (ALT and AST) and lower glutathione 
levels at 20:00, an increased concentration of the toxic metabolite 
N-actyl-p-benzoquinone occurs in mice synchronised with 12:12 h light-dark cycles 
with light onset at 07:00 and light off set at 19:00 (Kakan et al., 2011). It is further 
reported that the APAP toxicity is several fold larger and arrhythmic in hepatic Bmal1 
knock out mice. Additionally, the study shows a decrease in Cyp2a1 and Cyp1a2 
resulted from reduced transcription activity of P450 cytochrome oxidoreductase (Por) 
in Bmal1 knock out mice (DeBruyne et al., 2014; Johnson et al., 2014). The mRNA 
expression of the phase III ABC transporter, P-gp and Mrp followed a circadian 
expression pattern. Abcb1a (Mdr1a) and Abcb1b (Mdr1b) are highest expressed near 
ZT16 in mouse liver and near ZT12 in mouse intestine, with large sex-related 





ZT08 in liver and at ZT04 in the intestine (Ando et al., 2005). The multid rug 
resistance-associated protein 2 (MRP2) and the organic anion transporter 1 and 2 
(SLC22A1 and SLC221B) are rhythmically expressed with acrophases at the end of 
the rest phase in mice (Panda et al., 2002)  
Regarding the elimination, studies in wildtype mice demonstrated an oscillat ing 
pattern of stool output during the active phase (CT20) and an increased muscle 
contractile response in colon to acetylcholine at the beginning of the dark phase 
(CT13). Those effects do not occur in Per1/2 knock out mice (Hoogerwerf et al., 
2010). Rena elimination is further circadian regulated (Firsov & Bonny, 2010). It is 
further reported that the glomerular filtration rate is highest during the late afternoon 
and lowest during the early morning hours in humans (Koopman et al., 1989).  
8 Chronopharmacodynamics of anticancer drugs 
A prominent target, especially for anticancer drugs, is the cell cycle which regulates, 
DNA synthesis, mitotic division, cell growth, apoptosis and autophagy. Schematica lly, 
the cell cycle exhibits different cell cycle phases which are called G0/G1, S (DNA 
replication), G2, and M (mitosis). The transition from one cell cycle phase to the next 
one is regulated by cyclin-dependent kinases (CDK) and cyclins (Morgan, 1995). 
CDK1 supports the transition from S-phase to mitosis initiated by cyclin A. CDK2 is 
involved in the transition from G1- to S-phase (Malumbres & Barbacid, 2009). Cell 
cycle phase transitions from G1 to S and from G2 to M are controlled by the circadian 
clock, at least via p21 and wee1. For instance, the protein WEE1 whose gene 
transcription is activated by CLOCK:BMAL1 heterodimer and suppressed by PER 
and CRY proteins, is shown to be rhythmic. A rhythmic phosphorylation and 
activation of CDK1 is promoted resulting in the activation of the G2/M transit ion 
(Matsuo et al., 2003). Additionally, clock genes Per1 and Per2 interact with the 
serine/threonine kinase ATM and the proto oncogene mdm2 controlling DNA repair. 
Disrupting the rhythmicity in clock gene expression due to environmental changes (e. 
g., chronic jet lag) down regulate the tumour suppressor gene p53. This results in the 
activation of cell proliferation and the down regulation of DNA repair mechanism as 
well as apoptosis (Hunt & Sassone-Corsi, 2007; Lévi, 2006). Recent research further 





cultured mouse fibroblasts with or without time cues (Bieler et al., 2014; Feillet et al., 
2014). This coupling is suggested to be altered in cancerous cell lines (Feillet et al., 
2015). It is argued that the fast proliferation of tumour cells is due in part to the 
uncoupling of the cell cycle from the circadian clock, and that entrainment of cancer 
cells could be a way to slow down tumour growth (Feillet et al., 2015). It is further 
proposed that mutations in clock genes could result in the dysregulation of the cell 
cycles thus promoting cancer cells proliferation and tumour progression (Lévi et al., 
2007). Therefore, understanding the link between the circadian clock and the cell cycle 
in healthy and cancerous cells appears critical for mapping the mechanisms that 
underlies the chronopharmacology of anticancer agents. 
Circadian rhythms in tolerability have now been identified for 50 anticancer agents 
belonging to eight pharmacology classes (Figure I-4) (Lévi, 2006; Lévi et al., 2010). 
Such classes are the antimetabolites, topoisomerase inhibitors, intercalating agents, 
cytokines, mitotic spindle poisons, nitrosoureas, small kinase inhibitors and alkylat ing 
agents. Representatives of each class exhibit different circadian times of best drug 
tolerability. For example the topoisomerase inhibitors irinotecan and etoposide display 
best tolerability at ZT7 whereas the cytokine interleukine-2 is best tolerated at ZT17 
(Lévi et al., 2010). The Lethal Dose (LD) 50 of the antimetabolite 5-fluorouracil (5-
FU) in mice is higher following drug injection at 11:00 (LD50: 450-500 mg/kg) as 
compared to 23:00 (LD50: 250-330 mg/kg) in mice synchronised with lights on from 
06:00 to 18:00 (Burns & Beland, 1984). A second in vivo study confirms that 
200 mg/kg 5-FU exhibit the highest toxicity at 04:00. Thus, 5-FU is best tolerated 
when administered during the early rest phase of mice (Popovic et al., 1982). The 
mitotic inhibitor docetaxel is best tolerated in mice following the i.v. injection of 30 
mg/kg docetaxel at ZT7 to ZT11. Strikingly, optimal antitumour efficacy of docetaxel 
is also achieved following dosing near the time of best tolerability. Thus, the inhibit ion 
of tumour proliferation is shown to be 2 to 3 times larger following docetaxel injection 
to pancreatic cancer-bearing male B6D2F1 mice at ZT7 as compared to ZT19 or ZT23 
(Tampellini et al., 1998). The time point of best docetaxel tolerability is further 
confirmed following the injection of 38.8 or 23.3 mg/kg/injection to male C3H/HeN 
mice. The same study demonstrates that male C3H/HeN mice injected with 13.8 and 





weight following treatment at ZT7, thus confirming earlier findings of best 
doxorubicin tolerability in male CDF1 mice (Granda et al., 2001; Sothern et al., 1988). 
The administration of docetaxel and doxorubicin at ZT7 prolonged tumour growth 
inhibition by 50% as compared to other circadian time points in breast cancer-bearing 
C3H/HeN mice. The co-administration of 16.3 mg/kg/injection docetaxel and 
2.5 mg/kg/injection doxorubicin once per week for 3 weeks leads to a persistent 
tumour inhibition of 45% with the best tolerability at ZT7 (Granda et al., 2001). 
Alkylating agents are another class to display marked circadian toxicity profiles. This 
is especially the case for platinum complexes cisplatin, carboplatin and oxaliplatin.  
 
Figure I-4: Overview of best timing of anticancer agents.  
The figure describes the circadian timing of anticancer agents in 8 pharmacologic classes. 
Platinum complexes such as cisplatin, carboplatin and oxaliplatin are best tolerated when 
given during the early hours of the active phase in nocturnal rodents, despite large differences 
in pharmacology and action mechanisms. The red polar curve depicts the average circadian 
rhythm in core body temperature (Lévi et al., 2010).  
9 Chronopharmacology of platinum complexes 
The anticancer activity of platinum compounds was first recognised in 1965 by 





the presence of the cisplatin, that was freed from the platinum electrodes as a result of 
electric current flow (Rosenberg et al., 1965). Following his discovery, clinical trials 
identified cisplatin as an anticancer drug which received FDA approval in 1978 
(Monneret, 2011). Platinum compounds like cisplatin, carboplatin and oxaliplat in 
today represent the most widely used drugs to treat cancer. Cisplatin is approved for 
the treatment of ovarian, breast, bladder, lung, head and neck carcinoma in 
combination with a taxane. It is further used for the treatment of gastric and 
esophagogastric adenocarcinoma in combination with paclitaxel and 5-FU as well as 
against prostate, cervical and biliary cancer (Dasari & Tchounwou, 2014). However, 
severe adverse effect such as renal failure, anemia, neutropenia and nausea are limit ing 
the use of cisplatin. Thus, the determination of the optimal cisplatin timing could 
contribute to the improvement of its tolerability. 
Initial studies in rats demonstrate a several fold improvement in cisplatin gross, renal 
and haematological toxicities through the delivery of this drug near ZT18, i.e. near the 
middle of the nocturnal active span in female F344 Fisher rats (Hrushesky et al., 
1982b; Levi et al., 1982). Interestingly the antitumour efficacy of cisplatin (in 
combination with doxorubicin) is highest following dosing near the middle of the 
nocturnal activity span in tumour-bearing rats (Sothern et al. 1989). Similar studies 
investigated the chronotolerance of cisplatin in male B6D2F1 mice and revealed that 
the time point of best drug tolerability is still located during darkness, yet slightl y 
earlier, i.e. near ZT15-16 (Boughattas et al., 1989). Subsequently, an experiment 
determining the tolerability and the antitumour efficacy of gemcitabine (deoxycytid ine 
analogue) in combination with cisplatin in tumour-bearing mice is performed. ZT15 
and ZT11 are identified as the most effective dosing times of cisplatin and gemcitab ine 
respectively, both as single agents and in combination (Li et al., 2005b).  
Subsequent chronopharmacology studies demonstrate similar chronotolerance and 
chronoefficacy patterns for carboplatin and oxaliplatin, with a simila r “optima l” 
timing at ZT15-ZT16 in male B6D2F1mice, despite major differences in toxicity 
target tissues, pharmacokinetics, and pharmacodynamics (Boughattas et al 1988, 
1989, 1990). While chronopharmacokinetics do not appear to play a major role, the 
circadian detoxification of these compounds with reduced glutathione (GSH) is 





buthionine sulfoximine (BSO) increases jejunum toxicity and oxaliplatin intestina l 
uptake (Lévi et al., 2000). Another study searched for the drug administration time 
associated with best antitumour efficacy of oxaliplatin, using Glasgow osteosarcoma-
bearing mice. A daily dose of 5.25 mg/kg of oxaliplatin achievs both best tolerability 
and best efficacy at ZT15 compared to ZT7 (Granda et al., 2002). In aggregate the 
delivery of cisplatin or oxaliplatin near the middle of the nocturnal active span of rats 
or mice demonstrate both best tolerability and best antitumour efficacy. However, sex 
and possibly species or strain could moderate their chronopharmacology to some 
extent. 
Clinical chronotherapy trials investigated the clinical relevance of these findings, with 
regard to both tolerability and efficacy in cancer patients. Initial randomised trials have 
shown that cisplatin is less toxic and possibly more effective following dosing in the 
late afternoon hours (16:00-18:00) as compared to early morning hours (04:00-06:00) 
in ovarian cancer patients (Hrushesky et al., 1982a; Levi et al., 1990). Subsequent 
clinical trials mostly investigate the relevance of oxaliplatin timing, in combination 
with the anticancer drug 5-fluorouracil (5-FU) and leucovorin in patients with 
metastatic colorectal cancer. The chronotherapy trials were the first ones to 
demonstrate any clinical efficacy of a platinum complex in human colorectal cancer 
(Levi et al. 1992). In two international randomised trials, oxaliplatin chronotherapy 
proved as less neurotoxic and more effective as compared to flat infusion (Levi et al. 
2001). Subsequently, a combination of 700 - 1100 mg/m2/day 5-FU (peak at 04:00), 
300 mg/m2/day leucovorin (peak at 04:00) and 25 mg/m2/day oxaliplatin (peak at 
16:00) is infused as circadian chronomodulated infusions for up to 12 courses in 
patients with metastatic colorectal cancer. The chronomodulated dosing schedule 
allows an increase in dose intensity for 5-FU up to 36%. Moreover the same schedule 
improves objective response rate up to 15% suggesting that chronotherapy has an 
impact on minimising side effects and improving the outcome of pharmacotherapy 
(Lévi et al., 1999). This study was followed by a clinical phase III trial comparing 
chronomodulated delivery to a non-time stipulated conventional drug administrat ion 
of the same drugs in 554 patients (338 male and 226 female). Safety, response and 
survival are monitored. The results report no difference in overall survival between 





improved haematological tolerability several fold and it significantly prolonged 
survival in men, but not in women as compared to conventional delivery (Giacchett i 
et al., 2006). 
The sex-chronotherapy schedule interaction is further confirmed in a meta-analysis of 
three randomised international trials comparing chronotherapy vs. conventiona l 
delivery (Giacchetti et al. 2012). Additional experimental studies and clinical trials 
suggest that the optimal timing could differ by nearly 6 h between males and females 
(Levi et al. 2007; Li et al. 2013). Ongoing research is aiming at the personalisation of 
chronotherapy delivery according to both sex and the CTS of cancer patients, using 
tele-monitored circadian biomarkers and a systems chronopharmacology approach 
(Ballesta et al, Pharm Rev 2017). Further, in silico models paired with in vitro models 
are promising new methods to assess the best time of drug administration through a 
system approach. This was first developed for irinotecan chronopharmacology. By 
applying a comprehensive mechanistic circadian PK-PD model on 
chronopharmacokinetic and chronopharmakodynamic data on irinotecan, the criticia l 
circadian rhythms in proteins involved in the mechanism of action are identified 
(Dulong et al., 2015). 
Another variable affecting the determination of the optimal timing of cancer drugs is 
the disturbance of the circadian clock (Ballesta et al., 2011). CTS disruption is 
associated with a lower survival rate in cancer patients. For example the disruption of 
daily cortisol patterns is related to a higher risk of an earlier mortality in patients with 
metastatic breast cancer (Sephton et al., 2000). A poorer survival is also demonstrated 
in patients with metastatic gastro-intestinal malignancies and circadian disruption of 
their rest-activity or body temperature rhythms (Ballesta et al., 2017). On the other 
hand, anticancer drugs could disrupt the CTS through altering core body temperature 
and/or rest-activity rhythms (Ballesta et al., 2017; Lévi et al., 2010). Hence, the 
determination of optimal drug timing should encompass both the identification of the 
least toxic drug administration time, but also the quantification and dosing time 
dependency in the effect of the anticancer drug on the circadian clocks. Other factors 
such as sex, age and feeding should also be considered jointly, as they could impact 
on the translation of the basic chronopharmacology findings toward their clinica l 





10 Organometallic osmium compounds FY25 and FY26  
In order to attempt at improving the therapeutic outcome and survival of cancer 
patients, a new generation of organometallic anticancer compounds entered the 
pipeline of drug development. These complexes involve different metal ions, 
including ruthenium, iridium and osmium (Fu et al., 2010; Liu et al., 2011; Novakova 
et al., 2003; Novakova et al., 2005). Iridium complexes have been the first compounds 
to demonstrate an anticancer activity different from platinum and ruthenium 
complexes. The findings suggested that the main mechanism of action is based on the 
induction of high ROS levels leading to the activation of cell death mechanisms 
through calcium release from the endoplasmic reticulum, which further destabilises 
mitochondria and initiates cell death mechanism (Liu et al., 2014; Liu & Sadler, 2014; 
Sanchez‐Cano et al., 2017). 
Table I-1: IUPAC name of the organo-osmium compounds FY25 and FY26 (van Rijt et al., 
2014). 












The main representatives of the organo-osmium compounds are FY25 and FY26. Both 
compounds display an aromatic hydrocarbon, also called arene, which binds to 
osmium as a mutual skeleton. FY25 and FY26 consist of the ligands p-cymene and 
phenylazopyridine bound to osmium. FY25 and FY26 can be distinguished through 
their fourth ligand which is the chloride for FY25 and the iodide for FY26 resulting in 






Figure I-5: General structure of an organo-osmium compound and the molecular structure of 
FY26 (Fu et al., 2010; Shnyder et al., 2011). 
Regarding their chemical properties, both compounds are soluble in water-based 
culture medium over a period of 24 h. Further, 50 µM of both compounds were diluted 
in a 10 mM phosphate buffer with deuterium water and then screened for structura l 
changes with 1H NMR. After an incubation time of 24 h, the H NMR spectra showed 
no structural changes demonstrating a stable molecular structure of both compounds. 
Results of the ESI-MS analysis indicate a strong osmium chloride bound as no 
hydrolysis in a 10% methanol/ 90% water solution occurred (Fu et al., 2010). Due to 
their stability, FY25 and FY26 were used for biological activity tests. The IC50 of 
FY25 and that of FY26 were by 2- to 3-fold and 10- to 15-fold lower, respectively, as 
compared to the IC50 of cisplatin in human lung cancer cells (A549), in human colon 
cancer cells (HCT116) and in human breast cancer cells (MCF-7) (Fu et al., 2010). 
Additionally, FY26 exhibits improved selectivity towards cancerous cells as compared 
to cisplatin. The IC50 ratio between fibroblasts (MRC5) and ovarian cancer cells 
(A2780) is reported to be 28 for FY26, as compared to 9.5 for cisplatin, thus 
demonstrating higher selectivity and enhanced anti-proliferative effects (Romero-
Canelón et al., 2015). To address the recurring problem of resistance after cisplatin 
treatment, the IC50 of FY25, FY26 and cisplatin were compared using cisplatin 
resistant and cisplatin sensitive human ovarian cancer cells (A2780-cis and A2780, 
respectively). In sensitive A2780 cells, the IC50 of FY26 (0.18 ±0.01 µM) is 10-fold 
as low those of FY25 or cisplatin (1.8 ± 0.1 µM). Interestingly, in the cisplatin-
resistant ovarian cancer cells, the IC50 of FY25 (1.77 ± 0.68 µM) and that of FY26 





(Fu et al., 2010). This finding indicate that the cytotoxicity of both Osmium complexes 
is not altered by cisplatin resistance. 
FY25 and FY26 are rapidly taken up during the first 30 min after administration with 
maximum intracellular uptake after 24 h in cultured human lung cancer cells (A549). 
Despite this observation, the measurement of the intracellular osmium concentration 
reveals a 3-fold larger uptake of FY26 as compared to FY25. This phenomenon could 
be explained with results from another study detecting free extracellular iodide that is 
released from FY26. However, no free extra- or intracellular chloride is released from 
FY25 (van Rijt et al., 2014). Intracellular FY26 is surprisingly bio-activated to 
FY26-OH through hydrolysis, which is mediated by the antioxidant glutathione (GSH) 
(Fu et al., 2010; Needham et al., 2017). The inertness of the osmium-iodide bound in 
FY26 explains the high intracellular uptake as well as the amplified biological activity 
as compared to FY25. Due to the higher reactivity of the osmium-chloride bound, 
FY25 already starts to undergo hydrolysis before the start of its cellular uptake, which 
reduces the intracellular amount of FY25. The hydrolysis might not necessarily be 
mediated by GSH but might be due to the higher reactivity of the chloride bond 
(Needham et al., 2017). GSH is known to act as an intracellular antioxidant which 
compensates and protects the cell against reactive oxygen species (ROS) and binds to 
and detoxifies metallodrugs like platinum compounds (Lu, 2013; Needham et al., 
2017). A reduction in GSH levels through its reaction with hydrolysed FY26 weakens 
cellular defence against ROS, thus increasing ROS production after FY26 
administration as shown in cultured A2780 cells. Exposing them to the IC50 of FY26 
(0.16 µM) for 24 h increases ROS levels (Hearn et al., 2015). ROS levels in fibroblas t 
(MRC5) only increased following the exposure to 28 time the FY26 IC50 of A2780 
cells (Romero-Canelón et al., 2015). This might be due to the intact mitochondria l 
activity in the fibroblasts which could balance the redox state, whereas the 
mitochondria in cancerous cells displays altered mitochondrial function (Gogvadze et 
al., 2008). GSH counterbalances excessive ROS production, thus restoring 
homeostasis (Armstrong et al., 2002; Mailloux et al., 2013). The co-administration of 
5 µM L-buthionine sulfoximine (L-BSO), a redox modulator which inhibits GSH 
biosynthesis, further elevates ROS production in A2780 cells, and lowers the IC50 of 





GSH, thus emphasising its crucial role as a potential target of FY26. High levels of 
ROS are further observed under the co-administration of L-BSO (Figure I-6) 
(Romero-Canelón et al., 2015).  
 
Figure I-6: Selectivity of FY26 towards non-cancerous cells and ROS induction.  
(A) The co-administration of L-BSO is further able to minimise the IC50 of FY26 and thus 
increase the selectivity towards non-cancerous cells. (B) FY26 induces ROS production at 
IC50 concentrations. The co-administration of L-BSO further elevates ROS levels. Compared 
to non-cancerous cells, FY26 lead to a  minor increase in ROS levels (Romero-Canelón et al., 
2015). 
Cellular distribution experiments reported an increased accumulation of FY26 in 
cellular membranes, including the mitochondrial ones, 24 h after drug exposure onset. 
About 74-80% of osmium cellular content is detected in mitochondria membranes, 
whereas only 4-15% of total osmium content is localised in the cytosol, nucleus and 
cytoskeleton (van Rijt et al., 2014). Additionally, a high extracellular calcium 
concentration is triggered with FY26 exposure. Nucleus defragmentation and 
membrane blebbing are further observed. It is suggested that in response to the high 





reticulum contributing to mitochondrial dysfunction and the activation of cell death 
mechanism (Figure I-7) (Sanchez‐Cano et al., 2017). 
 
Figure I-7: Hypothesised mechanism of action of FY26.  
After being taken up into the cell, FY26 undergoes hydrolysis mediated by GSH. Thus 
bioactive FY26-OH as well as thiolato (GS-) and sulfenato (GSO-) adducts are formed. GSH, 
as an antioxidant, balanced ROS levels. Depleted ROS levels leads to further production of 
ROS, which causes calcium release from the endoplasmic reticulum. High cytosolic calcium 
levels contribute to mitochondrial dysfunction and promote the initiation of cell death 
mechanisms (Sanchez‐Cano et al., 2017). 
The ability of FY26 to induce apoptosis is assessed in A2780 (ovarian cancer) and 
A549 (lung cancer) cells by exposing them for 24 h to their respective FY26 IC50 
concentrations. No increase in the population of apoptotic cells is observed after this 
timespan. The exposure of A549 cells to FY26 concentrations that are 10 times higher 
than the IC50 only merely increased the number of apoptotic cells. Co-administrat ion 
with L-BSO results in higher rates of apoptotic cell deaths (Romero-Canelón et al., 
2015; van Rijt et al., 2014). However, exposure of A549 cells to 1 µM of FY26, 
activates cytochrome c release, a marker of early apoptosis, without cells completing 
apoptosis. Cell cycle analysis reveals an arrest in G1-phase after exposing A2780 cells 
to 0.16 µM (IC50) to. The same observation is found in A549 cells exposed to 2.5 µM. 





which is also reported for platinum complexes (Romero-Canelón et al., 2015; van Rijt 
et al., 2014). In vivo studies, compared the efficacy of FY26 to that of cisplatin. Colon 
cancer (HCT116) xenografted mice received a single injection of 40 mg/kg of FY26 
or 8 mg/kg of cisplatin (Shnyder et al., 2011). Tumour growth was determined for 13 
days after drug administration. A significant delay in tumour growth is demonstrated 
in FY26-treated mice as compared to both untreated controls and cisplatin-trea ted 
animals (Shnyder et al., 2011). 
 
Figure I-8: Tumour growth inhibition of human colorectal cancer cell line (HCT116) in nude 
mice.  
Forty mg/kg of FY26 and 8 mg/kg of cisplatin were injected as a single dose in tumour bearing 
mice. Tumour growth was monitored over 13 days revealing a significant delay in the tumour 
growth after FY26 administration as compared to cisplatin and the untreated control (Shnyder 
et al., 2011). 
The pharmacokinetics and pharmacodynamics investigations suggest a different 
mechanism of action of the organo-osmium compound FY26 as compared to platinum 
complexes. Although FY26 causes an increase of S-phase cells, the main mechanism 
of action of FY26 was different from that of the platinum drugs. Whilst GSH binding 





FY26-OH which increases intracellular levels of ROS. ROS production triggers 
calcium release from endoplasmic reticulum, which further contributes to 
mitochondrial dysfunction and initiation of cell death mechanism. However, the 
mitochondrial target of FY26 still remains to be determined. 




11 Scope of the thesis 
The aim of my doctoral project is to unravel the chronopharmacology of the potential 
osmium anticancer drug FY26, so as to optimise tolerability through drug timing and 
to determine its links to the physiological core body temperature cycles. The 
chronopharmacological investigations were conducted using in vitro and in vivo 
models.  
The use of the in vitro cell culture models addressed the following research questions : 
1. Is temperature synchronisation of cell cultures a suitable method for 
chronopharmacology studies? And if so, in which conditions? 
2. Does FY26 circadian timing in vitro alter the extent of its toxicity?  
3. If FY26 exhibits a circadian in vitro toxicity, what are the main determining 
factors responsible for its in vitro chronotoxicity? 
4. Does FY26 affect the circadian clock?  
The studies that were performed in mice sought to answer the questions:   
5. Is there a consistent circadian rhythm in FY26 tolerability? If so, when is this 
osmium complex best tolerated? 
6. Does FY26 inhibit tumour growth in hepatocarcinoma-bearing mice? 
7. Does FY26 antitumour efficacy differ following dosing at the time points of 
highest or worst tolerability? 
8. Does FY26 affect core body temperature and liver PER2 protein expression 
rhythms when dosed at the time points of best and worst tolerability? 
9. Can programmed in vitro 24-h periodic temperature cycles be used to predict 
in vivo chronotoxicity, using FY26 as an example? 
Answering to those questions is a crucial part not only for the optimisation of FY26 
through chronotherapeutic delivery, but also for developmental cancer 
chronotherapeutics in general. Thus, my research was integrated within a 
multidisciplinary project that has been seeking to further improve chronotherapy with 
metallodrugs through automatic nanoparticle chronodelivery system sensing the 
circadian rhythm in each cell. This project has involved the research groups of 
Professor Peter Sadler, Professor Sebastien Perrier, Professor David Rand and Doctor 




Annabelle Ballesta. Indeed, the determination of the best time of drug administrat ion 
constitutes an important aspect for developmental cancer chronotherapeutics as 
efficacy and survival rates can be improved. Moreover, dosing at the time of highest 
tolerability increases side effects and thus can improve life quality of patients 
undergoing chemotherapy.  










II Methods and Materials 
  




1 In Vitro Methodology  
1.1 Cell lines and cell culture 
The in vitro chronopharmacology of a new generation of osmium metal compounds 
was assessed by using an epithelial hepatocarcinoma cell line (Hepa1-6, ATCC® 
CRL-1830™) arising from BW7756 tumour in C57L mouse and the epithelia l 
colorectal carcinoma cell line (HCT116, ATCC® CRL-247™) from a male adult 
patient. Modified clones of the Hepa1-6 cell line were engineered within the C5SYS 
ERASYSBIO+ project (FP7) and were kindly provided, together with the HCT116 
cell line, by Dr. Sandrine Dulong from INSERM U935 (Villejuif, France). Hepa1-6 
and HCT116 were transfected with the Per2-luc and Bmal1-luc reporter construct 
(Figure II-1). The transfection of the Bmal1-luc reporter into the HCT116 cell lines 
was done by our laboratory team within our facility. The gene Bmal1 was silenced 
with shBmal1 RNA (expression of shBmal1 shown in Chapter III) in Hepa1-6 Per2-
luc by Professor G.T.J. van der Horst (Erasmus University, Rotterdam).  
 
Figure II-1: Plasmid map of Per2-luc reporter construct inserted in Hepa1-6 cells. 
The plasmid contained the sequence of the Per2 promoter (light blue), of luciferase as well as 
the CMV promotor, 5’ and 3’ LTR, Gag and the Rev Response Element (RRE).  




All cell lines were grown at 37°C, 5% CO2 and 90% humidity in a cell culture 
incubator (Memmert INCO 153, Memmert, Schwabach, Germany) or stored 
at -196°C. Cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM)  
containing 10% heat inactivated fetal calf serum (FCS, Labtech, Heathfield, UK), 
100 μg/mL Penicillin/Streptomycin (Prep room, Life Sciences, University of 
Warwick) and grown in 10 cm Petri dishes (Sarstedt, Nürnbrecht, Germany). The 
media was prepared by the prep room in the Life Sciences Department of Warwick of 
University. 
1.2 Cell thawing and freezing 
Cells were plated in a 10 cm Petri dish and frozen until further use once reaching 80% 
confluency. The media was removed by suction. Cells were washed with 10 mL 
Phosphate Buffered Saline (PBS, Prep room, Life Sciences, University of Warwick) 
and incubated with 1 mL Trypsin-EDTA (Prep room, Life Sciences, University of 
Warwick). The incubation time varied from 1 to 5 min in between cell lines. Nine mL 
media was the added. The 10 mL cell suspension was then transferred into a 15 mL 
FALCON tube (Sarstedt, Nümbrecht, Germany) and centrifuged at 200 rcf (Relative 
Centrifugal Field) for 4 min. Following this, the supernatant was removed and the cell 
pellet was resuspended in 4 mL media [DMEM with 10% DMSO (Mediatech, Inc., 
Corning, New York, USA)]. Vials were labelled and frozen at -80°C for 24 h before 
being stored in liquid nitrogen.        
To defrost a cell line, a frozen vial was taken out from the liquid nitrogen tank, put on 
dry ice and transported to the laboratory. The vial with frozen cells was then defrosted 
in the Stuart water bath (Cole-Parmer, St. Neots, UK) at 37°C for 3 min. The 1 mL 
cell suspension was transferred into a 15 mL Falcon™ tube. Using a 10 mL serologica l 
Fisherbrand™ pipette (Thermo Fisher Scientific, Waltham, USA), 9 mL cell culture 
media was added gradually to avoid cell death due to high osmotic pressure caused by 
DMSO. The cells were separated from DMSO containing media by centrifugation for 
3 min at 1000 rcf. The supernatant was removed and the cell pellet suspended in 1 mL 
fresh media. The new cell suspension was pipetted in a 10 cm Petri dish containing 
9 mL media.  




1.3 Cell counting 
Cells were counted with the Countess automated cell counter (Invitrogen, Thermo 
Fisher Scientific, Waltham, USA). The media was removed from a 10 cm Petri dish 
and the adherent cells were washed with 10 mL PBS and incubated with 1 mL 
Trypsin-EDTA. The incubation times ranged from 1 to 5 min according to cell line. 
Nine mL fresh media was added into the 10 cm Petri dish to stop trypsination and to 
homogenise the cells. Ten μL of the cell suspension was used to determine the number 
of cells per millilitre by homogenising it with 10 μL of the diazo dye 0.4% 
Trypan-Blue (Invitrogen, Thermo Fisher Scientific, Waltham, USA) solution. Half of 
the volume was pipetted into a Countess counting chamber slide (Invitrogen, Thermo 
Fisher Scientific, Waltham, USA) and put into the counting chamber.  Due to its ability 
to permeate damaged cell membranes of dead cells, the dye Trypan-Blue is able to 
exclude living cells as it is not able to permeate the cell membrane (Strober, 2001). 
1.4 Generation of reporter cell lines 
1.4.1 Lentivirus production 
The Bmal1-luc (pLV7-Bsd-P(Bmal1)-dLuc) and Per2-luc (pLV7-Bsd-P(Per2)-dLuc) 
reporter construct were introduced in the human colon cancer cell line HCT116 
(ATCC® CRL-247™) (Liu et al., 2008; Ramanathan et al., 2012). Highly 
proliferating HEK293FT cells were cultured in 10 cm Petri dishes in DMEM media 
containing 10% FCS and 100 µg/mL Penicillin/Streptomycin. A confluent dish of 
HEK293TF cell was split 1:1 24 h before transfection to ensure 60% to 80% 
confluency at time of transfection. On transfection day, the Transfection (TF)-DNA 
complex, was calculated. For a 10 cm Petri dish, media was added to the TF-DNA 
complex to obtain a final volume of 1 mL which was added later on the HEK293TF 
cells. The TF-DNA complex was composed of plasmid, 1.918 µg/µL packaging 
(pCMVR8.74) (Addgene, Cambridge, USA) and 2.496 µg/µL envelop (pMD2.G) 
(Addgene, Cambridge, USA). The ratio between the three components was 3:2:1. The 
ration between the TransIT®-Lenti (Mirus BIO LLC, Madison, USA) transfect ion 
reagent and the TF-DNA complex was 3:1. A final TF-DNA complex contained thus 
7 µg plasmid, 3.5 µg packaging, 1.75 µg envelop and 21 µg TransIT®-Lenti 
transfection reagent. According to the DNA concentrations, the volumes of the 




packaging, envelop and TransIT®-Lenti transfection reagent were calculated and FCS 
and antibiotic free DMEM media were added to obtain a final volume of 1 mL. The 
TF-DNA complex was mixed and incubated at room temperature for 20 min. 
Meanwhile, the media from the HEK293TF cells was replaced with an 
antibiotics-containing media, to avoid any contaminations. The TF-DNA mix was 
added, then followed with a 48 h incubation time at 37°C and 5% CO2. Once the 48 h 
incubation time was completed, the media containing the lentivirus was collected and 
centrifuged at 400 rcf for 10 min at 4°C. The supernatant was filtered through a 
0.22 µm filter and aliquots of 1 to 5 mL were made and frozen at -80°C for further 
use.  
1.4.2 Lentiviral transduction 
With the lentiviral transduction, the Bmal1-luc reporter was introduced into HCT116 
cells. HCT116 cells were cultured to reach a confluence of 50% in a 10 cm Petri dish 
on the transduction day. The media was removed and 1 mL of the previously produced 
lentivirus solution, with 8 µg/mL polybrene, was pipetted onto the cells and incubated 
for 6 h at 37°C and 5% CO2. After the incubation time was completed, the access to 
the lentiviral solution was replaced by 10 mL DMEM media with 10% FCS and 
100 µg/mL Penicillin/Streptomycin. After another 3 to 4 days, the successfully 
transduced cells were selected from the non-transfected cells using the antibiot ic 
blasticidin (Corning, New York, USA). As the plasmid carried a blasticidin resistance 
gene, no cell death should occur following the exposure of blasticidin concentrations. 
Prior to the transduction, HCT116 cells have been subjected to 1 µg/mL, 2 µg/mL, 
4 µg/mL, 8 µg/mL, 16 µg/mL or 32 µg/mL blasticidin, followed by a visual 
examination of living HCT116 cells under the microscope. It was observed that under 
8 µg/mL blasticidin cell death occurred in 80 to 90% of the cells (data not shown). No 
cell survival was seen under 16 µg/mL blasticidin. Thus, a final concentration of 10 
µg/mL blasticidin was used for selection. The transduced HCT116 cells were kept 
under antibiotic selection for 2 weeks before switching to blasticidin free DMEM 
media.  




1.5 In Vitro synchronisation protocols 
1.5.1 Defining target cellular conditions for synchronisation protocols  
The purpose of these initial experiments was to determine the number of cells as well 
as the luciferin concentration needed to synchronise a cell population which remained 
synchronised for at least 6 days. This allowed to conduct circadian experiments, while 
keeping the cells synchronised to stable periods, acrophases and amplitudes. All 
parameters were tested by seeding a given cell suspension in 35 mm NUNC Petri dish 
(Scientific Laboratories Supplies, Nottingham, UK). Such a cell suspension contained 
30 000, 50 000, 75 000, 100 000 or 200 000 cells in 3 mL media. These conditions 
were applied to cell populations which were synchronised either with dexamethasone 
(see chapter II.1.5.2) or with temperature cycles (see chapter II.1.5.3). Next, the 
different luciferin concentrations were tested in order to optimise bioluminescence 
detection. The aim was to define a balanced luciferin concentration which would 
provide luciferin for a 7 day long experiment and ensure stable periods, acrophases 
and amplitudes of the synchronised cell population (Feeney et al., 2016). The 
optimisation of the luciferin concentration was done in 35 mm NUNC Petri dishes 
seeded with 50 000 Hepa1-6 Per2-luc cells in 3 mL phenol red free media. Upon cell 
thawing, luciferin was added in the media so as to obtain concentratio ns of 50 µM, 
100 µM, 200 µM, 400 µM, 800 µM and 1.6 mM. Each concentration was tested in 
three individual dishes. Immediately after seeding, cells in each Petri dish were 
subjected to temperature cycle D (Figure II-2) as described in 1.5.3, and put into the 
LumiCycle (Actimetrics, Willmette, USA) to record bioluminescence for one min 
every 10 min over a period of 6 to 7 days. The data were recorded and analysed as 
described in the paragraph “Statistical Methods”. 
1.5.2 Synchronisation with dexamethasone 
Cells were synchronised with a single dexamethasone shock (Balsalobre et al., 2000). 
Seventy-five-thousand cells in a 3 mL media cell suspension were seeded in a 35 mm 
NUNC Petri dish. Synchronisation was started by adding 3 µL of a 1 mM 
dexamethasone to generate a working concentration of 1 nM dexamethasone (Sigma 
Aldrich, Gillingham, UK). Cells were exposed for 30 min to the dexamethasone-med ia 
solution. The Media was then removed by suction. The cells were washed with 1 mL 




PBS, then 3 mL phenol red free DMEM (Sigma Aldrich, Gillingham, UK) containing 
100 µM luciferin (Promega, Madison, USA) was added to the dish. The 35 mm NUNC 
Petri dishes were sealed with a thin layer of silicone grease (RS Components Ltd., 
Corby, Northants, UK) and put into a LumiCycle (Actimetrics, Wilmette, USA) for 
bioluminescence monitoring (Chapter II.1.7).  
1.5.3 Synchronisation with temperature cycles 
It has been shown that temperature cycles mimicking the in vivo core body temperature 
rhythms were able to synchronise the circadian clocks of cells in culture (Brown et al., 
2002). To further study the synchronisation properties of exogenous temperature 
cycles in our model systems, a 50 000 to 100 000 cells were seeded in 3 mL phenol 
red free DMEM with 100 µM luciferin in 35 mm NUNC Petri dishes. Dishes were 
sealed with silicone grease and put into the LumiCycle. The optimal temperature cycle 
protocol was determined by testing several different temperature cycles. The 
temperature cycles differed by (i) period length (T = 24 h for schedules A-D, G, H; 
T = 20 h for schedule E; T = 26 h for schedule F) and (ii) subsequent entrainment 
using temperature cycles consisting of 12-h temperature plateaus differing by 1°C 
(schedules C, D, E and F) or subsequent “free-running” condition at constant 37°C 
(schedules A and B) (Figure II-2).  





Figure II-2: Temperature cycles tested in Hepa1-6 Per2-luc.  
Temperature cycles A to D, G and H were programmed to entrain cells to a 24 h  period 
whereas cells subjected to the temperature cycles E and F were entrained to a 20 h and 26 h 
period respectively. Temperature cycle A (5-5-constant) started at 37°C for 12 h and 
decreased to 32°C for another 12 h. This cycle was repeated once, then the temperature was 
kept constant at 37°C. Temperature cycle B (5-constant) started with a temperature plateau 
at 37°C for 12 h followed by 32°C for another 12 h, then the temperature was kept constant 
at 37°C. Temperature cycles C (5-5-1-1-1) and D (5-1-1-1-1 involved initial ”temperature 
shocking cycles” similar to those in schedules A and B, followed with 24 h temperature cycles 
with alternating 12-h-plateaus at 37°C and 36°C. The temperature profiles of schedules E (5-




1-1-1-1) and F (5-1-1-1-1) were similar to schedule D except the cycle period which was set 
at 20 h for schedule E (alternating10-h temperature plateaus at 37°C and 36°C), and at 26 h 
for schedule F (alternating 13-h temperature plateaus at 37°C and 36°C). 
In vitro circadian experiments were carried out on cell populations synchronised with 
temperature cycles. The purpose was to determine any time dependent changes in 
cellular toxicity which was assessed through the measurement of cell death, cellula r 
pharmacokinetics (drug uptake and efflux) and pharmacodynamics (drug-induced cell 
cycle arrest, apoptosis or autophagy (Figure II-3). Depending on the circadian 
experiment, e.g. cell sampling for (i) RNA extraction, aiming at the determination of 
circadian patterns in gene expressions or (ii) measuring cell proliferation and 
determining cell cycle phase distribution, measurements were taken every 4 h or 6 h 
in a 24 h period. In order to accommodate a 24 h circadian experiment within a 12 h 
working schedule, cells were subjected to antiphase temperature cycles. For example, 
if temperature cycle D (5-1-1-1-1) starts at 37°C, an antiphase temperature cycle 
would start at 32°C. The time of onset of the 12 h plateau at 37°C was defined as Time 
0 (T0). Consequently, Time 12 (T12) corresponded to the start of the 12 h plateau at 
32°C or 36°C. For the circadian experiments involving antiphase temperature cycles 
starting at 18:00, this clock hour would then correspond to T0 and T12. Sampling cells 
or supernatants at T02, T06, T10, T14, T18 and T22 would hence take place at clock 
hours 08:00 (T02 and T14), 12:00 (T06 and T18) and 16:00 (T10 and T22). Such 
circadian or chronopharmacology experiments were performed 2.5 days after the start 
of the selected temperature cycle schedule, to ensure adequate and stable circadian 
synchronisation of the cells in each culture dish. 





Figure II-3: Common features of the experimental design of the circadian in vitro studies. 
The figure depicts the time line from the start of temperature synchronisation until the start of 
several in vitro studies involving drug administration as well as RNA and cell pellet sampling 
at different circadin time points. This was done in order to determine circadian toxicity profile 
of FY26, expression of clock genes, circadian inhibiton of bioluminescence, time dependent 
intracellular FY26 uptake and cell cycle phase distribution following FY26 administration at 
different circadian times. 
1.6 Cytotoxicity assessment with Sulforhodamin B Assay  
FY26 in vitro cytotoxicity was assessed by using the Sulforhodamin B (SRB) assay. 
This assay is based on the measurement of intracellular protein content (Skehan et al., 
1990). Sulforhodamin B is a colorimetric assay which stains proteins by binding to 
protein basic amino residues depending on pH. This assay was chosen because of its 
advantageous sensitivity, reproducibility and linearity as compared to tetrazolium 
assays like MTT and XTT (Keepers et al., 1991; Rubinstein et al., 1990). It was further 
used to determine the IC50 of FY26 both in synchronised and in non-synchronised 
Hepa1-6 Per2-luc, Hepa1-6 Per2-luc shBmal1 and HCT116 Per2-luc cells. The 
measurements were carried out using a standard protocol (Skehan et al., 1990). Four 
thousand Hepa1-6 cells and 8 000 HCT116 cells in 200 μL media per well were seeded 
irrespective of subclone in a 96-well FALCON plate (Corning, New York, USA). To 




determine the IC50 in non-synchronised cell cultures, cells were incubated for 48 h at 
37°C and 5% CO2 to adhere and grow. In contrast, cells on a circadian experiment 
underwent temperature synchronisation immediately after seeding. After 2 days for 
non-synchronised cells, and 2.5 days for synchronised cells, cells were exposed to the 
vehicle (control) or to different drug concentrations as shown in Table II-1. 
Table II-1: FY26 concentration scales used for the determination of the FY26 IC50 
concentrations. 
Concentration Scale Concentrations included (µM FY26)  
A 100, 10, 1, 0.1, 0.01 and 0.001 
B 100, 10 , 6 , 3 , 1 and 0.1  
C 12, 10 , 8 , 6 , 4 , 2 , 1 , 0.5 and 0.1 
D 20 , 16 , 12 , 8 , 4 , 2 , 1 , 0.5  and 0.25 
E  16, 12, 10, 8, 6, 4, 2, 1 and 0.5  
F  30 , 15 , 10 , 8 , 6 , 4 , 2 , 1 and 0.5 
G  21, 14 , 7 , 6 , 5 , 4 , 2 , 1 and 0.5  
H  3.2, 1.6, 0.8, 0.4, 0.2, 0.1 , 0.05, 0.025  and 0.0125  
I 25.6, 12.8, 6.4, 3.2, 1.6, 0.8, 0.4, 0.2 and 0.05  
 
Six to 18 wells of a 96-well plate were treated with the same drug concentration or 
vehicle control. After completion of the 24 h drug exposure, the drug-media was 
removed, cells were washed with 200 µL PBS and new drug-free media was added. 
Cells were allowed to recover for 3 days before protein content determinations. The 
cells were fixed by adding 50 μL of cold 50% trichloracetic acid (TCA) (Sigma 
Aldrich, Gillingham, UK) directly into the media to obtain a final working 
concentration of 10% TCA. After 1 h of incubation at 4°C, cells were washed 10 times 
under slow running tap water, then air-dried. The fixed cells were treated with 50 μL 
of 0.4% SRB (Sigma Aldrich, Gillingham, UK) solution using 1% acetic acid (Sigma 
Aldrich, Gillingham, UK) as vehicle for 30 min. Cells were washed 5 times with 1% 
acetic acid and air dried. Two hundred µL of 10 mM Tris Base (pH 10) (Fisher 
Scientific, Waltham, USA) was added in each well and incubated for 1 h before 




measuring the absorbance at 570 nm using a Cytation 3 (Biotek, Swindon, UK) plate 
reader. The obtained endpoint absorbance measurements of the colorimetric assay 
were normalised by setting the average of the control 100%. The data points presenting 
the protein content after the incubation of different FY26 concentrations were divided 
by the hundreds part of the average absorbance of the control. The obtained normalised 
data were plotted against the negative logarithms of the FY26 concentration in µM. 
The IC50 was calculated as the non-linear fit of the logarithm of the concentration 
against the response using Graph Pad Prism 6 (GraphPad Software, Inc., La Jolla, 
USA). 
1.7 Real-time bioluminescence recording 
Bioluminescence measurement is based on the oxidation of luciferin to oxylucifer in 
under the contribution of luciferase, adenosine triphosphate (ATP) and oxygen (O2) 
(Figure II-4). A by-product of this reaction is light (photons) (Buccioni et al., 2011). 
In order to study the synchronisation properties of dexamethasone shock, temperature 
cycles and the influence of drug on circadian genes expression, two different luciferase 
reporter with the promoter of either Per2 or Bmal1were used (Chapter II.1.1).  
 
Figure II-4: Oxidation reaction of luciferin with luciferase.  
This chemical reaction depicts the formation of photons as a side product of the reduction of 
luciferin to oxyluciferin in the presence of oxygen (O2) and adenosine triphosphate (ATP) 
(Buccioni et al., 2011). 




To start recording real time bioluminescence, 50 000 up to 100 000 cells harbouring a 
stable luciferin reporter construct were seeded in 35 mm NUNC Petri dishes 
containing 3 mL phenol red free and high glucose (4.5 g/mL) DMEM (Sigma Aldrich, 
Gillingham, UK) media. The media further contained 20 mM Hepes (Life 
Technologies, Carlsbad, USA), 3.75 mM L-glutamine (Prep room Life Sciences, 
University of Warwick), 100 µg/mL Penicillin/Streptomycin (Prep room Life 
Sciences, University of Warwick), 5% heat inactivated FCS and 100 µM lucifer in 
(Promega, Madison, USA). Dishes were sealed with a thin layer of silicone grease and 
put into the LumiCycle (Actimetrics, Wilmette, USA). The LumiCycle is a black, 
closed apparatus that was put within a temperature programmable incubator which 
allowed to synchronise the cells (Figure II-5). The LumiCycle is equipped with four 
photon multiplier tubes (PMT) which are located 2.34 cm above a turntable with 32 
slots, in which sealed NUNC Petri dishes can be placed. Sealing the dishes served the 
purpose to avoid media evaporation as humidity was set to 0% during the whole 
experimental duration to avoid any damage to the PMTs. The bioluminescence of each 
cell culture dish was measured through counting the number of photons detected by 
the photomultipliers over 1 min, every 10 min for a minimum of 4 days, and up to 7 
days.  
 
Figure II-5: Experimental setup to record circadian changes in real-time bioluminescence.  




1.8 RNA extraction and Reverse Transcription 
Gene expression patterns were determined by RNA extraction from cells and 
transcription to cDNA. The amount of gene expression was then quantified by 
Real-time PCR. RNA was sampled from synchronised or non-synchronised as well as 
from treated or non-treated cells cultured in wells of a 6-well plate (Falcon) (n = 3). 
Cells in a 6-well plate (Thermo Fisher Scientific, Waltham UK) were washed with 1 
mL PBS and suspended in 1 mL Trizol (Thermo Fisher Scientific, Waltham, UK). The 
cell-Trizol suspension was transferred in a prelabelled 1.5 mL micro tube (Sarstedt, 
Nümbrecht, Germany). Cells were frozen at -80°C until the sampling process was 
finished. The RNA extraction started with defrosting the cell-Trizol samples at 20 to 
22°C. Samples were kept on ice throughout the extraction and reverse transcript ion 
process to avoid degradation of the RNA. The defrosted samples were centrifuged for 
1 min at 106 rcf at 4°C in order to separate cell debris from the diluted RNA, DNA 
and proteins. The supernatant was pipetted into a new pre-labelled tube and 200 μL of 
chloroform (Thermo Fisher Scientific, Waltham, UK) was added into each sample. 
The samples were gently mixed for 10 sec using a Stuart vortex mixer (Cole-Parmer, 
St. Neots, UK) and incubated for 3 min at 20 to 22°C. This step was crucial to separate 
DNA, RNA and proteins. The formation of the three phases was promoted by 
centrifugation for 15 min at 15294 rcf at 4°C. The upper transparent phase contained 
RNA, the middle white phase contained DNA and the lower pink phase contained the 
proteins. Using a 200 μL pipette (Eppendorf, Wesseling-Berzdorf, Germany), 400 μL 
of diluted RNA were taken out and transferred to a new prelabelled 1.5 mL micro tube. 
The RNA was precipitated by adding 500 μL isopropanol (Thermo Fisher Scientific, 
Waltham, UK) into each sample. The samples were incubated for 10 min at 20 to 22°C 
to ensure a complete precipitation of the RNA. The RNA was separated from the 
supernatant by centrifugation for 10 min at 15294 rcf and 4°C. The supernatant was 
carefully eliminated from the white pellet and 1 mL 75% Ethanol (VWR Chemica ls, 
Lutterworth, UK) was added into each sample. The samples were again centrifuged 
for 5 min at 5974 rcf at 4°C. Ethanol was removed and the white pellet was left at 20 
to 22°C to air dry. Once the white pellet has become transparent, the RNA was diluted 
in 15 μL diethylpyrocarbonate (DEPC, Amresco, Radnor, USA) water which was free 
from RNAase and DNAase. The next step involved the elimination of remaining DNA 




in the diluted RNA samples. According to the number of samples, a master mix of 
DNase Buffer (Promega, Madison, USA), DNase and (Promega, Madison, USA) 
DEPC water was prepared. Per sample, the master mix contained of 1 μL DNase 
Buffer, 3 μL (3U) DNase and 2 μL DEPC water. A total amount of 6 μL 
DNA-elimination mix together with 3 µL diluted RNA was pipetted into 0.2 mL PCR 
tubes (Starlab, Milton Keynes, UK) and incubated for 30 min at 37°C in order to digest 
the remaining DNA. The DNase was inactivated by adding 1 μL Stop Solution 
(Promega, Madison, USA). All samples were run on a 1% Agarose gel (Geneflow, 
Lichfield, UK) to confirm the success of the genomic DNA elimination. To produce 
the gel, 1 g Agarose was weighed in and suspended in 100 mL 1:5 TBE-DEPC water 
(Prep room, Life Sciences, University of Warwick). The suspension was heated up in 
the SHARP microwave (Scientific Laboratory Supplies, Nottingham, UK) at P80 for 
2 min. Once the dilution cooled down and no bubbles sustained, the warm solution 
was poured into the electrophoresis plates. Whilst the gel was hardening, a mix 
containing 1 μL Midori Green (Geneflow, Lichfield, UK) and 8 μL DEPC water was 
prepared. One μL of DNA free RNA samples were added into each sample. One 
sample was treated with 1 μL DNA ladder (GeneDireX, Las Vegas, USA) instead of 
RNA. A total amount of 10 μL was pipetted into the pockets of the gel. The gel was 
covered with 1:5 TBE-DEPC water. The electrophoresis plates were covered and the 
separation of the RNA samples from possible DNA fragments was started by the 
exposure to 120 V and 140 A. The amount of RNA in a DNA free solution was 
determined with the BioDrop µLite (BioDrop, Cambridge, UK). The 
spectrophotometer was calibrated with 1 μL DEPC water. The amount of RNA per 
sample was then determined by using 1 μL per sample which was pipetted on the 
sensor. The amount of RNA was measured in ng/μL. Additionally, the ratio of 
A260/A230 and A260/280 representing the phenol/chloroform and 
protein/background purity was determined respectively. Based on the RNA amount 
per sample, DEPC water was added to generate a final concentration of 200 ng/μL in 
each sample. In order to start the Reverse Transcription, a master mix of 1 μL (200 ng) 
Random Primers (Thermo Fisher Scientific, Waltham, UK), 1 μL 10 mM dNTP Mix  
consisting of equal volumes of 100 mM dATP, dCTP, dGTP and dTTP (VWR, UK) 
and 8 μL DEPC water per sample was prepared according to the total number of 
samples. Per sample, 10 μL of the master mix and 2 µL of RNA (400 ng/μL total RNA 




concentration) were pipetted into the new 0.2 mL PCR tubes. The mixture was heated 
up for 5 min at 65°C. Per sample, 6 μL containing 2 μL 0.1 M DTT (Invitrogen, 
Waltham, USA) and 4 μL 5X First-Standard Buffer (Invitrogen, Waltham, USA) were 
added. The content per tube was gently mixed and incubated for 2 min at 25°C. The 
reverse transcription reaction was initiated by transferring 1 μL (200 U) of Superscript 
II RT (Invitrogen, Waltham, USA) into each tube. The content was homogenised and 
then incubated in the Q-Cycler 96 (HAIN Technology, Byfleet, UK) for 10 min at 
25°C, 50 min at 42°C and 15 min at 70°C to stimulate reverse transcription. Once the 
temperature cycle was finished, the cDNA was stored until further use at -20°C. 
1.9 Real-time Polymerase Chain Reaction (PCR) 
The previously obtained cDNA was used to determine circadian clock gene 
expression. Therefore, Real-time PCR (RT-PCR or qPCR for quantitative PCR) was 
applied to determine the expression of the clock genes Bmal1, Per2 and Rev-erbα. 
36B4 was chosen as a reference housekeeping gene as its expression remained stable 
(Ramanathan et al., 2012; Zhang et al., 2016). Three technical replicates were taken 
from each of the 3 biological cDNA replicates. Thus, 9 samples corresponded to each 
experimental condition. Based on the number of samples, a reaction mix was prepared. 
The reaction mix for one sample was composed of 0.4 µL forward primer 0.4 µL 
reverse primer (Integrated DNA Technologies BVBA, Leuven, Belgium), and 3.2 µL 
purified water from PURELAB® flex (ELGA Veolia, High Wycombe, UK) and 5 µL 
2X SensiFAST SYBER No-ROX Mix (Bioline, London, UK). Each gene required a 
different reaction mix since one reaction mix contained primer for only one gene. 
Thus, 5 different reaction mixes were prepared containing the forward and reverse 
primer of the genes Bmal1, Per2, Rev-erbα, LC3B and 36B4 (Table II-2). In a 96-well 
plate or 384-well plate (AXYGEN Scientific, New York, USA), 9 µL of reaction mix 
was pipetted in each well followed by the addition of 1 µL cDNA. The plate was sealed 
using MicroAmp® Clear Adhesive Film (Life Technologies, Carlsbad, USA) and put 
in the FluoroCycler® 96 (HAIN Technologies, Byfeet, UK). The samples were 
subjected to the preprogrammed temperature cycles consisting of an initial heating up 
phase for 2 min to 95°C. This was followed by a cycle at 95°C for 6 min and 60°C for 
25 min. This second cycle was repeated in total 40 times before the melting curve was 
initiated to test whether single and specific DNA products have been produced. 




Table II-2: Forward (F) and reverse (R) sequences of mouse (m) clock gene and autophagy 
primers. 
Primer Sequence 
m36B4-F 5` GCT GAT GGG CAA GAA CAC CA`-3 
m36B4-R 5` CCC AAA GCCTGG AAG AAG GA`-3 
mBmal1-F 5` GGC TGG ACG AAG ACA ATG AGC`-3 
mBmal1-R 5` GTT GTG GAA CCA TGT GCG AGT`-3 
mPer2-F 5` AGA GCA CAG GGT CTG GAG GA`-3 
mPer2-R 5` TGG AAC ACA GGT AGG GGG TAA`-3 
mRev-erbα-F 5` GGC TGA TTC TTC ACA CAC ACA C`-3 
mRev-erbα-R 5` GGT CTT GGG GTG GCT ATA CTG`-3 
mLC3B-F 5` CCC ACC AAG ATC CCA GTG AT`-3 
mLC3B-R 5` CCA GGA ACT TGG TCT TGT CCA`-3 
 
1.10 Time dependent pharmacodynamics endpoints of FY26 
1.10.1 Effect of FY26 on apoptosis 
In order to test the effect of FY26 on the induction of apoptosis, Hepa1-6 Per2-luc, 
Hepa1-6 Per2-luc shBmal1 and HCT116 Per2-luc cells from each well of a 6-well 
FALCON plate (Corning, Liversedge, UK) were incubated with different FY26 
concentrations (5 µM, 7.5 µM and 10 µM FY26) 2.5 days after the start of temperature 
synchronisation. The cell pellet sampling took place 24 h after the start of drug 
exposure. Cell pellets were sampled every 4 h in a 12 h time span using antiphase 
temperature cycles of the temperature program D as described in the previous chapter 
II.1.5.3. The whole media content in each well was transferred into a 15 mL tube to 
collect the dead cells (Sarstedt, Nümbrecht, Germany). Adherent cells in each well 
were washed with 1 mL PBS. PBS as well as media were pipetted into the 15 mL tube. 
Cells were treated with 300 μL Trypsin-EDTA. Trypsinisation was stopped by adding 
700 μL fresh media followed by the collection of the whole 1 mL cell suspension into 
the 15 mL tube. Cells were centrifuged at 200 rcf for 5 min at 22°C to separate the 
cells from the media. The supernatant was removed and the cell pellet was suspended 
with 5 mL PBS. In order to add the staining solution, PBS was removed from the cells 




after centrifugation (200 rcf, 5 min at 22°C). Each cell pellet was suspended in 100 μL 
staining solution composed of 2.5 μL of a 1 mg/mL Propidium iodide solution (PI, 
Cambridge Bioscience LTD, Cambridge, UK), 2.5 μL Annexin-V (Biolegend, San 
Diego, USA) and 95 μL 1X Binding Buffer (Biolegend, San Diego, USA), and 
transferred into a FALCON polystyrene flow cytometry tube (Corning, Liversedge, 
UK). Three controls were required, of which one was stained only with Annexin-V 
(5 μL Annexin, 195 μL 1X Binding Buffer) and a second one with PI (5 µL PI and 
195 μL 1X Binding Buffer). The third control was left unstained and diluted in 
200 μL 1X Binding Buffer only. After a 30 min incubation time in the dark at 22°C, 
the respective total numberss of apoptotic, necrotic and viable cells were determined 
by exposing cells to different lasers using a flow cytometer (Fortessa, BD Bioscience, 
Berkshire, UK). A yellow laser (YG561-610/20 nm) and a blue laser (B488-530 nm) 
were chosen to detect PI and Annexin-V respectively at 200 V. PI is able to penetrate 
the cell membrane of dead cells due to the loss of membrane integrity. Annexin-V is 
characterised by a high affinity towards phosphatidylserine. As the cell undergoes 
apoptosis, phosphatidylserine is translocated from the inner to the outer cell membrane 
resulting in Annexin-V binding. Through use of PI and Annexin-V in combination, 
apoptotic (Annexin-V positive, PI negative), necrotic (Annexin-V positive, PI 
positive) and viable cells (Annexin-V and PI negative) were detected due to a loss of 
membrane integrity according the cellular stage (Koopman et al., 1994; Vermes et al., 
1995). The Flowing Software 2.5.1 (by Perttu Terho, University of Turku, Finland) 
was used for data analysis. 
1.10.2 Time dependent effect of FY26 on cell cycle phase distribution 
Sample collection and preparation matched the description in 2.12 until the staining 
step. The cell pellet was suspended in 1 mL ice cold 70% ethanol and incubated for at 
least 1 h at 2°C to 8°C in order to fix them. Cells were allowed to stay fixed in 70% 
ethanol for up to 24 h until the sample collection at different time points was finished. 
Once all the cells were collected, the sample preparation took place simultaneous ly. 
Therefore, ethanol was separated from the cells through centrifugation at 200 rcf for 
5 min at 22°C and removed. The cell pellet was transferred into a polystyrene tube 
with 500 μL staining mix composed of 25 μL 1 mg/mL PI, 50 μL 100 mg/mL RNase 
(VWR, Lutherworth, UK) and 425 μL PBS. After 30 min of incubation, the cells were 




separated from the staining solution by centrifugation at 200 rcf for 5 min and 
suspended in 500 μL PBS. One replicate of the control was left unstained to better 
adjust the laser settings for the measurement with the flow cytometer (Fortessa flow 
cytometer, BD Biosciences, Wokingham, UK). A yellow laser (YG651-610/20 nm) 
with a voltage of 200 V was used during the whole measurements. The gating of the 
different cell cycle phases, G0/G1-phase, S-phase and G2/M- phase, was done with the 
free flow cytometry data analysis software “Flowing Software 2.5.1” developed by 
Perttu Terho (University of Turku, Finland). The gates were set using controls which 
were stained or not with PI in order to set a template for the gates. This template was 
subjected to all treated controls. The cell number was acquired by the software and 
further expressed as relative number of cells per phase normalised to the non-treated 
controls. 
1.11 Circadian Rhythm-Dependent in vitro Pharmacokinetics of 
FY26 
1.11.1 Aim of the study 
This study aimed to determine whether cellular chronopharmacokinetics would drive 
circadian patterns in in vitro toxicity. The main focus was the measurement of the time 
dependent cellular uptake, intracellular concentrations, and elimination of FY26 over 
the 72 h following initial drug exposure. The study further assessed circadian changes 
in the time (tmax) and quantity (Cmax) of maximum drug uptake, and subsequent 
intracellular and extracellular pharmacokinetics. 
1.11.2 Experimental design 
Fifty thousand Hepa1-6 Per2-luc cells per 3 mL media were seeded in each of 3 wells 
of a 6-well FALCON plate. In total, 60 6-well FALCON plates were prepared. Each 
of them corresponded to a different experimental condition. After seeding, half of the 
plates were put in a first temperature programmable incubator and the other half in the 
second incubator. The temperature cycle program D in the first incubator was in 
antiphase to the second one thus starting at 37°C in incubator 1 and at 32°C in 
incubator 2 (Figure II-6). After 2.5 days, the media was replaced by media containing 
1 µM FY26 for all the dishes except for the six “baseline” samples labelled as “0 h” 




which served as FY26-free controls. Cells were treated with 1 µM FY26 starting 2 h, 
6 h and 10 h after the last temperature switches (i) from 36 to 37°C after 2.5 days, 
corresponding to T02, T06 and T10 and (ii) from 37 to 36°C, corresponding to T14, 
T18 and T22. Following FY26 exposure at each circadian time point (T02, T06, T10, 
T14, T18 and T22), cells and media from 3 wells (triplicates of each experimenta l 
condition) of a 6-well FALCON plate were harvested 1 h, 3 h, 9 h, 12 h, 18 h, 24 h, 
30 h, 36 h, 48 h and 72 h after drug exposure in order to determine the in vitro 
chronopharmacokinetics of FY26 through the measurement of extracellular (media) 
and intracellular (cells) osmium concentrations (Figure II-6 and Figure II-7). 
Importantly, cells were exposed to 1 µM FY26 throughout the experiment.   
 
Figure II-6: Experimental design of time dependent intracellular FY26 uptake.  
Hepa1-6 Per2-luc cells were synchronised to antiphase 24 h temperature cycles with an initial 
5°C difference followed by cycles with a 1°C difference with a start at 37°C and a 12 h later 
decrease to 32°C for incubator 1 and  start at 32°C with an increase to 37°C for incubator 2. 
Cells were kept under synchronisation for the total experimental duration. After 2.5 days of 
synchronisation, cells were exposed to 1 µM FY26 at T02, T06, T10, T14, T18 and T22 with 
3 replicates per condition. 
With regard to the extracellular osmium concentration, 1 mL from each of 3 wells in 
a 6-well FALCON plate was transferred into a labelled 1.5 mL micro tube and 
centrifuged at 10 621 rcf for 4 min. With a 1 000 µL pipette (Eppendorf, Wesseling-
Berzdorf, Germany), 900 µL of the media supernatant were taken out and relocated 
into a new 1.5 mL micro tube. Those samples were stored at -80°C. The remaining 
media in each well was removed and cells were washed with 2 mL PBS in order to 




determine the intracellular osmium content. After the removal of PBS, cells were 
incubated with 300 µL Trypsin-EDTA for 3 min. The trypsinisation process was 
stopped by adding 700 µL fresh media. The cells were counted. The 1 mL media cell 
suspension was pipette into a 1.5 mL micro tube and cells were separated from the 
media through centrifugation at 10 621 rcf for 4 min. The supernatant was removed 
and the cell pellet was frozen at -80°C as well as the media sample for the 
measurement of osmium content with inductively-coupled plasma-mass spectrometry 
(ICP-MS).  
In order to ensure the collection of each cell pellet and media sample, I was kindly 
offered help from Doctor Swati Kumar. She sampled the cell pellets and media 
samples on Day 2 from 11:00 to 23:00.  
 
Figure II-7: Time schedule of media and cell pellet sampling referred to circadian time of 
drug addition, with corresponding clock hours and days of the experiment.  
After drug addition at T02, T06, T10, T14, T18 and T22 cells were harvested and media 
samples were taken at 1 h, 3 h, 9 h, 12 h, 18 h, 24 h, 30 h, 48 h and 72 h after the beginning 
of drug exposure. Cell pellets and media samples were stored at -80°C for ICP-MS. 
1.11.3 Drug content determination through inductively-coupled plasma-mass  
spectrometry  
In a next step, the osmium concentration in digested cells (cell pellet) and in media 
was determined. Cellular osmium content (189Os) was measured by incubating each 
cell pellet with freshly distilled 73% nitric acid and double deionized water overnight 
at 80°C. After the incubation time was finished, the resulting solutions were diluted 
with thiourea and ascorbic acid to a working concentration of 3.6% v/v nitric acid, 




10 mM thiourea and 0.1 g/L ascorbic acid. The addition of thiourea and ascorbic acid 
served the purpose to stabilise osmium and to prevent oxidation to OsO4 (Venzago et 
al., 2013). The sample preparation to determine the osmium concentration in the cell 
media was done by diluting 50 µL cell media with 4950 µL of stock solution 
containing 10 mM thiourea, 0.1 g/L ascorbic acid in 3.5% v/v nitric acid. The 
concentration of osmium in the cell and in the cell media was determined by ICP-MS 
(Agilent Technologies 7500 Series ICP-MS, Cheshire, UK) in no gas mode. Before 
the sample measurement, the ICP-MS was calibrated using calibration standards 
ranging from 0.1 to 100 ppm diluted in a solution of 36% v/v nitric acid, 10 mM 
thiourea and 0.1 g/L ascorbic acid. The isotope of erbium (167Er) was used as interna l 
standard. Data acquisition and analysis were carried out using ICP-MS B.03.06 
software (Agilent Technologies, Cheshire, UK). The amount of osmium was obtained  
in parts per million (ppm) and normalised to nanogramm per 1 million cells (ng Os/ 
million cells).  
Doctor Carlos Cano-Sanchez (Department of Chemistry, University of Warwick, and 
Coventry, UK) and myself prepared the samples and determined the osmium 
concentration with the ICP-MS.  
  




2 In Vivo Methodology 
2.1 Animals and housing 
In vivo studies were carried out using adult “wildtype” or PER2::LUC transgenic 
C57BL/6 mice, or CD1-Foxn1nu mice. Male C57BL/6 mice aged 5 to 9 weeks were 
used for the determination of circadian toxicity patterns of FY26 or FY25. The 
PER2::LUC C57BL/6 mouse served the determination of FY26 toxicity and its effect 
on the PER2 expression and core body temperature. This mouse was initia lly 
engineered by the laboratory team of Joseph Takahashi (UT Southwestern Medical 
Center, Dallas, SA) (Yoo et al., 2004). The luciferase gene was knocked in the 
sequence of clock gene Per2 after the terminal exon of the endogenous mPer2 locus 
resulting in the expression and translation of a PER2::LUCIFERASE fusion protein. 
It has been shown that PER2::LUC fusion protein is expressed in the SCN, pituitary, 
lung, tail, kidney and liver with highest expressions in the SCN and in liver. No 
phenotypic difference was shown between C57BL/6 wildtype mice and C57BL/6 
PER2::LUC mice (Yoo et al., 2004). The CD1-Foxn1nu mice are athymic 
immunodeficient nude mice on CD1 background. These male mice were implanted 
with 1 ∙ 106 Hepa1-6 Per2-luc cells in a 100 µL suspensions at 9 to 15 weeks of age, 
in order to investigate FY26 efficacy at different dosing times, in the absence of 
immunologic rejection of the cancer cells. 
C57BL/6 mice were purchased from Charles River (London). PER2::LUC mice were 
kindly gifted by Doctor Xiao Mei Li, from INSERM U935 (Villejuif, France) and bred 
in our animal facility. The CD1-Foxn1nu mice were either purchased from Charles 
River (London) or bred in the animal facility at Warwick University. A single up to 4 
mice were kept in Techniplast Blue Line 1284L individually ventilated cages (IVC) 
(Techniplast, Leicester, UK) under positive pressure and permanent ventilation in the 
animal facility unless otherwise specified. Mice had access to food and water ad 
libitum.  




2.2 Entrainment of mice using Light-Dark Cycles with light onsets at 
different real-times 
The purpose of the entrainment of mice to different light dark cycles was to fit a 24 h 
circadian experiment into a 12 h working day. This was achieved by exposing mice to 
regular alternations of light (L) for 12 h and darkness (D) for 12 h (LD12:12) with 
light onset and offset occurring at different clock hours. Light onset was defined as 
Zeitgeber Time 0 (ZT0), and dark onset as ZT12 under LD12:12 entrainment. For 
example, in order to treat a first group of mice at ZT06 and a second one at ZT18 at 
the same clock hour 13:00, light onsets were programmed at clock hours 07:00 and 
19:00 respectively (Figure II-8 B). The entrainment was achieved using a dedicated 
chronobiological cabinets (Eurobioconcept, Vitry, France) consisting of 5 
compartments each (Figure II-8 A). For each compartment a different light-dark cycle 
can be programmed. Each chronobiological cabinet is equipped with a system that 
provides adjustable continuous air flow through filters to each compartment, which 
are thus exposed to minimal environmental contamination and fresh air. Temperature 
and light intensity were automatically recorded through sensors in each compartment 
that were transmitting data wireless to a dedicated computer every 10 sec throughout 
the whole experimental duration starting with the beginning of the light-dark 
entrainment. Environmental temperature in the animal facility was kept between 20 
and 24°C. The light intensity in the cabinets varied between 100 and 160 lux at cage 
level. The light source was a 300*1200 LED Panel CW/DW/WW (Eurobioconcep t, 
Vitry, France) with 4200Lm/5200Lm. Room humidity was monitored daily by a 
humidity meter installed and kept between 45 and 65% respectively. All the mice had 
free access to food and water throughout each experiment.  





Figure II-8: Experimental set up of mice entrainment to LD 12:12 cycles. 
(A) Chronobiologic cabinet consisting of 5 compartments allowing the programming of 
different light dark cycles with a different light on and off set. (B) Example for an antiphase 
entrainment schedule using two compartments. 
2.3 Drug preparation 
The anticancer drug candidates FY26 and FY25 were synthesised and purified (> 98% 
purity) in the laboratory of Professor Peter J. Sadler in the Chemistry Department of 
the University of Warwick (Fu et al., 2010). Throughout the different studies, mice 
were injected with 20 mg/kg, 30 mg/kg, 40 mg/kg, 50 mg/kg, 60 mg/kg, 80 mg/kg or 
160 mg/kg of FY26 and/or FY25. Both drugs were diluted in the vehicle, composed 
of 1% TWEEN 80 (Sigma Aldrich, Gillingham, UK), 5% DMSO (Corning, New 
York, USA) and 94% of 0.9% Saline (Prep room, Life Sciences, University of 
Warwick). The drug preparation was done under laminar flow guaranteeing aseptic 
conditions. Each mouse was injected with a volume of 10 µL drug-vehicle dilution per 
gram body weight. The dose was confirmed following drug preparation by Doctor 
Carlos Cano-Sanchez using ICP-MS as described previously. 
With regard to the drug preparation, it was essential to know the number of mice 
receiving treatment as well as the average mouse body weight. Based on these data, 
the quantity of drug needed was calculated. The calculation for the treatment of 35 




mice with 50 mg/kg FY26 are explained in Figure II-9. This method required to 
determine the body weight of each mouse before injection in order to ensure the 
injection of the precise volume and dose. All injections were administe red 
intraperitoneally (i.p.) using 1 mL sterile Plastipak™ syringes and sterile 0.5 and 16 
mm Microlance™ 3 needles (BD, Wokingham, UK).  
 
Figure II-9: Example of FY26 dose calculation for in vivo studies.  
2.4 Humane endpoints 
Throughout the in vivo experiments, any mouse showing signs of pain or distress 
exceeding the severity limit ‘moderate’ was culled. Body weight loss was used as a 
marker for mouse welfare. A mouse with a body weight loss of 20% or more within 
24 h or a persistent body weight loss of 15% over 72 h without recovery was 
euthanized. Additionally, tumour-bearing mice were allowed to have a maximum 
tumour weight of 2 g. Mice with a tumour weight exceeding those limits, were 
sacrificed during the study but data obtained from these mice were still included in the 
study. All these regulations applied at any time and were followed regardless of the 
success of the ongoing experiments. 




2.5 Overview of in vivo studies 
Five mouse studies aimed to respectively determine the maximum tolerated dose 
(MTD) of FY26, the time dependent changes in the toxicity of this FY26 and FY25, 
the effects of FY26 on biomarkers of the CTS, including circadian rhythms in core 
body temperature and liver PER2 expression. The fifth study assessed the antitumour 
efficacy of FY26 and preliminary time dependent changes in tumour growths 
inhibition (Table II-3). The specific design details are explained in the following 
section




Table II-3: Overview of the in vivo studies (N=number) 
Study goal Specific objective Mouse 
strain (sex) 
Main endpoints Total N of 
mice 
N of mice per 
experiment 
N of experiment 
 
Dose Finding Determination of the 
MDT of FY26 and FY25 
C57BL/6 
mice (male) 




circadian toxicity profile 
of FY26 and FY25, and 
identification of the 
circadian time points of 
best and worst tolerability 
C57BL/6 
mice (male) 
Body weight change 
Survival 
234 78 3 
Histopathology  Determination of FY26-





apoptosis, necrosis tissue 
alterations 
6 6 1 
CTS effects on 
temperature 
Determination of FY26 
effects on core body 
temperature rhythm 




Core body temperature 
rhythm and body weight 
changes 
6 6 1  ̀




CTS effects on the 
liver clock 
Simultaneous 
determination of circadian 
patterns in PER2 liver 
expression and core body 
temperature following 




Circadian rhythms in PER2 
expression, and core body 
temperature, and changes in 
body weight 
9 3 3  
Tumour growth 
inhibition  
Determination of the 
therapeutic FY26 dose 




Tumour and body weight 18 18 1 




of tumour growth 
inhibition following FY26 
dosing at ZT06 or ZT18 
CD1-Foxn1nu 
mice (male) 
Tumour and body weight 20 20 1 
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2.6 Dose finding study 
2.6.1 Aim  
This study was conducted in order to determine the maximum tolerated dose level of 
FY26 and FY25, to be selected to further identify any circadian toxicity pattern in a 
follow up experiment. The requirement for the optimal dose levels was a body weight 
loss between 15 to 20%. 
2.6.2 Experimental design 
Twelve male C57BL/6 mice aged 5 to 6 weeks were housed in 4 cages containing 3 
mice each. Mice were used for 2 consecutive experiments and kept in the common 
animal facility with lights on at 07:00 and lights off at 19:00. Each dose was given as 
a single intraperitoneal (i.p.) injection. Eight to 9 weeks old mice in cages 1 and 2 were 
injected with vehicle (control) or FY26 (30 mg/kg, three mice). The body weights of 
all mice were measured 6 h after injection and daily for 5 days thereafter. On day 5, 
the same mice received a second i.p. injection of vehicle or FY26 (40 mg/kg). Body 
weight was measured as previously mentioned daily for 7 days. A further experiment 
involved the i.p. administration 40 mg/kg of FY26 to the 3 mice in cage 3 and 
60 mg/kg of FY26 to the 3 mice in cage 4, now aged 10-11 weeks, and subsequent 
body weight determinations as per previous protocol for 5 days. 
2.7 Circadian toxicity of FY26 and FY25 
2.7.1 Aim  
The purpose of this study was to investigate whether FY25 and FY26 toxicities would 
display a circadian pattern in vivo. The study involved three consecutive experiments 
with a similar design. Experiment (Exp) II and III had identical designs, whereas the 
design of Exp I differed slightly. First the common features and secondly the 
specificities of the Exp are outlined. 
2.7.2 Common features of experimental designs  
Two hundred-thirty four male C57BL/6 mice aged 5 to 9 weeks were purchased from 
Charles River (London, UK). Mice were allocated into cages hosting 1 to 3 mice per 
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cage. They were allowed to adjust for one week to the common animal facility before 
the start of light-dark entrainment in the dedicated chronobiological cabinets. Mice 
were distributed amongst 18 groups. Six groups of 18 mice each per drug and time 
point were injected with 50 mg/kg of FY25 or FY26 at ZT02, ZT06, ZT10, ZT14, 
ZT18 or ZT22. Three mice in each of six control groups were injected with vehicle 
only at the above-mentioned circadian time points. All the mice were aged 11 to 12 
weeks at the time of treatment administration. Mice were weighed twice a week before 
injection, and daily thereafter. Moreover, they were visually inspected every day 
following treatment. 
2.7.3 Specific aspects of each experiment design 
Specific aspects were related to the age of the mice upon purchasing, the time left for 
adjustment to the common animal facility, the allocation of mice to cages and groups, 
and the duration and schedules of light-dark entrainment.  
Mice arrived from the breeder at ages 5 to 6 weeks for Exp I, and 8-9 weeks for Exp 
II & II. Mice in the first Exp were allowed to adjust to the common animal facility for 
two weeks followed by an entrainment period of 30 days. The adjustment time of mice 
from Exp II & III was only 5 days long in the common animal facility before the start 
of the light-dark entrainment for 21 days. 
 
Figure II-10: Experimental differences in the allocation of mice in groups.  
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This figure presents the distribution of mice per treatment group and emphasises that in Exp 
I the control mice were entrained individually in two additional compartments whereas in Exp 
II & III all mice injected at one time point were entrained to the same light dark cycle. 
Regarding the allocation of mice, 8 compartments of the chronobiological cabinets 
were used. The light dark cycles in the first 6 compartments were programmed with a 
lights on at clock hours 05:30 to 17:30 (for ZT02 treatment, corresponding to 07:30), 
03:30 to 15:30 (ZT06), 01:00 to 13:00 (ZT10), 23:30 to 11:30 (ZT14), 21:00 to 09:00 
(ZT18), 19:00 to 07:00 (ZT22), 08:00 to 20:00 (Control ZT02, ZT06, ZT10) and 04:30 
to 16:30 (control ZT14, ZT18, ZT22). Each of the compartments contained 4 cages 
with 3 mice of which half of the mice were treated with 50 mg/kg FY25 and the other 
half with 50 mg/kg FY26. The circadian treatment times ZT02, ZT06, ZT10, ZT14, 
ZT18 and ZT22 corresponded to clock hours 07:30, 09:30, 11:00, 13:30, 15:00 and 
17:00 respectively. The last 2 compartments contained three cages with one mouse per 
cage serving as the vehicle control. Those mice were injected with the vehicle at clock 
hours 10:00 (ZT02), 10:30 (ZT14), 14:00 (ZT06), 14:30 (ZT19), 17:00 (ZT22) and 
18:00 (ZT10) (Figure II-10 and Figure II-11). 




Figure II-11: Entrainment protocol of Exp I.  
Eight light dark cycles were programmed enabling a treatment of 6 mice each with 50 mg/kg 
FY26 and FY25 at the circadian time points ZT02, ZT06, ZT10, ZT14, ZT18 and ZT22 in a 
12 h time span. The 6 control mice were programmed to 2 additional light dark cycles different 
from the mice treated with FY26 and FY25. 
Compared to Exp II & III, only 6 compartments of the chronobiological cabinet were 
used of which each compartment was programmed with a different light dark cycles 
with a light on and off set at 08:00 to 20:00 (ZT02), 04:30 to 16:30 (ZT06), 01:00 to 
13:00 (ZT10), 23:00 to 11:00 (ZT14), 19:30 to 07:30 (ZT18) and 16:00 to 04:00 
(ZT22). Treatment was thus possible at clock hour 10:00 (ZT02), 10:30 (ZT06), 11:00 
(ZT10), 13:00 (ZT14), 13:30 (ZT18) and 14:00 (ZT22). Each compartment hosted 13 
mice allocated in 5 cages of which 3 cages contained 3 mice and 2 cages 2 mice. Six 
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of the mice received treatment with 50 mg/kg FY25, another 6 mice with 50 mg/kg 
FY26 and the 13th moue was injected with the vehicle (Figure II-10, Figure II-12).  
 
Figure II-12: Entrainment schedule of Exp II & III to access circadian toxicity.  
Six light dark cycles were programmed to enable treatment of each mouse at ZT02, ZT06, 
ZT10, ZT14, ZT18 and ZT22 during daytime hours.  
2.8 Histopathology Study 
2.8.1 Experimental design  
Six male PER2::LUC C57Bl/6 mice, aged 12 to 15 weeks, were kept in LD12:12 with 
L from 07:00 to 19:00. Mice were treated with 4 intraperitoneal injections of FY26 
(50 mg/kg i.p., 4 mice) or vehicle (2 mice) at ZT06 every other day. Mice were 
weighed and visually inspected daily. Twenty-four hours after the fourth injectio n, 
mice were sacrificed, and liver, both kidneys, stomach, ileum, colon and the sternum 
were excised, washed in PBS and fixed in 10% Neutral Buffered Formalin (CellPath 
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LTD, Powys, UK). After 24 h in formalin, organs were transferred into PBS and send 
for slicing to the Histology Facility, University of Manchester (Mr Peter Walker). 
Histopathological lesions were kindly assessed by Dr Kishore Gopalakrishnan 
(University Hospital Coventry and Warwickshire, UK). 
2.9 Effect of FY26 administration on core body temperature 
2.9.1 Aim  
This was designed in order to assess the effect of FY26 on mice core body temperature 
representing one of the outputs of the circadian timing system.  
2.9.2 Implantation of the Anipill® and intraperitoneal temperature recording 
The continuous recording of intraperitoneal temperature involved the use of an 
implanted electronic capsule, equipped with a temperature sensor and tele-emitte r 
(Anipill®, Bodycap, Paris, France). The Anipill®, a 1.77 cm long and 0.89 cm wide 
capsule with a weight of 1.7 g, measured core body temperature every 5 or 15 min 
according to the investigator’s selection. The stored measurements were transmit ted 
to the data receiver, the Aniview Monitor® (Bodycap, Paris, France). The Aniview 
Monitor® was then connected to a computer for data uploads, and their organisat ion 
and visualisation in the Anipill Software V2 (Bodycap, Paris, France). The data files 
were then transferred into Excel formats for further analyses. In this experiment, core 
body temperature was measured every 5 min, and data were tele-transmitted through 
placing the monitor within 1 meter of the Anipill®- implanted mouse. The data 
synchronisation between the Anipill® and the Aniview Monitor® took place every 
other day (Figure II-13). 
The capsule was surgically implanted into six male C57BL/6 mice aged 9 to 10 weeks, 
before the start of circadian entrainment. Surgery tools were sterilised. Each Anipill® 
was activated using the Aniview Monitor® and the Anipill® activator device by placing 
the Anipill in the activator with the monitor next to it. The activation was initiated by 
pushing the “Start” button. Afterwards, the Anipill® was washed with mild detergent 
and sterilised with disinfectant (CIDEX PLUS®) for at least 10 h. On the surgery day, 
the Anipill® was taken out from the disinfectant solution and placed in a 10 cm Petri 
dish (Sarstedt, Germany) filled with sterile saline solution. Prior to implantation, each 
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mouse was injected with 100 µL of a solution of 0.01 mg/mL of buprenorphine 
(0.3 mg/mL Vetergesic, Bonaventura Locums LTD, UK) and 100 µL of a solution of 
0.04 mg/mL of meloxicam (0.5 mg/mL Metacam, Bonaventura Locums LTD, UK). 
The mouse was introduced to 1.5 to 3.5% isoflurane with an oxygen flow rate of 
2 L/min. The skin area to be operated was cleaned and a straight longitudinal incis ion 
of 1 to 2 cm of the skin, then the peritoneum was made using a sterile razor blade. The 
skin was separated from the abdominal muscle wall using the round tip of scissors. To 
open the abdomen, the muscle was held up with tweezers and a small horizontal 1 to 
2 cm cut was made. With sterile tweezer, the Anipill® was positioned into the left side 
of the peritoneal cavity. The peritoneum was then sutured, the skin moisturised with 
0.9% saline and closed with 3 to 4 wound clips. The mouse was allowed to recover in 
a cage situated on a heated mat.  
 
Figure II-13: Experimental procedure to measure core body temperature in mice.  
Mice were inspected 1, 2 and 4 h after surgery, then visually checked and weighed 
daily for 7 days. The staples were removed 7 to 14 days after surgery.  
2.9.3 Experimental design after implantation 
The mice were randomly allocated to 2 groups of 3 mice each and subjected to LD 
12:12, with L from 08:00 to 20:00 for Group 1, and from 20:00 to 08:00 for Group 2 
(Figure II-14). Mice were single housed with access to water and food ad libitum. 
Mice were kept under entrainment, while core body temperature was measured every 
5 min and automatically stored in the capsule’s memory throughout the experimenta l 
duration. They were injected intraperitoneally with the vehicle on day 34, then with 
FY26 (50 mg/kg i.p.) on day 43, and euthanized on day 55. The data transmiss ion 
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followed a 5 min synchronisation process between capsule and data receiver. The 
Anipill® was removed post mortem from the abdomen of each mouse, cleaned and 
deactivated.  
 
Figure II-14: Experimental set up of the determination of the effect of FY26 on the circadian 
clock using body temperature rhythm as a circadian biomarker.  
2.10 Effect of FY26 on PER2::LUC liver expression and core body 
temperature  
2.10.1 Aim  
This study aimed to determine the effect of FY26 on the circadian timing system and 
on the molecular clock, using the PER2::LUC mouse model. Towards this goal, liver 
PER2::LUC expression and core body temperature 24-h patterns were jointly 
measured at baseline and after a single i.p. injection of 50 mg/kg of FY26.  
2.10.2 Experimental design 
Nine PER2::LUC mice, aged 9 to 11 weeks, were entrained to antiphase LD12:12 
cycles, with L (light) onset at 07:00 for four mice, or at 19:00 for the other five animals. 
Treatment was scheduled at ZT06 and ZT18, corresponding to clock hour 13:00. The 
study consisted of 3 experiments, each of them including one mouse in a given LD 
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12:12 schedule, and two mice in an antiphase LD 12:12 regime or the reverse. The 
start of entrainment for Exp I was scheduled 2 weeks before the start of Exp II and 4 
weeks before the start of Exp III. Each group experienced a total entrainment period 
of 3 weeks which was split into 2 weeks of entrainment in the chronobiologic cabinets 
and one week of entrainment in the Real-time Biolumicorder (RT-BIO, LESA 
Technology, and Geneva, Switzerland) with the implantation of the Anipill® occurring 
2 weeks after the start of the LD 12:12 entrainment. Three RT-BIOs were kindly 
loaned by INSERM-Villejuif (France) to the Chronotherapy Team at WMS. The 
RT-BIO is equipped with a bioluminescence measuring system engineered for the 
continuous, non-invasive and high frequency measurements of bioluminescent gene 
expression in freely moving mice for weeks, thus enabling in vivo molecular circadian 
dynamics investigations. It consists of a mouse cylindrical metal cage, with a photon 
multiplier situated on the top of the cage, as well as a food hopper and water reservoir 
to ensure food and water supply ad libitum (Saini et al., 2013). The cylindrical cage is 
closed by a second cylindrical lead to ensure a complete isolation from external light 
sources. Through a ventilation system, air exchange was guaranteed throughout the 
experimental duration (Figure II-15). In order to study molecular clock function in 
vivo, transgenic mice expressing the fusion protein PER2::LUC were used. A water 
solution containing 0.78 mg/mL of luciferin filled the cage bottles. Since fur prevents 
the emission of photons, the area of the right lower back of the mice was shaved so as 
to predominantly count the photons emitted by the liver (Saini et al., 2013). This 
method allowed to investigate the effect of FY26 on predominantly liver PER2::LUC 
expression as a biomarker of the liver molecular circadian clock. The photon counts 
and locomotor activity records were stored on a connected PC. Data were then 
analysed with Spectrum Analysis (explained in “Statistical Methods”). 




Figure II-15: Real-time Biolumicorder (RT-BIO).  
The RT-BIO enables bioluminescence recording from living organism mice with the aim to 
study circadian gene expression given the linkage of such gene to the luciferase sequence and 
the supply of luciferin in drinking water. Due to the expression of the gene luciferase fusion 
protein and its reaction with luciferin, photons can be detected by the PMT.  
Two weeks after the start of entrainment, mice were implanted with the telemetr ic 
temperature sensor Anipill® as described in Section 2.8.2. Three days after surgery, 
mice were transferred into the RT-BIO for a 1-week adaptation including an additiona l 
synchronisation in the same LD12:12 as before surgery into this cage system. Mice 
were then exposed to constant darkness (DD). Feeding and drinking were ad libitum. 
With the intake of luciferin in drinking water, photons are produced as a by-product 
from the oxidation of luciferin to oxyluciferin and thus detected by the PMT. In order 
to minimise background noise related to the photons emitted by the bedding, mouse 
bedding was put into RT-BIO two days before the start of the experiment, so that such 
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“noise” could be recorded. After 1 week in DD, mice were injected with either vehicle 
or FY26 (50 mg/kg i.p.) at ZT06 or at ZT18, then PER2::LUC expression was 
monitored in the RT-BIO for 7 additional days. The injection of mice required the 
removal of the mice from their cylindrical cages. This was done under dim red light. 
This possibly would have resulted in false positive photon counts detected by the 
PMT, if the PMT was not turned off and the shutter had not been closed before 
removing the cylindrical lead to take out the mouse for injection. Throughout the 
whole experimental duration, PER2::LUC expression and core body temperature were 
both recorded every 1 min and every 15 min, respectively. Data transfer between the 
Anipill® and the temperature receiver was accomplished on day 5 to 6 during 
treatment. Mice were visually checked every other day. The whole procedure was 
repeated for mice in Exp II and III (Figure II-16). 
 
Figure II-16: Experimental set up of the effect of the PER2 expression in the liver clock.  
(A)Three experiments were included in this study with one mouse entrained to LD12:12 and 
two other mice to antiphase LD12:12 cycles. (B) The entrainment of Exp II and Exp III started 
2 weeks and 4 weeks later than Exp I onset. 
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2.11 Determining dose levels of FY26 to inhibit tumour growth 
2.11.1 Aim  
This study aimed to identify the therapeutic dose levels needed for FY26 to inhib it 
tumour growth. Such doses would then be used to determine whether tumour growth 
inhibition could differ according to circadian dosing time. 
2.11.2 Experimental design 
Tumour growth inhibition of FY26 was studied in 18 male CD1-Foxn1nu, aged 10 to 
11 weeks, using the Hepa1-6 model. The mice were allocated to 4 cages (cages 1 to 
4), harbouring 2, 3, and 4 mice each, respectively. Mice were kept in the common 
animal room of the BSU with lights on at 07:00 and lights off at 19:00. A cell 
suspension containing 1 ∙ 106 Hepa1-6 Per2-luc cells in 100 µL PBS was prepared and 
kept on ice until injection. For each mouse, two syringes were loaded with 100 µL cell 
suspension. Mice under anaesthesia were injected subcutaneously (s.c.) with 100 µL 
cell suspension into the left and right dorsum. Tumour growth and body weights were 
measured for the subsequent 6 days. On day 7, then on every other day for 18 days, 
mice were injected with an intra peritoneal injection of vehicle, 40 mg/kg, 60 mg/kg 
or 80 mg/kg of FY26. Both, tumour inoculation and treatments, took place at clock 
hour 13:00, which corresponded to ZT06. Tumour was inoculated in the procedure 
room and drug was administered in the common animal facility. Throughout the 
experimental duration, body weight changes and tumour growth were monitored daily 
until 18 days after the start of treatment (Figure II-17). 
 
Figure II-17: Time line of tumour growth inhibition study.  
Methods and Materials 
100 
 
2.12 Circadian tumour growth inhibition of FY26 
2.12.1 Aim  
The purpose of this experiment was to seek whether dosing FY26 near the times of 
best or worst tolerability would affect antitumour efficacy. 
2.12.2 Experimental design 
Antitumour efficacy was assessed following FY26 dosing at circadian time points ZT6 
or ZT18 using tumour growth as an endpoint in 20 male CD1-Foxn1nu mice. Mice 
were 4 to 5 weeks old and allocated to 6 cages containing either 4 or 3 mice each. 
Mice were entrained with opposite LD12:12 cycles to enable treatment at ZT06 or 
ZT18 at clock hours 13:00 and 13:15 respectively. Ten mice were entrained with L on 
from 07:00 to 19:00, and another 10 mice with L on from 19:15 to 07:15 for 4 weeks, 
prior to tumour inoculation. Tumour inoculation took place between 13:30 and 15:00 
clock hour under either blue or red light using anaesthesia. Seven days after tumour 
inoculation, treatment was started. Four mice were injected with vehicle and 6 mice 
with 50 mg/kg FY26 i.p. every other day at ZT06 or at ZT18 for 11 days (6 injections ; 
cumulative dose, 300 mg/kg). Body weights and tumour growth were measured every 
day until the day after the 6th injection, day 16. All the mice were euthanized seven 
days after the last treatment (end of experiment) or whenever human endpoints were 
exceeded (Figure II-18). 




Figure II-18: Experimental design of time dependent tumour growth inhibition study.  
(A) Schedule of light dark 12:12 entrainment. (B) Overview of the experimental time line.  
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3 Statistical Methods 
3.1 Calculation of the population doubling time 
The population doubling time describes the average time a cell population needs to 
double. In order to compute and calculate the PDT, cells were counted (described in 
chapter 2.3) every 24 h starting 24 h after cell seeding for up to 72 h. The PDT was 
calculated for individual cell counts every 24 h until the last day of cell counting by 
using the equation shown in Figure II-19. The PDT for the whole growth curve was 
obtained by calculating the average of the individual 24-h PDTs.  
 
Figure II-19: Equotion to calculate the population doubling time (PDT). 
3.2 Time series Analysis of in vitro bioluminescence 
The LumiCycle Analysis software Version 2.56 (Actimetrics, Wilmette, USA) was 
used to upload, to analyse and to export time series data into Excel (Microsoft Office 
Professional Plus 2013, Redmond, USA). In order to depict the time series in a graph, 
the background signal (photon counts of an empty spot in the turntable) was subtracted 
from the raw data. The transformed data were plotted in Graph Pad Prism 6. The 
two-sided running average was calculated by the average of the photon counts in a 
24 h time span and was then subtracted from the centre photon counts in each 24 h 
time span. For example, if the first photon count would have taken place at 15:49 clock 
hour and the last at 15:39 the next day, the average of all the photon counts obtained 
between 15:49 and 15:39 (next day) would have been subtracted from the photon 
counts measured at 03:45. Plotting the time series of the raw data and the time series 
of the detrended data would thus leave out the first 12 h of data (Figure II-20).  




Figure II-20: Example of raw (panle A) and detrended data (panel B) of bioluminescence time 
series. 
As shown in Figure II-20, bioluminescent reporter time series were first detrended, so 
as to visualise sinusoidal oscillations and to compute the rhythm characterist ics, 
including period, acrophase and amplitude. The period of an oscillation describes the 
interval of time between two peaks. The acrophase is the time at which the peak occurs 
in a periodic cycle, and the amplitude measures the difference between the maximum 
value at the acrophase and the mean of the oscillation, also called MESOR for 
midline-estimating statistic of rhythm (Figure II-23). The LumiCycle Analysis software 
was used to determine the period, acrophase and amplitude. Time series data were 
uploaded and imposed to a polynomial order of 5 to 7. The period, acrophase and 
amplitude were then calculated from 2.5 days after the start of synchronisation until 
the end of the experiment. The acrophase was normalised through the subtraction of 
the acrophase from the period and presented as acrophase relative to the period. The 
area under the photon counts curve (AUC) were further computed for specific time 
spans. The mean and the standard error of the mean (SEM) of the mentioned 
parameters were determined. 
3.3 Analysis of real-time polymerase chain reaction data 
The obtained Ct-values (cycle threshold) were analysed using the Fluoro-Software 
R&D 1.3.22 (HAIN Technologies, Byfeet, UK). The C t-values were defined as the 
number of cycles needed until the fluorescence signal was above the fluorescence 
background signal. The Ct-values were normalised to the baseline and the threshold 
was set at the start of the linear phase of the fluorescence curve. The obtained data 
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were exported to Excel and the quantification of the gene expression was analysed by 
using the 2∆∆Ct-method, also called “Livak Method”. The method normalised the 
expression of the interest gene against the reference gene. In a first step, the difference 
between the Ct-value of the interest gene control and the housekeeping gene (36B4) 
control [∆Ct (control gene)] as well as the difference between the treated gene and the 
treated housekeeping gene [∆Ct (treated gene)] was calculated. Next the difference 
between the difference of the control gene and treated gene was calculated [∆∆Ct 
(control gene – treated gene)] and the logarithm of the ∆∆Ct- value was taken to base 
2 (2∆∆Ct) (Livak & Schmittgen, 2001; Schmittgen & Livak, 2008). As Ct-value of each 
technical replicate of one biological triplicate was calculated, the median of the three 
technical replicates was picked and graphically plotted. The median C t-value of each 
technical replicate was statistically analysed using either ANOVA or Cosinor 
Analysis.  
3.4 Analysis of circadian rhythm dependent pharmacodynamics 
endpoints of FY26 
The number of apoptotic cells and that of cells in the different cell cycle phases in each 
sample were counted using a BD LSR Fortessa flow cytometer (BD Sciences, 
Berkshire, UK) and analysed with the Flowing Software 2.5.1 (by Perttu Terho, 
University of Turku, Finland). The untreated controls were used to set the condition 
for the analysis. Therefore, the results of the non-treated samples (controls) were 
depicted in dot plot diagram using the Flowing Software showing all single measured 
cells represented by a dot in the graph. The viable cells were situated in the lower left 
quadrant, the apoptotic cells in the right upper quadrant and the necrotic cells in the 
lower right quadrant. The gates were set separating the different cell population from 
each other. This template was then transferred to the treated cells. The number of 
apoptotic, necrotic and living cells were further normalised to the total number of 
events which were predefined as 10 000 cell counts per sample. The normalised data 
were depicted in Graph Pad Prism 6 and statistical test were conducted.  
The analysis of the cell cycle phases was done using the same software. FACS files 
were uploaded and the total number of events (10 000 cell counts) were presented in 
a histogram. Using the untreated control, the different cell cycle phases, G0/G1-phase, 
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S-phase and G2/M-phase, were selected. As for the analysis of the apoptotic cells, the 
same template was used to determine the number of events in each phase of the cell 
cycle on the treated controls. The number of cells in each cell cycle phase was further 
normalised to the number of events and depicted in Graph Pad Prism 6.  
3.5 Analysis of core body temperature and PER2 liver expression 
time series 
The time series of mouse core body temperature records obtained with the Anipill ® 
and the time series of the PER2::LUC liver expression recorded with the RT-Bio were 
analysed using Spectrum Analysis. Spectrum Analysis is based on the decomposition 
of periodic and frequently measured time series into different oscillations (Rayner, 
2001). As the core body temperature was measured every 5 to 15 min, and the PER2 
expression every min, the hourly average of the core body temperature and the PER2 
expression were calculated. The hourly data were used to apply Sampling-Resampling 
Spectrum Analysis. A 6-h sliding window of a 1-day window size was used for the 
core body temperature and a 2-h sliding window of a 1 day window size for the PER2 
liver expression. The period, acrophase and amplitude with a 1st harmonic (24 h 
period) and a 2nd harmonic (12 h period) was calculated and plotted. The period, 
acrophase and amplitude of core body temperature and PER2::LUC expression were 
calculated over the 24 h before and the 24 h after vehicle or FY26 injection. The data 
were analysed using Spectrum Analysis. The script was written by Doctor Qi Huang 
(Costa et al., 2013; Komarzynski et al., 2018).  
3.6 Analysis of tumour growth 
The Tumour burden was assessed by measuring the horizontal and vertical diameter 
(mm) of each tumour using callipers. The weight of each individual tumour in a given 
mouse was estimated by multiplying the smallest diameter by itself and then with the 
larger diameter. The product was then divided by two (Figure II-21). The obtained 
quotient represented the estimated tumour weight in mg, a standard procedure used 
for experimental chemotherapy studies (Tampellini et al., 1998).  




Figure II-21: Tumour measurement (panel A) and equation to calculate tumour weight (panel 
B).  
The tumour weights, collected throughout the experimental duration, were normalised 
to the tumour weight before the start of treatment and plotted in Graph Pad Prism 6. 
The changes in tumour weights according to drug dose or injection time were assessed 
by calculating the AUC and the slope of the linear regression of the tumour growth 
curve from the start of treatment until the end of experiment.  
3.7 Survival analysis 
Kaplan-Meyer Analysis was used to compare survival curves and to determine 
statistically significant differences between groups. Therefore, the number of observed 
deaths over a defined time span was computed in a survival diagram in Graph Pad 
Prism 6. After the defined end of the experiment, log-rank test was applied to test the 
statistical difference of the occurrence of an earlier death in one group as compared to 
the other one. The log-rank (Mantel-Cox) test (Figure II-22) calculates the probability 
between the number of expected events and the number of observed events. The 
equation calculates a p-value. For a p-value of p<0.05 the number of events between 
two groups is statistically different whereas a p-value of p>0.05 indicates that the 
difference between the groups is insignificant in view of the power of the experiment, 
that depends upon sample size and number of events (Goel et al., 2010). 




Figure II-22: Equation of the log-rank test to calculate the statistically difference between the 
survival of predefined groups. 
3.8 Cosinor Analysis 
Data obtained from sampling over time, regardless of in vitro or in vivo data were 
analysed using Cosinor Analysis. Cosinor Analysis describes a mathematical model 
which is able to estimate the pattern of a curve while eliminating the noise coming 
from raw data. Data sampled as a function of time were fitted to a cosinor funct ion 
using the least square method. The least square method describes the difference 
between the squares of the measurements and the squares of the estimated values 
according to the sampling time point. The mesor, acrophase and amplitude were 
computed in order to quantify the circadian characteristics of the data. The mesor is 
defined as the midline estimating statistic of rhythm, i.e. the mean of the fitted cosine 
function. The acrophase represents the time of the maximum in the fitted cosine 
function. The amplitude is the difference between the maximum of the cosine function 
and the mesor. These parameters are given with their statistical confidence limits  
(Figure II-23) (Cornelissen, 2014; Refinetti et al., 2007).  




Figure II-23: Curve characteristics of a cosine curve with the mesor, acrophase and amplitude 
(Cornelissen, 2014).  
In this thesis, data were fitted against a 24-h and 12-h period, also called 24-h and 12-h 
harmonic, with at least 4 data point per sample and measurements taken every 6 hours. 
Cosinor Analysis was done using IBM SPSS Statistics 24 (IBM, New York, USA) 
(Cornelissen, 2014; Li et al., 2013).  
3.9 Analysis of variance 
One-way, two-way or three-way ANOVA’s with or without repetitive measurements 
were used as a statistical tests. ANOVA stands for analysis of variance and was used 
to test whether there was a significant difference between groups. One-way ANOVA 
tested differences in one independent variable between groups. Multiple -way 
ANOVA’s compared groups regarding two or three independent variables and their 
interaction terms. The null hypothesis meaning that the population mean were equal 
in groups for all factors and no interaction between any two or three factors, was 
rejected if the p-value was calculated as p<0.05. ANOVA was conducted either using 
Graph Pad Prism 6 for the IC50-studies or RStudio.Ink, (RStudio, Boston, USA) for 
the pharmacodynamics and in vivo studies and the analysis of the period, phase or 
amplitude of in vitro time series data. The significance levels were defined as: p<0.01 
(*), p<0.001 (**), p<0.001 (***), p<0.0001 (***) and p<0.00001 (****). The null 
hypothesis was rejected with p-values > 0.05.  
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4 List of Reagents 
The following table summarised the reagents mentioned this chapter. It states from 
which company they were purchased as well as their LOT number. 
Reagent Company LOT/ Purchase number 
Acetic acid Sigma-Aldrich SZBF3440V 
Annexin V BioLegend B193871 
Annexin V Binding Buffer BioLegend B205844 







Dexamethasone SIGMA Life Science 101560166 
DNase Buffer Promega 0000106382 
DNase Stop Solution Promega 0000227803 
dNTP Set VWR 733-1364 
Dulbecco’s Modified 
Eagle’s Medium, high 
glucose 
SIGMA Life Science RNBF0188 
Ethanol absolute VWR Chemicals 16L214009 
HEPES Buffer Solution 
(1M) 
GIBCO by Life 
Technologies 
1894696 
HI-Res Standard Agarose Geneflow AGLF45140056 
Beetle Luciferin, 
Potassium Salt 
Promega In vitro: 0000195918 
In vivo: 0000248305 
Methanol VWR Chemicals 15D270505 





Purified water ELGA DN0494-023 
Primer Per2 Reversed IDT 69318473 
Primer Per2 Forward IDT 69318472 
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Primer Rev-erbα Reversed IDT 69318470 
Primer Rev-erbβ Forward IDT 69318471 
Primer Bmal1 Reversed IDT 69318469 
Primer Bmal1 Forward IDT 69318468 
Primer 36B4 Reversed IDT 69318467 
Primer 36B4 Forward IDT 69318466 
Primer LC3B Reversed IDT 73868232 
Primer LC3B Forward IDT 73868231 
Propan-2-ol Fisher BioReagents 1480987 
Propidium Iodide Biosciences  MLQ5500123358 
Random Hexamer 
Primers 
Thermo Scientific 00449534 
RNase free DNase Promega 0000205548 
Ribonuclease A 
(RNase A) 




TransIT-Lenti Reagent Mirus 61054350 
Tris Base Fisher BioReagents 152695 
Trifluoroacetic acid Sigma-Aldrich STBF6942V 
TRIzol® Reagent Ambion by life 
technology 
14174601 
Trypan Blue stain Invitrogen by Thermo 
Fisher Scientific 
1856900 
Silicon Grease RS Components Ltd 494-124 
Sulforhodamine B  Sigma Aldrich MKBT0470V 














III Results - Temperature Synchronisation 
 
  





Investigating the in vitro chronopharmacology of FY25 and FY26 requires adequate 
circadian synchronisation of the cell populations to be used in population assays. The 
experimental conditions should meet the following specifications: (i) to synchronise 
different types of cancer cell lines with a circadian period (a priori ranging from 18 to 
30 hours), (ii) to allow for cells to remain viable for a minimum duration of 5 days, so 
as to enable drug effects to be measured over a sufficient time span, (iii) to keep cells 
synchronised with a consistent period, amplitude and acrophase throughout the 
experiment. 
It is reported that dexamethasone shock was able to synchronise the circadian clocks 
of rat fibroblasts (Balsalobre et al., 2000). Further, it was described by the same team 
that exogenous temperature cycles mimicking core body temperature could also 
synchronise circadian rhythms of cultured fibroblasts (Brown et al., 2002). 
Dexamethasone shock was considered as a possible synchronisation method of murine 
hepatocarcinoma cells, using Hepa1-6 Per2-luc cell line as a model. Then, several 
candidate temperature cycles were tested to synchronise Hepa1-6 Per2-luc cells and 
to assess the consequence of genetic clock disruption on circadian entrainment through 
silencing clock gene Bmal1 using the Hepa1-6 Per2-luc shBmal1 cell clone. 
Furthermore, human colon cancer cell lines (HCT116 Per2-luc and HCT116 
Bmal1-luc) were subjected to the established “optimal” temperature cycle in order to 
determine its synchronisation properties on different cancer cell lines. Cell culture 
conditions were further optimised according to initial cell counts seeded and to the 
luciferin concentration used. The synchronisation properties of the temperature 
schedules tested, were determined for the circadian clock using bioluminescence 
reporters and mRNA circadian expressions of core clock genes Per2, Bmal1 and 
Rev-erbα. Further, I have explored the relationship between the circadian clock and 
the cell cycle at a cell population level using temperature cycle synchronised Hepa1-6 
cells with and without Bmal1 silencing. 
  




2 Synchronisation using dexamethasone shock 
In a preliminary study, 5% or 10% FCS in cell culture media proved adequate for 
properly growing Hepa1-6 Per2-luc cells (not shown). Thus, 5% FCS was used in 
media concentration for all subsequent in vitro experiments. Luciferin was added to 
the media at a final concentration of 100 µM, except when mentioned otherwise. 
To test whether a 30-min dexamethasone shock was a suitable method resulting in 
regular oscillations of Hepa1-6 cells, 75 000 Hepa1-6 Per2-luc cells were exposed to 
1 mM dexamethasone for 30 min. Per2-luc bioluminescence oscillations of raw and 
detrended data (subtraction of the running average as described in chapter II.2) were 
observed for 2 days after the onset of dexamethasone shock. 
 
Figure III-1: Synchronisation of Hepa1-6 Per2-luc cells by dexamethasone shock.  
Seventy-five thousand Hepa1-6 Per2-luc cells were incubated with 1 mM dexamethasone for 
30 min. The experiment was done in duplicate. Bioluminescence was recorded starting 
directly after washout. The media always contained 5% FCS. Time “0.0” refers to the end of 
dexamethasone exposure, when the media was replaced by dexamethasone-free media. 
Both replicates exhibited periods of 20.4 h and 24.3 h, with corresponding acrophases 
occurring at 15.8 h and 17.4 h (modulo the respective period) and amplitudes of 514 
and 388 photon counts per second. Yet, a steady decline in photon counts per second 
by 85.4% for replicate A and 57.8% for replicate B was observed from 0.9 days 
(replicate A) and 0.8 days (replicate B) until day 2. This decline in photon counts per 




second was coherent with a severe dampening of the oscillations thus likely reflect ing 
a substantial amount of cell deaths (Figure III-1and Figure III-2). 
 
Figure III-2: Period, amplitude and acrophase (modulo the corresponding period) of Hepa1-6 
Per2-luc after dexamethasone shock. 
These parameters were computed from time “0”, defined as time of serum shock end, using 
the detrended data time series of each replicate over 2 days.  
3 Circadian synchronisation of cell populations with 
exogenous temperature cycles 
3.1 Synchronisation of a murine hepatocarcinoma cell line with 
temperature schedules A and B 
Exogenous 24-h periodic temperature cycles were tested with the aim to identify those 
which would meet our preset requirements. Schedules A and B involved two (schedule 
A) and one (schedule B) 24-h periodic temperature cycles before subjecting the cells 
to constant 37°C until 5 days after the start of temperature synchronisation (chapter 




II.1). Both schedules were applied to 100 000 Hepa1-6 Per2-luc cells cultured in 5% 
FCS-containing media. 
 
Figure III-3: Synchronisation of Hepa1-6 Per2-luc by temperature cycles A and B.  
Panel A depicts the raw and detrended bioluminescence curves of Hepa1-6 Per2-luc subjected 
to temperature schedule A. Panel B shows the raw and detrended data of Hepa1-6 Per2-luc 
under the subjection of temperature schedule B. 
The raw data of Hepa1-6 Per2-luc bioluminescence curves are characterised by a 
broad distribution. This can be explained by a decrease in luciferase expression due to 
possible cell death or insufficient synchronisation. The high variability between the 
replicates on schedule A precluded the computation of a mean circadian period of 
Per2-luc expression, as individual period length ranged from 19.4 h to 32.6 h in the 5 
replicates. In contrast, the raw data of Hepa1-6 Per2-luc obtained under temperature 
schedule B, were characterised by a small variability resulting in a mean period 
(± SEM) of 20.2 ± 0.6 h (Figure III-3). Such periods represented the endogenous 
period of Hepa1-6 Per2-luc. The same variability was observed for the amplitudes. 




Under temperature schedule A, the amplitude exhibited broad single values ranging 
from 457 photon counts per second to 1803 photon counts per second. However, due 
to the small variability achieved under temperature schedule B, the mean (± SEM) 
amplitude was 85 ± 32 photon counts per second. Considering the acrophases, a small 
variability between single values was obtained under both temperature schedules. The 
mean (± SEM) acrophase under temperature schedule A occurred at 21.7 ± 0.9 h and 
under temperature schedule B at 13.9 ± 0.9 h (Figure III-4). 
A t-test compared the periods, acrophases and amplitudes of the cells exposed to either 
temperature cycles. No statistically significant difference was found for the period 
(p=0.089) as a result of large variability. The acrophases and the amplitudes differed 
with statistical significance with respective p-values of 0.0006 and 0.025. This showed 
that although both temperature cycles synchronised Hepa1-6 Per2-luc to simila r 
periods, differences were seen regarding acrophases and amplitudes. However, a 
synchronisation to a 24 h period was not achieved which led to the investigation of the 
temperature cycles C and D. 
 
Figure III-4: Periods, acrophases and amplitudes of Hepa1-6 Per2-luc cells synchronised to 
temperature cycle A and B.  




The parameters were taken after 2.5 days until 5.5 days after the start of synchronisation from 
100 000 Hepa1-6 Per2-luc cells synchronised to temperature schedule A or B. A t-test 
revealed no significant difference between the periods (p=0.089) but between the acrophases 
(p=0.0006) and the amplitudes (p=0.025). 
3.2 Synchronisation of murine hepatocarcinoma cell lines with 
temperature schedules C and D 
Here, we replaced the release into constant temperature in schedules A and B, with 
alternating temperature plateaus at 37°C for 12 h and 36°C for 12 h in schedules C and 
D respectively. Under both temperature schedules, oscillations lasted until day 5, with 
obviously reduced variability between the single replicates generated under 
temperature cycle D as compared to schedule C (Figure III-5). The raw data presenting 
the photon counts per second showed that, under synchronisation on temperature 
schedule C, the highest photon counts per second ranged between 519 (day 3.3) and 
1166 (day 3.2). These figures were twice as high as those found in cells synchronised 
with temperature cycle D, with highest photon counts per second ranging from 236 
(day 3.4) to 530 (day 3.5). 





Figure III-5: Synchronisation of 100 000 Hepa1-6 Per2-luc cells to temperature cycle C and 
D. 
Both schedules synchronised Hepa1-6 Per2-luc to respective mean periods ( SEM) 
of 25.2  1.1 h and 25  0.8 h. The acrophases occurred at 22.4 ± 1.3 h on schedule C 
and at 23.6 ± 1.7 h on schedule D (modulo their respective periods) with much less 
variability between the individual acrophases of the replicates, as compared to 
schedule B.  
The detrended data of cells synchronised with temperature cycle C showed a large 
variability of single amplitudes ranging from 266 to 686 photon counts per second 
with a mean (± SEM) of 468 ± 87 photon counts per second. The mean amplitude on 
temperature schedule C was thus 21-fold as large as that on schedule D (22 ± 4 photon 
counts per second). 
A t-test was performed on the periods, acrophases and amplitudes. No statistica lly 
significant differences were detected in the bioluminescence periods and acrophases 
on both temperature schedule (p=0.929 and p=0.573 respectively), whereas a 
statistical difference was seen in the amplitudes (p=0.007) (Figure III-6). 




To conclude, both temperature schedules synchronised Hepa1-6 Per2-luc cells, yet 
with higher variability in amplitudes and acrophases for culture dishes on temperature 
cycle C as compared to temperature cycle D.  
 
Figure III-6: Periods, phases and amplitudes of 100 000 Hepa1-6 Per2-luc cells after 
synchronisation with temperature cycle C and D. 
The parameters were taken after 2.5 days until 5.5 days after the start of synchronisation from 
100 000 Hepa1-6 Per2-luc cells synchronised to temperature schedule C and D. A t-test was 
conducted showing no differences between the temperature cycle C and D for the period 
(p=0.929) and the phase (p=0.453). However, a statistically significant difference was seen 
between the amplitudes of Hepa1-6 Per2-luc cells synchronised under temperature cycle C 
and D (p=0.0006). 
3.3 Subjecting hepatocarcinoma cells to different τ-cycles matching 
temperature schedule D 
Here, the temperature schedule D was further modified in order to test its 
synchronisation properties in Hepa1-6 Per2-luc clocks, near the known limits of 
circadian entrainment. Hepa1-6 Per2-luc cells were therefore synchronised to a period 




of 20 h (T=20 h) or to a period of 26 h (T=26 h). I further examined whether starting 
cell seeding counts at 50 000 or 100 000 mattered regarding such entrainment (Figure 
III-7).  
 
Figure III-7: Effects of a shortened and prolonged exogenous period on the endogenous 
period of Hepa1-6 Per2-luc with both tested τ-cycles of temperature according to modified 
schedule D.  
Fifty-thousand (Left panels) or hundred-thousand cells (right panels) were seeded in 5 Petri 
dishes each then they were subjected to modified schedule D whose temperature cycle had a 
period of either T=20 h (schedule E, upper rows) or, T=26 h (schedule F, lower rows). 
Bioluminescence was recorded for 1 min every 10 min for up to 7 days. 
Both T-cycles generated oscillations lasting until day 6 for an initial seeding cell count 
of 100 000 and until day 7 for 50 000 cells, this latter seeding count being also 
associated to a low variability between replicates.  
Temperature schedule E (Figure III-8) with an imposed period of 20 h, synchronised 
Per2-luc expression to a mean period of 20.2 ± 0.1 h or 19.8 ± 0.1 h according to 




whether the initial cell count was 50 000 or 100 000 cells. In contrast, the periods of 
Per2-luc oscillations on temperature schedule F (T=26 h), displayed average circadian 
periods of 24.9 ± 2.06 h or 30.4 ± 0.2 h for initial seeding counts of 50 000 or 100 000 
cells. The periods obtained after synchronisation to a 20-h exogenous period showed 
no significant difference between 50 00 and 100 000 starting cell counts (t-test with 
p-value of 0.096). Entraining 50 000 and 100 000 Hepa1-6 Per2-luc cells to a 26-h 
exogenous period led to statistically significant different periods (t-test with p-value 
of 0.029). The comparison between the synchronisation of 50 000 starting cell counts 
with temperature cycle E (T=20 h) and F (T=26 h) did not result in any significant 
difference (t-test with p-value of 0.049). Comparing 100 000 starting cell counts with 
temperature cycle E and F, however, showed a significant difference between the 
periods according to the T-cycle (t-test with p-value of <0.0001) (Figure III-8 and 
Table III-1). The data suggested that a more consistent synchronisation to the imposed 
period was achieved by temperature schedule E (T=20 h) as compared to F (T=26 h). 
This was further confirmed through comparing their SEMs. Indeed, the imposed 20-h 
period of temperature schedule E (T=20 h) was close to the endogenous period of the 
Hepa1-6 Per2-luc cells, which could have facilitated the synchronisation, in contrast 
to the large variability in periods for the replicates submitted to the 26-h periodic 
temperature schedule F (T=26 h).  
The phases relative to the period of 50 000 and 100 000 starting cell counts were 
similar in Per2-luc expression under synchronisation of the temperature cycle E 
(T=20 h). Subjecting the same amount of Hepa1-6 Per2-luc cells to the temperature 
cycle F (T=26 h) resulted in a phase delay of 6 h for 50 000 cells and of 8 h for 100 000 
cells (Table III-1). The t-test was significant comparing temperature cycle E (T=20 h) 
and F (T=26 h) with a starting cell count of 100 000 cells (p=0.0001) and comparing 
50 000 with 100 000 starting cell counts under the synchronisation with temperature 








Table III-1: Level of significance between the T-cycle with a 20- and 26-h period and between 






(T= 20 h) 
t-test 
(T= 26 h) 
20-h vs. 26-h 20-h vs. 26-h 50k vs. 100k 50k vs. 100k 
Period p=0.049 p<0.0001 p=0.096 p=0.029 
Phase p=0.121 p=0.0001 p=0.303 p=0.004 
Amplitude p=0.494 p=0.188 p=0.012 p=0.0004 
 
The amplitudes, achieved under the synchronisation of temperature cycle F, were for 
both starting cell counts, 50 000 and 100 000 cells, 4.3-fold higher as the amplitudes 
under the synchronisation with the temperature cycle E. Those differences were not 
significant according to the t-test (50 000 cells: p=0.0494, 100 000 cells: p=0.188) 
(Table III-1). Comparing the amplitudes from the initial cell counts showed a 1.4-fold 
higher amplitude for a starting cell count of 100 000 cells as compared to 50 000 cells 
(Figure III-8). This was observed for the temperature cycle E and F. The t-test (50 000 
vs. 100 000 cells) showed statistically significant results with p=0.012 in temperature 
cycle E and p=0.0004 in temperature cycle F (Table III-1).  
To conclude, temperature cycle E (T=20 h) synchronised 50 000 starting cell counts 
of Hepa1-6 Per2-luc cells to similar periods and acrophases, while larger variabilit ies 
in both parameters were found under temperature cycle F (T=26 h). This suggested 
that the 20-h period of temperature cycle E was close to the endogenous period of 
Hepa1-6 Per2-luc. Further, the results demonstrated that the entrainment of a lower 
starting cell count of 50 000 cells to a 20-h period resulted in less variability suggest ing 
that the number of cells played a crucial role in the synchronisation of a cell 
population. 





Figure III-8: Periods, acrophases and amplitudes after synchronisation with temperature 
cycle E (T=20 h) and F (T=26 h).  
The periods, acrophases and amplitudes were calculated for 50 000 and 100 000 Hepa1-6 
Per2-luc cells taken from day 2.4 to 5.4 and from day 2.8 to 5.8 respectively.  
3.4 Synchronisation of clock altered cells with temperature cycle D 
The objective of this experiment was to investigate the synchronisation properties of 
temperature cycle D in clock-altered cells. To this end, the experiment was conducted 
using Hepa1-6 Per2-luc cells with silenced Bmal1 expression. 
To verify the extent of Bmal1 silencing in Hepa1-6 Per2-luc shBmal1, the Bmal1 
mRNA levels were compared between Hepa1-6 Per2-luc shBmal1 and Hepa1-6 
Per2-luc taken from confluent 35 mm NUNC Petri dishes with an initial cell seeding 
number of 50 000 cells cultured at constant temperature at 37°C. A 64% inhibition in 
Bmal1 mRNA expression was found in the shBmal1 clone as compared to the origina l 




Hepa1-6 Per2-luc clone (1.8 ± 0.7 vs 5.1 ± 1.4 relative gene expression) with a p-value 
of 0.112 from t-test and Wilcoxon test with p-value of 0.25 (Figure III-9). 
 
Figure III-9: Expression of Bmal1 in Hepa1-6 Per2-luc and Hepa1-6 Per2-luc shBmal1 
(n=3). 
The clock alteration in Hepa1-6 Per2-luc shBmal1 was further investigated by 
subjecting 50 000 Hepa1-6 Per2-luc shBma11 cells to temperature cycle B where cells 
were released at a constant temperature of 37°C, following a single 24-h temperature 
cycle with a 5°C magnitude. The raw data in Figure III-10 further revealed that even 
though the number of photon counts per second increased with a peak at day 4, no 
synchronisation to a stable period, phase and amplitude was achieved. A mean period 
(± SEM) was calculated as 28.9 ± 1.6 h, with a mean acrophase as 18.4 ± 1.0 h and a 
mean amplitude of 34 ± 18 photon counts per second. Figure III-10 further showed 
that no sustained oscillations were detected in such conditions for Hepa1-6 Per2-luc 
shBmal1, in sharp contrast with the Bmal1-proficient parent clone (Figure III-3).  





Figure III-10: Bioluminescence (non-subtracted and subtracted) and periods, acrophases and 
amplitudes of Hepa1-6 Per2-luc shBmal1 cells under synchronisation of temperature cycle B. 
Fifty-thousand Hepa1-6 Per2-luc shBmal1 cells were seeded in a 35 mm NUNC Petri dish 
(n=4) and subjected to temperature cycle B while recording bioluminescence for 1 min every 
10 min over an experimental duration of 5 days. 
In a subsequent experiment, the synchronisation properties of temperature cycle D 
were assessed on Hepa1-6 Per2-luc and its altered-clock clone. Therefore, 50 000 
Hepa1-6 Per2-luc and 50 000 Hepa1-6 Per2-luc shBmal1 were synchronised with 
temperature schedule D for up to 5 days (Figure III-11).  
The raw data presented with a consistent increase of bioluminescence with a maximum 
ranging from 687 to 1724 photon counts per second from day 3.8 to 4.6. As expected, 
sustained and consistent oscillations were obtained from Hepa1-6 Per2-luc 
synchronisation whereas the oscillations of Hepa1-6 Per2-luc shBmal1 varied with a 
triangular shape pattern. The mean ± SEM period was 23.7 ± 0.4 h and 23.7 ± 0.2 h 




for the Bmal1-proficient and the Bmal1 silenced Hepa1-6 clones respectively (p-value 
of 0.889 from t-test).  
The mean ± SEM acrophase for the clock deficient clone occurred at 18.4 ± 1.4 h, i.e. 
with a 4.5 h advance as compared to that at 22.9 ± 0.5 h in Hepa1-6 Per2-luc (p-value 
from t-test of 0.017). In contrast, no statistically significant difference in amplitudes 
were found according to shBmal1 silencing (27. 3 ± 4.4 in wt vs. 36.8 ± 9.0 photon 
counts per second in shBmal1, with p-value from t-test of 0.369) (Figure III-12). 
 
Figure III-11: Synchronisation of 50 000 starting cell counts of Hepa1-6 Per2-luc and 
Hepa1-6 Per2-luc shBmal1 by optimised temperature cycle D.  
This experiment pointed out that the temperature cycle D was able to synchronise 
Hepa1-6 Per2-luc under the established conditions and to entrain the Bmal1-silenced 
Hepa1-6 Per2-luc clone. Considering the “triangular” shape of the shBmal1 oscillat io n 
peaking regularly at the end of the 36°C plateau, as well as the differences between 
the acrophases in both clones, it was concluded that schedule D induced 
pseudo-rhythmic bioluminescence patterns. The latter ones likely reflected changes in 




temperature sensitivity of Hepa1-6 Per2-luc shBmal1, whose severe clock alteration 
was shown through both a 64% inhibition of Bmal1 mRNA and the lack of consistent 
circadian oscillations in Per2-luc following the release in constant temperature. 
 
Figure III-12: Synchronisation properties of Hepa1-6 clones after temperature 
synchronisation with schedule D. 
Periods, acrophases and amplitudes of Hepa1-6 Per2-luc and Hepa1-6 Per2-luc shBmal1 
after synchronisation with the optimised temperature schedule D. T-test revealed a significant 
difference between the acrophase of Hepa1-6 Per2-luc vs. Hepa1-6 Per2-luc shBmal1 with 
p=0.017. No statistically significance was observed between the period (p=0.889) and the 
amplitude (p=0.369). 
3.5 Clock genes expressions in temperature-synchronised Hepa1-6 
Per2-luc cells 
The highest expression of Per2 mRNA was observed at T12 with 0.18 ± 0.03 relative 
gene expression (RGE) (mean ± SEM) and the lowest one at T24 with 0.04 ± 0.01 
RGE. The circadian expression of Bmal1 was in antiphase to the expression of Per2. 
Thus, the maximum of the Bmal1 expression occurred at T24 with 2.46 ± 0.6 RGE 




and the minimum at T08 with 0.46 ± 0.16 RGE. Rev-erbα mRNA expression peaked 
at T16, i.e. 4 h after that of Per2 with 1.39 ± 0.3 RGE (Figure III-13). 
 
Figure III-13: Per2, Bmal1 and Rev-erbα expression in Hepa1-6 Per2-luc under temperature 
synchronisation using temperature cycle D.  
The gene expression was normalised to the house keeping gene 36B4. The graphs depict the 
mean of the median (n=3) and SEM.  
Cosinor Analysis with a 24-h period was conducted on the clock gene mRNA 
expressions of Per2, Bmal1 and Rev-erbα in Hepa1-6 cells synchronised with 
temperature cycle D. Bmal1 and Rev-erbα circadian expressions showed an additiona l 








Table III-2: Results from Cosinor Analysis of the circadian mRNA expression of clock genes 
Per2, Bmal1 and Rev-erbα in Hepa1-6 Per2-luc cells synchronised with temperature cycle D 
(mean ± SEM, n=3). 
24 h period 
 Amplitude (RGE) Acrophase (h) p-Value 
Per2 0.4 ± 1.2 13.0 ± 1.4 0.007 
Bmal1 0.4 ± 1.2 0.6 ± 1.3 0.017 
Rev-erbα 0.3 ± 0.1 17.7 ± 1.4 0.034 
12 h period 
 Amplitude (RGE) Acrophase (h) p-Value 
Per2 - - - 
Bmal1 0.7 ± 0.2 0.9 ± 0.4 <0.0001 
Rev-erbα 0.4 ± 0.1 2.4 ± 0.6 0.006 
  
The acrophase in Per2 mRNA expression was compared to that in Per2-luc in Hepa1-6 
Per2-luc cells synchronised with temperature schedule D using an initial cell counts 
of 50 000 cells. The mean ± SEM acrophase of the Per2-luc reporter construct was 
located at 22.9 ± 0.5 h (Figure III-12) and that of Per2 mRNA at 13.0 ± 1.4 h (Table 
III-2). Thus, both acrophases differed by 9.9 h. The acrophase of the Per2-luc reporter 
construct only described the acrophase of the luciferase expression whose 
transcription is linked to the promoter of Per2. Thus, the acrophase form the Per2-luc 
reporter construct does not represent the acrophase of Per2. This explains why the 
acrophase of bioluminescence curve differs from that of Per2 mRNA expression. 
Nevertheless, the reporter construct was adequate to determine the synchronisat ion 
properties of temperature cycles. 
3.6 Circadian cell cycle phases of Hepa1-6 Per2-luc and its altered 
clock clone 
A cell cycle analysis examined whether a circadian rhythm regulated cell cycle stage 
progression in Hepa1-6 Per2-luc or Hepa1-6 Per2-luc shBmal1 synchronised with the 
optimised temperature cycle D.  
Therefore, fifty-thousand Hepa1-6 Per2-luc and Hepa1-6 Per2-luc shBmal1 cells in 
35 mm NUNC Petri dishes were subjected to antiphase temperature cycles D starting 
at 37°C in incubator 1 and at 32°C in incubator 2 as described in chapter II.1. Another 




50 000 Hepa1-6 Per2-luc cells were not subjected to temperature schedule D and 
served as an unsynchronised control. After 2.5 days, non-synchronised and 
synchronised cells (5 to 6 replicates per time point) were harvested every 4 h in a 12 h 
working schedule. Using antiphase synchronisation schedules ensured the sampling 
of cells of a 24 h experiment. Thus, the same clock hour referred to 2 circadian time 
points. Following the cell cycle analysis protocol (chapter II.1), the number of 
Hepa1-6 Per2-luc and Hepa1-6 Per2-luc shBmal1 cells in G0/G1-phase, S-phase or 
G2/M-phase were determined excluding apoptotic cells from the analysis. Across all 
6 time points, the average number of apoptotic cells was 4.9% with a maximum (mean 
± SEM) at T14 (9.3 ± 1.3%) and a minimum at T18 (2.4 ± 0.1%) (Data not shown). 
No statistically significant difference was observed (p-value from ANOVA with 
0.425). 
The non-synchronised cells were harvested at the same three real time points as the 
synchronised cells (Figure III-14) in a 12 h working schedule. The highest number of 
cells (mean ± SEM) in G0/G1-phase occurred at T06/T18 with 34.6 ± 1.0% and the 
lowest one at T02/T14 with 32.1 ± 0.5%. Regarding the S-phase, a maximum of cells 
was observed at T10/T22 with 34.5 ± 1.6% and the minimum at T02/T12 with 32.1 ± 
1.2%. The G2/M-phase showed similar maxima and minima as compared to 
G0/G1-phase. At T06/T18 a maximum with 35.4 ± 1.4% of cells were detected in 
G2/M-phase. The minimum occurred at T02/T14 with 31.8 ± 1.7% cells. The data 
showed a consistent level of cells measured at different time points. ANOVA revealed 
no significant difference between the counts in specific cell cycle phases according to 
sampling time (p=0.148 for G0/G1-phase, p=0.463 for S-phase and p=0.507 for G2/M-
phase). 





Figure III-14: Cell cycle phases of non-synchronised Hepa1-6 Per2-luc cells (n=5).  
Next, the circadian rhythm of the cell cycle phases was investigated in Hepa1-6 
Per2-luc and in Hepa1-6 Per2-luc shBmal1 (Figure III-15). The highest number of 
cells (mean ± SEM) distributed in G0/G1-phase was observed at T14 for Hepa1-6 
Per2-luc with 36.9 ± 1.1% and at T06 for Hepa1-6 Per2-luc shBmal1 with 31.7 ± 
0.3%. In S-phase, both Hepa1-6 Per2-luc and its altered clock mutant showed the peak 
of cell accumulation at T18 to T22 with 39.3 ± 2.0% to 39.1 ± 2.6% for Hepa1-6 
Per2-luc and at T22 with 46.4 ± 4.8% for Hepa1-6 Per2-luc shBmal1. Regarding the 
G2/M-phase the highest number of cells were obtained at T02 and T10 for Hepa1-6 
Per2-luc with 33.4 ± 2.5% and 33.4 ± 2.3%. On the contrary, Hepa1-6 Per2-luc 
shBmal1 showed the highest number of cells at T22 with 39.2 ± 1.4%. Cosinor 
Analysis was conducted to investigate whether a circadian rhythm was present in the 
above stated cell cycle phases after temperature synchronisation (Table III-3). 
The results of the Cosinor Analysis confirmed that under temperature synchronisat ion, 
a 24-h rhythm in Hepa1-6 Per2-luc was observed in S-phase with a mean ± SEM 
acrophase at 17.3  ± 1.2 h and with an amplitude of 0.1 ± 0.03% (p=0.006). For the 




altered clock mutant, a 24-h rhythmicity was detected in G0/G1-phase with an 
acrophase of 10.9  ± 1.4 h and an amplitude of 0.17 ± 0.06% (p=0.035). 
 
Figure III-15: Circadian cell cycle phases of Hepa1-6 Per2-luc (n=11) and Hepa1-6 Per2-luc 
shBmal1 (n=6) after synchronisation with temperature cycle D. 
Even though previous experiments have proven the ability of the temperature cycle D 
to synchronise Hepa1-6 Per2-luc cells, a circadian pattern of the different cell cycle 
phase distribution was only detected for the S-phase in Hepa1-6 Per2-luc and G0/G1-
phase for Hepa1-6 Per2-luc shBmal1. The results suggest that temperature 
synchronisation with a 24-h period did not synchronise the cell cycle of both Hepa1-6 
clones although the clock gene expression were antiphase (chapter 3.5). 




Table III-3: Results from Cosinor Analysis of the cell cycle phase distribution in 24-h 
temperature synchronised Hepa1-6 Per2-luc and Hepa1-6 Per2-luc shBmal1 (mean ± SEM, 
n=6). 







Synchronised Hepa1-6 Per2-luc 
G0/G1-phase 24-h 33.2 ± 0.9 - - 0.204 
S-phase 24-h 35.9 ± 0.8 3.7 ± 1.0 17.3 ± 1.2 0.006 
G2/M-phase 24-h 30.8 ± 0.1 - - 0.49 
Synchronised Hepa1-6 Per2-luc shBmal1 
G0/G1-phase 24-h 25.3 ± 1.1 4.3  ± 1.6 10.9 ± 1.4 0.035  
 12-h 25.3 ± 1.1 7.2 ± 1.6 4.4 ± 0.4 0.0003 
S-phase 24-h 40.9 ± 0.1 - - 0.395 
G2/M-phase 24-h 33.8 ± 1.3 - - 0.919 
 12-h 33.8 ± 1.3 4.9 ± 1.9 8.9 ± 0.7 0.044  
 
  




4 The effect of different luciferin concentrations on period, 
phase and amplitude  
It was recently reported that extracellular luciferin concentration could alter circadian 
period, phase and amplitude of mouse fibroblasts synchronised with a temperature 
schedule involving the alternation of a 12-h plateau at 32°C with 12-h plateau at 37°C 
for 5 days (Feeney et al., 2016). Based on this publication, the effect of different 
luciferin concentrations on the period, acrophase and amplitude of Per2-luc 
expression was investigated in Hepa1-6 cells, using temperature schedule D. So far, 
all experiments were performed using 100 µM luciferin. The purpose of this study was 
to identify and confirm the luciferin dose level that ensured a stable period, acrophase 
and amplitude as well as guaranteed enough luciferin supply for an experimenta l 
duration of 7 days. 
Temperature schedule D was applied to 50 000 Hepa1-6 Per2-luc cells cultured in 
media containing 50 µM, 100 µM, 200 µM, 400 µM, 800 µM or 1.6 mM lucifer in. 
Three replicates were prepared for each concentration. The occurrence of the 
maximum of the photon counts per second (Table III-4) pointed out that a higher 
luciferin concentration (400 µM to 1.6 mM) resulted in higher photon counts per 
second which occurred 0.8 days later as compared to the lower luciferin concentrat ions 
(50 µM to 200 µM). 
Table III-4: Overview of the occurrence of the maximum photon counts per second according 
to the different luciferin concentrations.  
Luciferin concentration Day of maximum 
photons counts per 
second 
Maximum average 
photons counts per 
second (± SEM), n=3 
50 µM 3.8 1126 ± 153 
100 µM 3.7 1572 ± 204 
200 µM 3.8 1568 ± 138 
400 µM 3.5 2134 ± 294 
800 µM 4.5 2261 ± 316 
1.6 mM 4.5 2561 ± 320 




The analysis of the detrended data revealed a consistent period (mean ± SEM) ranging 
from 24.1 to 25.2 h, for up to 6 days, irrespective of luciferin concentration (Table 
III-4 and Figure III-17) (p-value from ANOVA with 0.347). This suggested that 
luciferin did not affect the period of the Hepa1-6 clock. However, lucifer in 
concentration was responsible for differences in circadian amplitudes and acrophases.  
 
Figure III-16: Oscillations of 50 000 starting cell counts of Hepa1-6 Per2-luc depending on 
the extracellular luciferin concentrations. 
Both figures shown the average (± SEM) of three replicates. 
Considering the raw data in Figure III-16, no toxic effect of luciferin was apparent. 
Moreover, a dose-response relation was reflected by consistent increments in circadian 
amplitude, from 35 to 173 photon counts per second along with increasing lucifer in 
concentrations (p-value from ANOVA with 0.006). The acrophase (modulo the 
respective period) was also delayed as a function of luciferin concentration, from 
16.1 h to 22.4 h (p-value from ANOVA with <0.001) (Table III-5).  
The amplitude and the acrophase were further plotted as dose response curves 
according to luciferin concentration (Figure III-18). The dose response curve of the 
amplitude was fitted to an exponential function. The inflection point of the fitted 
exponential function of the amplitude against the luciferin concentration occurred at a 
luciferin concentration of 110.9 µM. The dose response curve of the acrophase 
followed a linear function.  





Figure III-17: Effect of extracellular luciferin concentration on the synchronisation properties 
of temperature cycle D.  
According to the Michaels-Menten-Kinetics, a higher concentration of extracellula r 
luciferin resulted in a higher rate of oxidation reactions with luciferase. Put into 
context with this experiment, more oxidation reactions and thus a higher number of 
photons were detected under increasing luciferin concentrations. This was supported 
by the increased amplitudes obtained by increased luciferin concentrations.  
Table III-5: Relevance of luciferin concentration for the period, acrophase and amplitude of 
the bioluminescence curve of Hepa1-6 Per2-luc cells (mean ± SEM, n=3). 
Luciferin 
concentration 
50 µM 100 
µM 

















































This experiment pointed out that luciferin did not exert any dose dependent effect on 
the clock period of Hepa1-6 Per2-luc cells. However, the acrophase occurred later and 
the amplitude increased along with increasing luciferin concentrations. At a lucifer in 
concentration of 100 µM, the amplitudes were “high enough” to study the effect of 
drugs on the Per2-luc reporter in follow-up studies. Regarding the acrophase, Table 
III-5 shows that a 100 µM, 200 µM and 400 µM luciferin concentrations did not 
change the acrophase. Whereas the acrophase was advanced for 50 µM luciferin and 
delayed for 800 µM and 1.6 mM luciferin. Considering all the different factors, a 
luciferin concentration of 100 µM was confirmed as the best option. 
 
Figure III-18: Dose response curve of the amplitude and phase relative to the period against 
the logarithm of the luciferin concentration.  
5 Synchronisation properties of the optimised temperature 
cycle D in a human colon cancer cell line 
Temperature schedule D was further applied to the human colon cancer cell line 
HCT116 Per2-luc in order to test whether this cell line could also be synchronised by 
the temperature cycle D. Further, the 24-h temperature cycle was switched over to 
constant 37°C after day 5. Releasing cells into constant condition aimed to investiga te 
whether the oscillation of HCT116 Per2-luc would persist in the absence of time cues, 
thus enabling the determination of the endogenous period of this human cancer cell 
line. 





Figure III-19: Synchronisation properties of HCT116 Per2-luc under temperature schedule 
D.  
The synchronisation of 50 000 starting cell counts HCT116 Per2-luc revealed 
consistent oscillations with a stable amplitude until day 5. Following the release at 
constant temperature, the regular oscillations persisted until day 9. The mean period 
(± SEM) was 23.6 ± 0.1 h under entrained conditions with a 1°C change between 37°C 
and 36°C and vice versa every 12 h from day 2.5 to day 5. The period increased to 
24.9 ± 0.1 h following the release of the cells at constant temperature at 37°C from 
day 5 to day 9.5. Such period lengthening was statistically validated by t-test with a 
p-value of <0.001.  
The mean ± SEM bioluminescence amplitude increased 3.4-fold from 38 ± 9 to 127 ± 
19 photon counts per second from the synchronised conditions (day 2.5 to day 5.0) to 
constant temperature (day 5.0 to day 9.5) (p-value from t-test with 0.001) (Figure 
III-19).  




The acrophases remained stable both during the temperature synchronisation (24.3 ± 
0.3 h) and following the release of the cells at constant temperature (22.7 ± 4.5 h). 
However the periods in both conditions differed significantly (p-value from t-test of 
<0.001). The lack of time cues likely accounted for rather large variations in the 
acrophases of Per2-luc expression among the replicates, as indicated with SEM of 
4.5 h, despite very similar periods. This observation supported the occurrence of 
desynchronisation, a phenomenon which could be avoided through maintaining 
temperature synchronisation throughout. 
In a second experiment (Figure III-20) the synchronisation properties of temperature 
cycle D were compared between HCT116 Per2-luc and HCT116 Bmal1-luc. The aim 
was to identify the phase relations between Per2-luc and Bmal1-luc expressions, so as 
to further support the presence of a functional clock in HCT116, as well as to verify 
the synchronisation of the clock genes promoters of Per2 and Bmal1 by temperature 
schedule D. 
HCT116 cells with the luciferase reporter Per2-luc and Bmal1-luc presented both with 
sustained oscillations and a trend for desynchronisation after the release in constant 
conditions on day 6. The mean ± SEM periods were calculated as 24.0 ± 0.2 h and 
24.6 ± 0.1 h in these respective conditions (p-value from t-test of 0.019).  





Figure III-20: Synchronisation of Hepa1-6 Per2-luc and Hepa1-6 Bmal1-luc to temperature 
cycle D and determining the periods, acrophases and amplitudes. 
The mean ± SEM acrophase of Bmal1-luc expression occurred at 20.1 ± 0.2 h, thus 
occurring 2.5 h later than that in Per2-luc expression, which was located at 17.5 ± 
0.5 h (p-value from t-test with 0.001).  
The amplitude of the HCT116 Bmal1-luc (469 ± 50 photon counts per second) was 
8.7-fold as high as compared to HCT116 Per2-luc (54 ± 7 photon counts per second) 
although the starting cell counts of both HCT116 clones were 50 000 (p-value from 
t-test with <0.0001). The reason for the difference between both amplitudes were 
traced back to the design of the reporter construct.  
Synchronising HCT116 Per2-luc and Hepa1-6 Per2-luc cells to temperature cycle D 
resulted in consistent oscillations. Interestingly, the same schedule applied to the same 
initial cell count synchronised both Hepa1-6 Per2-luc and HCT116 Per2-luc cells to 
~24 h, yet the mean ± SEM acrophase of photon counts per second occurred at 22.9 ± 
0.5 h and at 17.5 ± 0.5 h, respectively (p-value from t-test with <0.0001). This 5.4 h 
phase difference further reflect cancer cell line specificities in clock properties. Indeed, 
the endogenous circadian period that was determined at a constant temperature of 




37°C differed profoundly between both cell lines. Exposing 100 000 Hepa1-6 Per2-luc 
cells to temperature cycle B resulted in a mean ± SEM period of 20.2 ± 0.6 h under 
constant temperature (Figure III-4). Interestingly, exposing 50 000 Hepa1-6 Per2-luc 
cells to temperature cycle D with 20- h period, synchronised the cells to a mean ± SEM 
period of 20.2 ± 0.1 h. Those results might suggest that the endogenous period of 
Hepa1-6 Per2-luc was close to 20 hours, whereas the endogenous period of HCT116 
was 24.6 h. 





The aim of the experiments reported here was to establish a synchronisation method 
which would allow synchronisation of cancer cell lines to a stable period, acrophase 
and amplitude and to ensure synchronisation duration for at least 5 days. 
The synchronisation with temperature schedule D with alternating 12-h plateaus at 36 
and 37°C, after an initial 24-h cycle ranging from 32 to 37°C, led to a stable period, 
acrophase and amplitude. T-cycle experiments of temperature schedule D revealed 
consistent synchronisation of Hepa1-6 Per2-luc cells with a 20-h temperature cycle, 
whilst somewhat variable synchronisation was observed under 26-h temperature 
cycles.  
Temperature cycle D was further used to investigate its synchronisation properties 
following severe molecular clock alteration resulting from Bmal1 silencing. The 
subjection of Hepa1-6 Per2-luc shBmal1 cells to constant temperature showed no 
sustained oscillations. However, “pseudo-rhythms” were observed under the 
synchronisation of temperature cycle D. The human colon cancer cells HCT116 
transfected with Per2-luc or Bmal1-luc were synchronised by temperature cycle D to 
sustained and antiphase oscillations. 
Temperature synchronisation thus proved as a suitable method to synchronise cancer 
cell cultures. It was hence used in the subsequent experiments that investigated the in 












IV Results In vitro Chronotoxicity  





Temperature cycle D was used to synchronise cancer cell lines in order to investiga te 
time dependent changes in the cellular toxicity of the novel osmium drug candidate 
FY26.  
The aim was to establish a concentration scale of different FY26 concentrations which 
would allow to study the time dependent changes of the IC50 (half maximal inhibito ry 
concentration = IC50) of FY26. This was used as an index of the cellular toxicity of 
FY26 in Hepa1-6 Per2-luc, Hepa1-6 Per2-luc shBmal1 and HCT116 Per2-luc cells. 
The required specifications for such a concentration scale were: (i) the achievement of 
extreme cell survival rates near 100% and 0% so as to calculate the IC50 and (ii) the 
definition of a core concentration row with narrow variations of FY26 concentrations, 
in order to ensure the precise determination of the time dependent changes in IC50.  
Toward this goal, the above-mentioned cancer cell lines were synchronised using 
temperature cycle D. After 2.5 days of synchronisation, the cell lines were exposed to 
the selected FY26 concentration scales at circadian times T04, T10, T16 or T22. After 
an exposure time of 24 h, the FY26-containing media was removed and replaced by 
drug-free media. The total cellular protein content was measured 96 h after the start of 
drug exposure. The measured absorption of the media controls were used to normalise 
the absorption values from the drug exposed cells. The normalised values were 
expressed as percentages. 
The time dependent changes in the IC50 of FY26 were compared between Hepa1-6 
Per2-luc, its clock-altered clone Hepa1-6 Per2-luc shBmal1, and the human colon 
cancer cell line HCT116 Per2-luc.  
  




2 Time dependent cytotoxicity of FY26 on clock proficient 
and clock altered mouse liver cancer cells 
2.1 Establishing the concentration scale to assess time dependent 
changes of FY26 cytotoxicity in the selected cancerous cell lines.  
The in vitro chronopharmacology was assessed through testing different ranges of 
FY26 concentrations on the clock proficient liver cancer cell line Hepa1-6 Per2-luc, 
on its clock altered clone Hepa1-6 Per2-luc shBmal1 and on the human colon cancer 
cell line HCT116 Per2-luc. All cell lines were exposed to the concentration rows 
shown in chapter II.1.  
Concentration scale A was characterised by 1:10 dilutions of FY26, in order to identify 
the range where the IC50 was situated. Based on this, concentration scales B, C and D 
were established, with closer values within the region of the IC50. All of them led to a 
dose response curve with a maximum cell survival near 100% and a minimum near 
0% as required to calculate the IC50 (Appendix Figure XI-1 and Figure XI-3).  
The Hepa1-6 Per2-luc cells were exposed to concentration scales A, B and C, with C 
representing the optimised scale. Its clock altered clone Hepa1-6 Per2-luc shBmal1 
was exposed to concentration scales A, B and D, with D representing the optimised 
scales. Mean IC50 ± SEM was 5.3 ± 0.4 µM for Hepa1-6 Per2-luc and 6.2 ± 0.4 µM 
for Hepa1-6 Per2-luc shBmal1 using the respective optimised concentration scales for 
both cell lines (p-value from t-test with 0.139) (Figure IV-1).  
Based on these findings, time dependent changes in IC50 were investigated using 
concentration scales E and F for Hepa1-6 Per2-luc and F and G for Hepa1-6 Per2-luc 
shBmal1. All three scales shared the same core FY26 concentration sequence to ensure 
a precise detection of the time dependent changes of the IC50. The maximum FY26 
concentration differed amongst the scales E, F and G, being 16, 30 and 21 µM 
respectively (Appendix Figure XI-2 ). 
 





Figure IV-1: IC50 of FY26 for Hepa1-6 Per2-luc and Hepa1-6 Per2-luc shBmal1 after the 
exposure to the concentration scale C (conc. scale C) and D (conc. scale D) (n=12, with mean 
± SEM).  
Regarding the human colon cell line HCT116 Per2-luc, concentration scales H and I 
achieved maximum and minimum survival rates near 100% and 0%, thus met the 
requirements for IC50 calculations (Figure IV-2 and Appendix Figure XI-3). In two 
separate experiments, 8 000 HCT116 Per2-luc cells were exposed to scale H. Mean ± 
SEM IC50 were 0.7  ± 0.0 µM and 1.5 ± 0.2 µM in the first and second experiment, 
respectively. In a third experiment, using concentration scale I, the mean ± SEM IC50 
was 4.9 ± 0.3 µM. ANOVA revealed significant differences in IC50 values according 
to the concentration scale (p<0.0001). Tukey’s multiple comparison test indicated 
statistically significant differences between the IC50 of each pair of experiments, thus 
highlighting the large inter-study variability that resulted from an extreme IC50 value 
estimation, along the concentration scale tested (Figure IV-2). Concentration scale I 
was selected to test the time-dependencies in FY26 toxicity for HCT116 Per2-luc. 





Figure IV-2: Mean ± SEM IC50 of FY26 using concentration scales H and I on HCT116 
Per2-luc with an initial seeding count of 8 000 cells (n=4 to 8 with mean ± SEM).  
3 Time dependent changes of the IC50 of FY26 on Hepa1-6 
Per2-luc cells 
Time dependent changes in FY26 IC50 were investigated in synchronised Hepa1-6 
Per2-luc cells, within two experiments using concentrations scales E and F, both of 
which meeting the predefined specifications.  
For both experiments, 4000 Hepa1-6 Per2-luc cells were initially seeded, and 
synchronised with temperature cycle D. After 2.5 days, cells were exposed for a fixed 
duration of 24 h to either concentration scales. Total cellular protein content was 
measured 72 h after FY26 withdrawal (Appendix Figure XI-4 and Figure XI-5 ). 
Highly reproducible dose response curves were achieved in both experiments, 
involving 18 and 12 replicates respectively. Different IC50 values were obtained 
according to the initial time of FY26 exposure. Mean ± SEM IC50 values ranged from 
4.1 ± 0.2 µM at T04 up to 5.9 ± 0.4 µM at T22 under concentration scale E, and from 
9.6 ± 0.1 µM at T04 up to 12.3 ± 0.5 µM at T22 for concentration scale F. Thus, the 
IC50 was consistently higher at T22 as compared to T04, by 44% and 28% under both 
respective concentration scales (Figure IV-3).  




ANOVA showed a significant difference between time points for both experiments 
with a p-value of p<0.0001. Tukey’s multiple comparison test further emphasised 
statistically significant differences between T04 vs. T16 (***), T22 (***) as well as 
between T10 vs. T22 (*) for the concentration scale E. The same test was conducted 
on the IC50 values computed after exposing cells to concentration scale F. It showed a 
significant difference between T04 vs. T10 (*), T16 (*) and T22 (***) and between 
T10 vs. T16 (*) and T10 vs. T22 (*). Two-way ANOVA confirmed statistica lly 
significant differences between the IC50 according to time (p<0.0001) and experiment 
(p<0.0001) without any interaction term (p=0.219). 
 
Figure IV-3: Circadian IC50 of Hepa1-6 Per2-luc in two independent experiments.  
Panel A shows the dose response curve (left panel) and the IC50 (right panel) according to 
time points of the concentration scale E (n=18 replicates) and panel B shows the dose 
response curve (left panel) and the IC50 (right panel) after the exposure of the concentration 
scale F (n=12 replicates). 




To conclude, the highest IC50 was observed at T22, i.e. 2 hours before the temperature 
was scheduled to increase from 36°C to 37°C in the incubator. This time point was 
associated with reduced FY26 toxicity. 
The interexperimental differences between the IC50 values at the different circadian 
time points might have been caused because the experiments were conducted on 
different days as well by the possible use of different concentrations scales. The 
median concentration in either scales was 6 µM FY26. However, highest 
concentrations amongst the scales differed. Whereas the highest concentrations of 
concentration scale E constituted of 16 µM and 12 µM FY26, the maximum 
concentrations of concentration scale F were 30 µM and 16 µM FY26. Strikingly, the 
lowest cell survival was obtained under the exposure to concentration scale E. The 
variability in the measurement of the total protein content might have been a further 
contributing factor. 
4 Time dependent changes of the IC50 of FY26 on Hepa1-6 
Per2-luc shBmal1 cells  
Next, possible time dependent changes in the IC50 were investigated in the 
clock-altered Hepa1-6 Per2-luc shBmal1 clone, using the same methodologica l 
approach as described for Hepa1-6 Per2-luc cells. However, concentration scales F 
and G were used here in two separate experiments, each one consisting of 12 
replicates. Both concentration scales met the predefined specifications (Appendix 
Figure XI-6 and Figure XI-7). 
The mean ± SEM IC50 values obtained under the use of the concentrations scale F 
were 8.7 ± 0.2 µM both at T04 and at T16. At T10, the mean ± SEM IC50 was 
calculated with 10.7 ± 0.3 and at T22 with 14.1 ± 0.4 µM. The exposure to the 
concentration scale G resulted in IC50 values ranging from 4.9 ± 0.2 µM at T04, and 
5.9 ± 0.1 µM at T16 up to 7.6 ± 0.2 µM at T10 and 7.4 ± 0.5 µM at T22. Thus, a 
bimodal pattern was identified using either concentration scales with the highest IC50 
corresponding to initial FY26 exposure starting at T10 (Figure IV-4). 
 





Figure IV-4: Circadian IC50 of Hepa1-6 Per2-luc shBmal1 in two independent experiments.  
Panel A shows the dose response curve (left panel) and the IC50 (right panel) according to 
time point of two independent experiment using the concentration scales F and panel B shows 
the dose response curve (left panel) and the IC50 (right panel) after the exposure to the 
concentration scale G at different time points. Each experiment consisted of 12 replicates 
(n=12 with mean ± SEM). 
For both concentration scales, ANOVA reported a significant difference between the 
IC50 of FY26 according to the time of administration. The p-value was p<0.0001. 
Tukey’s multiple comparison test highlighted a difference between T04 vs. T10 (***), 
T16 (*) and T22 (***), between T10 vs. T16 (***) as well as between T16 vs. T22 
(**) for concentration scale G. A difference between time points of FY26 
administration was seen for concentration scale F between T04 vs. T10 (***), T22 
(***), between T10 vs. T16 (***), T22 (***) and between T16 vs. T22 (***). 
Two-way ANOVA detected a significant difference between time points (p<0.0001) 
and between both experiments (p<0.0001). Further, a significant interaction between 
time and either experiments was obtained (p<0.0001). 




To conclude, FY26 showed the lowest toxicity in Hepa1-6 Per2-luc shBmal1 both at 
T10 and at T22, that respectively referred to 2 h before the temperature rose from 36°C 
to 37°C and decreased from 37°C to 36°C. Thus, the data differed from Hepa1-6 
Per2-luc as the IC50 was higher at T10 and T22 whereas in Hepa1-6 Per2-luc T22 was 
clearly identified at the time with least toxicity.  
5 Time dependent changes of the cellular toxicity of FY26 on 
synchronised human colon cancer cells 
Concentrations scale I was used for exposing synchronised HCT116 Per2-luc cells at 
T04, T10, T16 or T22, after 2.5 days of synchronisation with temperature schedule D. 
Concentrations scale I was adequate, since minimum mean ± SEM survival ranged 
from 7.9 ± 1.7% to 11.7 ± 2.2% and maximum survival varied from 94.6 ± 1.7% to 
104.7 ± 2.2% (Appendix Figure XI-8). Two experiments were performed. 
The mean ± SEM IC50 values ranged from 1.1 ± 0.1 µM for T04, to 3.3 ± 0.4 µM for 
T10, 2.6 ± 0.3 µM for T16 and 3.6 ± 0.2 µM for T22 in the first experiment. In the 
second one, the mean ± SEM IC50 also followed a bimodal pattern, with values ranging 
from 5.5 ± 0.2 µM for T04, to 7.1 ± 0.2 µM for T10, 4.9 ± 0.1 µM for T16, and 7.1 ± 
0.3 µM for T22. Thus, initial exposure of the cells at T10 or T22 was associated with 
least toxicity, by 22.7% to 45% as compared to T04 or T16 according to experiment. 
ANOVA on each individual experiment resulted in a significant difference between 
the IC50 values according to time with a p-value of p<0.001. Tukey’s mult ip le 
comparison test further confirmed a difference between the time points T04 vs. T10 
(***), T16 (**) and T22 (***) as well as between T16 vs. T22 (*) of the firs t 
experiment. A significant difference between the time points T04 vs. T10 (***), T10 
vs. T16 (***), T16 vs. T22 (***) and between T04 vs. T22 (***) was also seen in the 
second replication study, 2nd experiment (Figure IV-5). Two-way ANOVA confirmed 
statistically significant differences in IC50 according to both FY26 timing (p<0.0001) 
and experiment (p<0.0001). A significant interaction was observed between the time 
and experiment (p<0.0001) meaning that the effect of time on the IC50 values is 
different from the effect of the experiment on the IC50 values. 





Figure IV-5: Circadian IC50 of HCT116 Per2-luc after FY26 exposure in two separate 
experiments using concentration scale I.  
Panle A shows the dose response curve (left panel) and the IC50 values according to time (right 
panel) after the exposure of the concentration scale I and panel B shows the replication 
experiment (n=5-12 for panel A, n=13 for panel B). 
6 Comparison of circadian toxicity patterns between clock 
proficient and clock altered cancer cell lines 
To further test the consistency of the results amongst the individual experiments, the 
IC50 values of FY26 were normalised to the average IC50 obtained separately in each 
experiment for Hepa1-6 Per2-luc, Hepa1-6 Per2-luc shBmal1 and HCT116 Per2-luc.  
The maximum normalised mean ± SEM IC50 for Hepa1-6 Per2-luc was 119.8 ± 4.7% 
for T22 and the lowest one 87.4 ± 2.9% for T04. The minimum normalised IC50 was 
99.5 ± 2.8% at T10 and 93.6 ± 2.9% at T16. ANOVA revealed a statistically significant 
difference between the normalised IC50 values according to time of FY26 exposure 




(p<0.0001). Tukey’s multiple comparison further revealed statistically significant 
differences between T22 and T04 (***), T10 (***) and T16 (****) (Figure IV-6).  
 
Figure IV-6: Comparison of the combined data of the normalised IC50 of FY26 in Hepa1-6 
Per2-luc (panel A) and in Hepa1-6 Per2-luc shBmal1 (panel B).  
Panel A shows the IC50 of Hepa1-6 Per2-luc (n=30) and panel B presents the IC50 of Hepa1-6 
Per2-luc shBmal1 (n=24). 
Regarding Hepa1-6 Per2-luc shBmal1, the highest normalised mean ± SEM IC50 was 
126.7 ± 4.2% at T22 and the lowest of 79.0 ± 1.8 % at T04. The average normalised 
IC50 for T10 and T16 were 109.6 ± 2.8% and 87.1 ± 1.7% respectively. ANOVA 
revealed a statistically significant difference between the IC50’s according to the time 
of drug administration (p<0.0001). Further, Tukey’s multiple comparison test 
emphasised a significant difference between T04 and T10 and T22 (***), between T10 
vs. T16 and T22 (***), T14 vs. T22 (***) and T16 vs. T22 (***) (Figure IV-6). 
Cosinor Analysis showed an acrophase for a 24-h rhythm at T20.9 for Hepa1-6 
Per2-luc whereas no 24-h and 12-h rhythm was detected for Hepa1-6 Per2-luc 











Table IV-1: Cosinor Analysis of the normalised IC50 of Hepa1-6 Per2-luc, Hepa1-6 Per2-luc 
shBmal1 and HCT116 Per2-luc (mean ± SEM). 











24-h 100.1 ± 1.7 11.0 ± 2.4 20.9 ± 0.9 0.0001 




24-h 99.6 ± 0.1 - - 1 
12-h - - 1 
HCT116 
Per2-luc 
24-h 98.9 ± 2.5 11.5 ± 3.7 19.9 ± 1.2 0.004 
12-h 31.6  ± 3.9 8.2 ± 0.01 <0.0001 
 
Thus, Hepa1-6 Per2-luc and Hepa1-6 Per2-luc shBmal1 exhibited different toxicity 
temporal patterns with the highest IC50 at T22 identified for Hepa1-6 Per2-luc. 
Hepa1-6 Per2-luc shBmal1 on the contrary, showed a higher IC50 at T10 and at T22 
thus presenting a bimodal pattern.  
7 Comparison of circadian toxicity between Hepa1-6 
Per2-luc and HCT116 Per2-luc cell lines 
In the last section, the IC50’s between the murine hepatocarcinoma cell line Hepa1-6 
Per2-luc and the human colon cancer cell line HCT116 Per2-luc were compared 
(Figure IV-7).  





Figure IV-7: Comparison of the combined data of the normalised IC50 of HCT116 Per2-luc 
(n=18-25) with Hepa1-6 Per2-luc (n=30).  
Panel A presents the IC50 of HCT116 Per2-luc and panel B shows the IC50 of Hepa1-6 
Per2-luc. 
At T22, the human colon cancer cell line HCT116 Per2-luc exhibited on average the 
highest normalised mean ± SEM IC50 with 127.1 ± 4.7% and at T04 and the lowest 
with 74.6 ± 5.9%. The IC50 at T10 was 107.4 ± 5.5% and at T16 86.4 ± 3.8%. ANOVA 
confirmed a significant difference between the IC50 values according to time with 
p<0.0001. Significant differences between T4 vs. T10 (***) and T22 (****) and T10 
vs. T16 (*) and T22 (*) as well as between T16 and T22 (****) were shown after 
conducting Tukey’s multiple comparison test. Cosinor Analysis identified a 24-h 
rhythm with a mean ± SEM acrophase at T19.9 ± 1.2 h (Table IV-1). Compared with 
the highest and lowest toxicity of FY26 in Hepa1-6 Per2-luc, HCT116 Per2-luc 
needed 7.3% more FY26 at T22 to achieve a cell survival of 50% whereas at T04, 
7.8% less FY26 was needed. This demonstrated that the time dependent IC50 of 
HCT116 Per2-luc was characterised by a wider range as compared to Hepa1-6 
Per2-luc. However, according to Cosinor Analysis, both cell lines were identified with 
the same time points of best FY26 tolerability. Two-way ANOVA showed a 
significant effect of FY26 timing on the IC50 (p<0.0001) as well as a significant 
difference between both cell lines (p=0.029), with an interaction term (p=0.028). 
The differences in the time dependent toxicity as well as in the magnitude of toxicity 
between Hepa1-6 Per2-luc, Hepa1-6 Per2-luc shBmal1 as well as HCT116 Per2-luc 
suggested that the different cell lines displayed different 24-h patterns in FY26 
toxicity, which could be further altered according to the status of the molecular clock.  





The dose and dosing time dependencies in FY26 toxicity were determined using 
iterative IC50 determinations in the murine, clock-proficient hepatocarcinoma cell line 
Hepa1-6 Per2-luc and in the human colon cancer cell line HCT116 Per2-luc as well 
as in the clock-altered clone Hepa1-6 Per2-luc shBmal1.  
In the absence of 24-h temperature synchronisation, the IC50 of FY26 was 20 to 30% 
lower in clock-proficient as compared to Bmal1-silenced Hepa1-6 Per2-luc cells, and 
10% larger than that in human colon cancer cells HCT116 Per2-luc.  
The synchronisation of cells with temperature cycle D revealed statistically significant 
24-h changes in the IC50 of FY26 in both cancer cell lines and in the Bmal1-silenced 
Hepa1-6 Per2-luc clone. For Hepa1-6 Per2-luc, a circadian rhythm in FY26 toxicity 
was demonstrated. Best FY26 tolerability corresponded to a 24-h drug exposure 
starting at T22, 2 h before the programmed temperature rise from 36°C to 37°C. In 
contrast, both Hepa1-6 Per2-luc shBmal1 and HCT116 Per2-luc exhibited bimodal 
toxicity patterns with lowest toxicity at T10 and T22. 
The next questions related to the ability of the in vitro chronotoxicity in 24-h 













V Results – In vivo Chronotoxicity of FY25 and 
FY26 
  





The studies aimed to determine (i) the FY26 sublethal dose level to be used for 
subsequent circadian toxicity experiments, (ii) any circadian toxicity pattern 
(chronotoxicity) of FY26 and FY25 and (iii) organ toxicities caused by FY26. All 
experiments were conducted in mice synchronised with LD12:12. 
The research questions were addressed in three different studies. The first study 
consisted of two experiments. Exp I and II tested 30, 40 and 60 mg/kg FY26 as 
potential sublethal doses. The second study involved three replicate experiments (Exp 
III, IV and V) for determining circadian toxicity pattern in FY26 (50 mg/kg i.p.), using 
body weight loss as main endpoint. 
The effect of dosing time on body weight changes were analysed using thre e 
parameters: value at nadir, area under the curve over the 7 days following the day of 
injection (day 0), and the slope of recovery from nadir using linear regression. Overall 
survival analyses were also performed in order to further characterise the circadian 
toxicity patterns of FY25 and FY26. 
Exp III to V not only served to determine the circadian toxicity patterns of both 
osmium complexes in mice, but also provided the bases for the subsequent studies 
investigating (i) FY26 effects on the circadian timing system of mice, using core body 
temperature and liver clock gene expression rhythms as circadian biomarkers, and (ii) 
tumour growth inhibition in hepatocarcinoma-bearing mice. 
Exp VI involved the determination of histopathological lesions in the main organs of 
mice after subacute treatment with FY26.  




2 Selection of sublethal dose levels of FY26 and FY25 
For Exp I, 30 mg/kg and 40 mg/kg of FY26 were intraperitoneally injected in male 
C57BL/6 mice on day 1 and on day 5 respectively. The dose selection was based on a 
previous dose escalation study involving 20, 40, 80 and 160 mg/kg FY25 and FY26. 
The study identified 160 mg/kg as LD for FY26 (Appendix Figure XI-9). The injection 
of 30 mg/kg resulted in a maximum body weight loss of 7.2% for mouse 1 and of 8.1% 
for mouse 2 24 h after the first injection. No body weight loss was detected for the 3 
other mice nor for the vehicle treated mouse. Body weight loss remained within the 
limits of the human endpoints.  
 
Figure V-1: Body weight loss after a single i.p. injection of 30, 40 and 60 mg/kg FY26.  
Panel (A) shows the body wieght loss after the treatment with 30 or 40 mg/kg FY26 and panel 
(B) shows the body weight loss after the treatment with 40 and 60 mg/kg FY26.  
Five days after the injection of 30 mg/kg FY26, the same mice were injected with a 
single i.p. dose of 40 mg/kg FY26. One day later, a maximum body weight loss of 
7.3% for mouse 2, 3.8% for mouse 3 and 6.6% for mouse 5 were observed. Mouse 3 
and mouse 5 recovered from the injection of 40 mg/kg FY26 and reached the 
pretreatment body weight 1 to 2 days after injection. Thus, mouse 2 lost 20% of body 
weight and exceeded the predefined human endpoints which led to its experimenta l 
exclusion. Throughout the whole experiment, the vehicle treated mouse did not lose 
any body weight (Figure V-1). 
In Exp II, 3 mice were injected with a single intraperitoneal injection of 40 mg/kg and 
60 mg/kg FY26. Maximum body weight loss was observed 24 h after drug injection 




for the 3 mice treated with 40 mg/kg and for a single mouse of 3 mice dosed with 
60 mg/kg. Two mice lost body weight down to 17.6% and 19.3% 3 days after 
treatment with 60 mg/kg FY26. Both mice were consequently euthanized for ethical 
reasons. Maximum relative body weight loss of the non-euthanized mice were 10.2%, 
12.5%, 4.4% and 12.7% 24 h after the injection of FY26. All the non-euthanized mice 
recovered their respective pretreatment body weights 5 days after drug injection 
(Table V-1). 
 
Figure V-2: Survival of mice after treatment with 30 mg/kg, 40 mg/kg and 60 mg/kg FY26.  
Panel (A) shows the survival after the treament with 30 and 40 mg/kg FY26 and panel (B) 
shows the survival after the treatment with 40 and 60 mg/kg FY26. 
Mouse survival was plotted as a function of dose level according to Kaplan-Meier. 
Although no spontaneous death was encountered, the time of mouse sacrifice for 
ethical reasons (~20% body weight loss and/or poor appearance) was considered as 
the time of death. While dose levels 30 and 40 mg/kg were in the sublethal dose range, 
this was not the case for 60 mg/kg (Figure V-2). Nevertheless, the Log-rank test 
(Mantel-Cox) revealed no statistically significant difference in the survival of mice 
receiving 30 mg/kg or 40 mg/kg (p=0.368), or those treated with 40 or 60 mg/kg 
(p=0.114), possibly as a result of the limited sample size. 
To summarise, the good tolerability of both lower doses tested, and the lack of 
statistically significant differences in both toxicity endpoints in these experiments, led 
to assume that a dose level of 50 mg/kg, i.e. midway between 40 and 60 mg/kg could 
ensure a decline in body weights which would be sufficient to detect circadian toxicity 




patterns without exceeding the predefined human endpoints. This dose level was 
chosen for the circadian testing of FY25 as well, since this compound presumably 
represents the active metabolite of FY26. 
3 Circadian toxicity profile of FY25 and FY26 
3.1 Distribution of mouse body weights before the start of treatment 
The in vivo chronotoxicity was investigated in three consecutive experiments 
conducted on 234 male C57BL/6 mice aged 5 to 9 weeks. Body weights were 
monitored twice to three times a week during the pre-treatment synchronisation period 
from the day of arrival until the day of treatment.  
The average mouse’s body weight (mean ± SEM) upon arrival for Exp III to Exp V 
was 18.5 ± 0.3 g for Exp III, 23.5 ± 0.4 g for Exp IV and 22.5 ± 0.5 g for Exp V. No 
differences in the body weights distribution amongst the groups was observed in any 
of the three experiments [p-value from ANOVA with p=0.747 (Exp III), p=0.575 (Exp 
IV) and p=0.913 (Exp V)]. On treatment day, the average mouse’s body weight was 
27.9 g ± 0.2 g (Exp III), 27.9 g ± 0.5 g (Exp IV) and 25.6 g ± 0.6 g (Exp V). No 
significant differences of mouse’s body weight distribution amongst the injection time 
points were calculated for Exp III (p-value from one-way ANOVA 0.220) and Exp IV 
(p-value from ANOVA 0.939). Only in Exp IV, average mouse’s body weight was 
significantly different amongst the different injection groups (p-value from ANOVA 
0.025). Thus, mouse body weights measured after the start of treatment were 
normalised to their pretreatment body weight (Figure V-3). 
The analysis of the body weight distribution showed that no significant effect of time 
on the body weight development on untreated groups was observed except for the 
second experiment. The effect of 50 mg/kg FY25 and 50 mg/kg FY26 on the body 
weights according to the time of injection was thus studied on the normalised body 
weight data. 
 





Figure V-3: Development of pretreatment mouse body weights distribution monitored from 
the day of arrival until the day of treatment.  
3.2 Combined results of the circadian toxicity patterns of FY25 and 
FY26 
3.2.1 Circadian changes of body weight loss after FY25 and FY26 administration 
In order to assess the circadian toxicity pattern after a single intraperitoneal injection 
of 50 mg/kg of FY25 or FY26, the results from Exp III, IV and V were pooled, plotted 
and analysed together. As shown in Figure V-4, maximum normalised body weight 
loss occurred 24 h after FY25 or FY26 injection.  
Mice receiving FY25, lost an average of 3.0 g (with average ± SEM body weight 
ranging from 26.6 ± 0.6 g to 23.6 ± 0.5 g) 24 hours after the treatment at ZT10. This 
corresponded to a relative decrease of mean ± SEM body weight of 10.9 ± 0.7%. 




Average mouse’s body weight loss was smallest in mice receiving treatment at ZT10 
as the average mouse boy weight dropped from 26.8 ± 0.6 g to 24.5 ± 0.5 g, 
corresponding to 8.3 ± 1.7% normalised body weight loss. The treatment of mice at 
ZT02, ZT06, ZT18 and ZT22 led to a decline of average mouse body weight of 9.1 ± 
1.0%, 8.3 ± 1.3%, 9.4 ± 0.6% and 8.9 ± 0.9% respectively. Further, Figure V-4 showed 
that injected mice recovered and gained their pretreatment body weights, 5 to 8 days 
after the intraperitoneal injection of 50 mg/kg FY25 (Figure V-4).  
Regarding FY26, maximum body weight loss was also seen 1 day after injection. 
Maximum weight loss was obtained at ZT18 and ZT22 with a decline from 100% 
pretreatment body weight of 9.0 ± 0.9% and 8.9 ± 0.9%. The minimum of body weight 
loss occurred when mice were injected at ZT02 (100% to 94.9 ± 1.1%). Following the 
curves of the body weight developments after injection of 50 mg/kg FY26, it was 
shown that mice reached their pretreatment body weight 4 to 8 days after drug 
administration (Figure V-4). 
In order to assess the statistical significance of the dosing time related differences, 
two-way ANOVA with repetitive measurements was performed using the normalised 
body weight data, from the day of injection until the end of experiment for both FY25 
and FY26. The Mauchly’s sphericity test demonstrated that FY25 and FY26 presented 
with a different toxicity profile (p<0.001) according to the time of drug administrat ion 
(p<0.001). Further, ANOVA with repeated measurements was conducted on the body 
weight changes according to the time point of FY25 and FY26 injection resulting in a 
significant difference of body weight changes between time points after injecting 50 
mg/kg FY25 (p<0.001) and 50 mg/kg FY26 (p<0.001). Tukey’s multiple comparison 
test showed a significant difference between the body weights at ZT2 vs. ZT14 (**) 
and ZT18 (*), ZT6 vs. ZT18 (**), ZT10 vs. ZT14 (*) and ZT14 vs. ZT18 (**) and 
ZT22 (*) after the treatment with 50 mg/kg FY25. Regarding the injection of FY26, a 
significant difference between body weights was observed between the time points 
ZT2 vs. ZT10 (*), ZT14 (**), ZT18 (**), ZT6 vs. ZT10 (*), ZT18 (**), ZT22 (*) and 
between ZT14 vs. ZT18 (*) and ZT22 (*).  
 





Figure V-4: Average body weight changes as a function of the circadian timing of a single 
injection of 50 mg/kg of FY25 or FY26.  
Panel (A) shows the body weight loss in g and panel (C) shows the normlised body weight loss 
after a single injection of 50 mg/kg FY25. Panel (B) and (D) presents the body weight loss in 
g and the normalised body wieght loss after a single injection of 50 mg/kg  FY26. 
Next, ANOVA and Cosinor Analysis were conducted on the minimum body weight 
loss (nadir of body weight) following FY25 or FY26 administration. No statistica lly 
significant difference characterised maximal weight loss as a function of FY25 dosing 
time. However, maximum body weight loss differed significantly according to the 
time of injection of FY26 (p=0.027). Tukey’s multiple comparison test further showed 
statistically significant differences in maximum body weight loss following FY26 
administrations at ZT2 vs. ZT18 (*) and at ZT2 vs. ZT22 (*) (Figure V-5).  





Figure V-5: Nadir of body weight loss after injection of 50 mg/kg FY25 (panel A) and FY26 
(panel B). 
Cosinor Analysis was applied to identify rhythmic patterns with 24-h or 12-h periods 
in relative maximum weight losses (Table V-1). No significant 24-h or 12-h rhythm 
was shown for FY25. In contrast, Cosinor Analysis revealed a significant 24 h 
rhythmicity in maximum  body weight loss for FY26, with an acrophase at 6.7 ± 3.3 h 
and an amplitude of 1.7 ± 1.3 % (p=0.039). 
Table V-1: Cosinor Analysis of nadir body weights, as percentages of pre-treatment values, 
after injection of 50 mg/kg FY25 or FY26 (mean ± SEM, n=18 per time point). 
 FY25 FY26 
Mesor (%) 90.8 ± 0.8 92.2 ± 0.9 
Period 24 h 12 h 24 h 12 h 
Acrophase (h)  - - 6.7 ± 3.3 1.9 ±1 .9 
Amplitude (%)  - - 1.7 ± 1.3 1.6 ± 1.3 
p-Value  0.564 0.498 0.039 0.061 
 
Thus, the changes in body weight at nadir did not differ significantly in the mice 
receiving FY25. In contrast, a circadian toxicity pattern was demonstrated for FY26. 
ANOVA’s and Cosinor revealed that the lowest toxicity resulted from FY26 dosing 
during the early to middle of the light, i.e. during the first half of the rest phase of the 
rest-activity cycle. Highest toxicity was encountered in mice dosed in the second half 
of the dark span, i.e. during the mid- to late activity phase of their rest-activity cycle. 
Confirmation was further sought using the area under the curve (AUC), the slope of 




body weight recovery and overall survival, as complementary chronotoxic ity 
endpoints.  
3.2.2 Circadian changes of the area under the curve of body weight curves  
The areas under the normalised body weight curves (AUC0-7d) were plotted against the 
time of injection (Figure V-6). The AUC0-7d was used as a further measure for probing 
any circadian toxicity pattern, where the larger the AUC0-7d value, the worse the 
toxicity. 
 
Figure V-6: Area under the curve (AUC0-7d) from day of injection of 50 mg/kg FY25 (panel A) 
and FY26 (panel B) until 7 days after injection in % ∙ d. 
Regarding FY25, AUC0-7d was least in the mice dosed at ZT18 (676.5 ± 1.8 %∙d) and 
highest in those treated at ZT14 with 684.9 ± 3.9 %∙d. However, no statistica lly 
significant difference according to FY25 timing was found according to both ANOVA 
(p=0.073) or Cosinor for periods of 24-h or 12-h (p=0.572 and p=0.204, respectively). 
In contrast, for FY26, the lowest AUC0-7d was identified at ZT22 with 661.3 ± 12.6 
%∙d and the highest one at ZT2 with 693.7 ± 2.7 %∙d. ANOVA demonstrated 
statistically significant difference between the AUC0-7d according to treatment time 
with a p-value of 0.048. Tukey’s multiple comparison further emphasized significant 
differences between the AUC0-7d of the time points ZT2 and ZT22 (*). No significant 
24-h (p=0.091) and 12-h (p=0.089) rhythm was obtained for the AUC0-7d after FY26 
administration.  
The analysis of the AUC0-7d data confirmed previous results supporting the occurrence 
of a circadian toxicity pattern for FY26, with least toxicity occurring during the early 




to middle of the light span, and highest toxicity occurring in the second half of the 
dark span. 
3.2.3 Circadian recovery from the nadir of body weight loss to pretreatment body 
weights 
Mice injected with 50 mg/kg FY25 exhibited a fast recovery at ZT14 with a mean 
reciprocal slope of 2.0 ± 0.2 body weight in %/h. The slowest or longest recovery was 
observed at the injection time point ZT18 with a reciprocal slope of 1.3 ± 0.3 body 
weight in %/h. ANOVA did not reveal any significant differences between the 
recovery after injecting 50 mg/kg FY25 (p=0.271). No significant 24-h or 12-h rhythm 
of the slope of recovery were detected (Cosinor Analysis: p=0.747) (Figure V-7).  
In contrast, the fastest recovery after FY26 administration was seen at ZT6 with a 
slope of 2.4 ± 0.3 body weight in %/h and the slowest one being 1.3 ± 0.3 body weight 
in %/h at ZT18. These differences did not differ significantly using ANOVA 
(p=0.203) (Figure V-7). However, Cosinor analysis showed a significant 24-h rhythm 
with an acrophase at T 6.2 ± 1.5 h and an amplitude of 0.3 ± 0.1 body weight in %/h 
with a mesor of 1.7 ± 0.1 body weight in %/h (p=0.034). 
 
Figure V-7: Slope of linear regression from nadir of body weight loss to recovery.   
Panel (A) shows the slope of recovery after the treatment with 50 mg/kg FY25 and panel (B) 
presents the slope of recovery after the injection with  50 mg/kg FY26.  
To summarise, recovery from maximum FY25 toxicity did not display any circadian 
rhythmicity, whereas this was the case for FY26, a result that was fully consistent with 




those obtained using nadir or AUC0-7d normalised body weight values. ZT06 was 
identified as the time point of FY26 delivery that achieved best tolerability.  
3.2.4 Circadian differences in overall survival after treatment with FY25 and 
FY26 
The overall survival rates in the mice treated with FY25 or FY26 were 91.7 ± 2.8% 
and 88.9 ± 3.2% respectively. As a result, the overall survival curves of the mice in 
Exp III-V showed no statistically significant differences according to circadian timing 
using the Log-rank (Mantel-Cox) test (p=0.189 and p=0.095, respectively). 
Interestingly however, mortality was only observed following dosing of either 
compound at ZT14, Z18, or ZT22, when mice reached humane endpoints, thus 
confirming improved safety of both osmium compounds following dosing during the 
rest span of mice (Figure V-8). 
 
Figure V-8: Overall survival of mice after treatment with 50 mg/kg FY25 and FY26.  
Panel (A) shows the survival after the treatment with FY25 and panel (B) after the treatment 
with FY26. 
3.3 Histopathological lesions 
Following the 4 repeated i.p. injections of either the vehicle or 50 mg/kg FY26 every 
other day in PER2::LUC mice, a maximum body weight loss after the vehicle injec tion 
ranged between 5.8% (32.3 g to 30.4 g) and 5.2% (30.8 g to 29.2g) on day 4 following 
the second treatment. A maximum body weight loss ranged between 12.9% (30.3 g to 




26.4 g) of mouse 3 on day 8 to 19.9% (33.0 g to 26.6 g) of mouse 6 on day 6. Mouse 
4 was euthanized on day 3 following the clinical inspection (Figure V-9).  
 
Figure V-9: Body weight changes after 4 repeated injections of the vehicle or 50 mg/kg FY26 
in PER2::LUC mice. 
The AUC from day 1 until day 3 (including mouse 3) was calculated (AUC1d to 3d). The 
AUC1d to 3d showed a statistically significant reduction of body weight with a mean ± 
SEM AUC1d to 3d for the vehicle of 199 ± 1 %∙d and for the FY26 treated of 185 ± 
1 %∙d (p-value from t-test with 0.001). 
 
Figure V-10: Area under the curve of body weight loss 24 h after the second treatment 
(AUC1d to 3d). 




Tissue sampling was done 24 h after the last injection under consideration of the 
predefined human endpoints. Thus, only three mice were euthanized after completing 
the full treatment plan of 4 doses. One mouse was culled on day 3, and two other ones 
on day 6 or 7. Liver, both kidneys, spleen, sternum, stomach, ileum and colon were 
sampled, washed in PBS and fixed in 10% Neutral Buffered Formalin for 24 h before 
being transferred into PBS for tissue slicing.  
No major toxicity was determined in stomach, ileum, colon, liver, kidney, spleen and 
bone marrow for both vehicle-treated mice. Mild steatosis in 10% of the hepatocytes 
was observed in the liver of a single FY26-treated mouse. Histopathological slides of 
the organs of the other two drugged mice showed no pathological changes (Appendix 
Figure XI-10, Figure XI-11, Figure XI-12, Figure XI-13, Figure XI-14, Figure XI-15 
Figure XI-16). 
4 Translating in vitro into in vivo chronotoxicity 
The determination of the in vitro and in vivo FY26 chronotoxicity identified T22 and 
ZT06 as the time points of best FY26 tolerability. As the in vitro FY26 chronotoxic ity 
was assessed by subjecting cells to temperature cycles mimicking the physiologica l 
core body temperature rhythm, the actual temperature cycle to which cells were 
exposed to in the cell culture incubator, was measured. This was done by placing a 
temperature sensor (Anipill®) in three 35 mm NUNC Petri dishes filled with cell 
culture media. In parallel, the Anipill® was implanted in the peritoneal of 3 mice in 
order to record core body temperature cycles. Cosinor Analysis was than applied on 
the hourly averaged in vitro and in vivo temperature cycles (Figure V-11 and 
Appendices Figure XI-17). The acrophase of the in vitro temperature cycle occurred 
at T6.7 ± 0.0 h with an amplitude of 0.6 ± 0.0°C and a mesor of 37.0 ± 0.0°C (p<0.001). 
The acrophase of the in vivo temperature cycle was in antiphase to the in vitro 
temperature cycle which occurred at T18.2 ± 1.0°C referring to the middle of the active 
phase. Its amplitude was identified with 0.6 ± 0.1°C and the mesor with 36.3 ± 0.1°C 
(p=0.001). Thus, the time point of best in vitro FY26 chronotoxicity, which was 
identified at T21, occurred 3 h after the bathyphase (nadir of temperature cycle). The 
same was observed for the in vivo FY26 chronotoxicity as the time point of best FY26 
tolerability occurred during the bathyphase of the in vivo core body temperature cycle. 




This leads to the conclusion that the lowest in vivo and in vitro toxicity occurred during 
the bathyphase of the temperature cycle.  
 
Figure V-11: In vitro (blue curve) and in vivo (red curve) core body temperature rhythm fitted 
to a cosine function.  
Cosinor Analysis was conducted on the in vitro temperature cycles (n=3) and on the mice 
core body temperatuer cycles (n=3). The marked lines depictes the pregrammed temperature 






   





For FY25, no significant toxicity pattern regarding the changes in body weights, the 
AUC0-7d as well as the survival was observed. On the contrary, FY26 toxicity differed 
significantly as a function of circadian timing, using body weight changes at nadir, as 
well as over 7 days (AUC0-7d) or the slope for expressing recovery. The lowest and 
highest toxicities corresponded to FY26 dosing near the middle of the rest phase and 
near the end of the activity phase of the rest-activity circadian cycle of the mice, i.e. 
at ZT06 and ZT18 respectively. Cosinor Analysis further revealed that FY26 is best 
tolerated following its administration during the bathyphase of either temperature 
cycles.  
The results clearly demonstrated that the toxicity profile of FY26 followed a circadian 
pattern, which is not the case for its active metabolite FY25.  
Based on these findings, the following circadian studies aimed at the determination on 
the relationship between FY26 chronotoxicity and its effects on selected physiology 
and molecular circadian biomarkers. Specifically, this included the investigations of 
the circadian effect of FY26 on both core body temperature as a measurement of CTS 
disturbance and circadian clock gene Per2 expression in liver. 
  











VI Results – In vivo efficacy of FY26 
  





The aim of this study was to determine whether (i) the FY26 activity that was 
demonstrated against Hepa1-6 Per2-luc cells in vitro, would be achieved in vivo and 
whether (ii) delivering FY26 at times of best or worst tolerability would impact on its 
efficacy in tumour-bearing mice. 
In a first study, tumour growth rates were determined in 18 tumour-bearing male 
CD1-Foxn1nu mice entrained to LD 12:12, with light onset at 07:00 and light offset at 
19:00. Mice were injected s.c. with 106 Hepa1-6 Per2-luc cells in 100 µL PBS in each 
flank. One week after tumour cell implantation, mice were injected with 0, 40, 60 or 
80 mg/kg of FY26 every other day for 12 days. Body and tumour weights were 
measured daily. 
The second study aimed at assessing whether FY26 timing would differentially affect 
tumour growth inhibition according to whether a subacute treatment with FY26 was 
given at the time point of lowest (ZT06) or highest (ZT18) toxicity.   




2 Determination of therapeutic dose levels of FY26 
2.1 Body weight changes after repeated FY26 treatment 
Mean body weights ± SEM were similar in the control and the three treatment groups 
on the first treatment day (controls: 30.3 ± 0.9 g; FY26 40 mg/kg: 30.6 ± 0.8 g; FY26 
60 mg/kg: 30.5 ± 0.8 g; FY26 80 mg/kg: 30.3 ± 0.9 g; p-value from ANOVA with 
0.992) (Figure VI-1). Thus, subsequent body weight changes could be ascribed to 
treatment effects. 
 
Figure VI-1: Body weight (g) distribution before the start of the six repeated injections with 
40 mg/kg, 60 mg/kg and 80 mg/kg FY26.  
A dose dependent reduction of body weights was observed during treatment (Figure 
VI-2). Minimum average mouse’s body weight was measured 14 days after treatment 
onset, being 30.4 ± 0.3 g (94.0 ± 1.7% of body weight on the first treatment day) for 
the mice dosed with 40 mg/kg/injection, and with 28.4 ± 0.8 g (92.3 ± 3.0%) for those 
dosed with 60 mg/kg/injection. The largest average mouse’s body weight loss was 
observed 8 days after treatment with 80 mg/kg/injection when it reached 25.5 ± 0.3 g 
(87.3 ± 9.8%). Body weight loss did not differ significantly according the FY26 dosing 
(p-value from ANOVA with 0.407). A linear relation was found between FY26 dose 
and body weight (as a percentage of its pre-treatment value) in each mouse (Figure 
IV-2). 





Figure VI-2: Body weight changes following repeated treatment with 40 mg/kg, 60 mg/kg or 
80 mg/kg of FY26 every other day for 12 days.  
The left panel (A) shows the normalised body weights and the right panel (b) the lowest body 
weight reached in each mouse (as a percentage of its pretreatment value) as a function of  
FY26 dose. 
To conclude, repeated treatments with 40 mg/kg or 60 mg/kg of FY26 induced 
maximum body weight loss of 6.0% and 7.7% three days after the 6th dose 
respectively. Subacute treatment with 80 mg/kg FY26 resulted in more than 20% body 
weight loss and was thus outside of the predefined humane endpoints. The body 
weight change dynamics on FY26 dosing documented here for CD1-Foxn1nu differed 
from those shown in C57BL/6 despite same sex, similar age and same LD12:12 
synchronisation (shown in III Result – In vivo chronotoxicity of FY25 and FY26). 
More specifically, body weight dropped to a nadir 24 h post dose in C57BL/6 mice, 
but not in CD1-Foxn1nu. These observations support strain-specific differences in 
FY26 toxicity profile. 
2.2 Survival as a measure of antitumour efficacy 
The survival rate varied from 0% in the mice receiving 80 mg/kg/injection to 40% for 
those treated with 60 mg/kg/injection and 62.5% for those receiving 40 mg/kg/inj. The 
survival rate in the control group was 33.3% because of tumour progression. Log-rank 
(Mantel-Cox) test revealed significant differences in survival curves with regard to the 
different treatment groups (p=0.0001) (Figure VI-3). The results highlighted a near 
doubling of survival in the mice dosed with 40 mg/kg/injection as compared to 




controls, while treatment at higher dose levels did not improve survival or even were 
detrimental due to excessive toxicity. 
 
Figure VI-3: Survival of Hepa1-6 Per2-luc-12 days bearing mice receiving six alternate day 
injections of 40, 60 or 80 mg/kg/injection of FY26.  
2.3 Tumour growth on subacute treatment with FY26 
The distribution of tumour weights on the first treatment day revealed some 
imbalances between groups, with arithmetic mean ± SEM values ranging from 12.7 ± 
1.5 mg for the vehicle group up to 40.8 ± 13.4 mg for the 80 mg/kg group. The 
differences were not statistically significant (p-value from ANOVA with 0.676). 
Nevertheless, tumour weight changes were compared as a function of drug dose using 
both raw data and percent changes relative to tumour weight on Day 1. 
 
Figure VI-4: Distribution of the tumour weight (mg) before the start of treatment with 
40 mg/kg, 60 mg/kg and 80 mg/kg FY26.  




In order to precisely determine any relation between tumour inhibition and FY26 dose, 
ANOVA with repeated measurements was applied to the normalised tumour weights 
over the initial 9 treatment days. Day 9 was chosen because all the mice treated with 
80 mg/kg had to be culled for humane reasons before day 10. A non-statistica lly 
significant trend was shown with a p-value of 0.071.  
Further, the area under the curve (AUC) from the tumour growth curve over time were 
calculated over both the initial 9 days when mice were alive in all groups (AUC1d to 9d) 
and over the whole Exp duration of 18 days (AUC1d to 18d) (Figure VI-5 and Figure 
VI-6). 
 
Figure VI-5: Tumour growth inhibition after six repeated injections with the mean ± SEM of 
vehicle, 40 mg/kg, 60 mg/kg and 80 mg/kg FY26.  
Panel (A) shows the tumour weight in g and panel (B) shows the normalised tumour weights 
to the tumour weight upon the start of the treatment in percentage.  
Using AUC1d to 9d as an endpoint, mean tumour growth inhibition was 3.3-fold for 
80 mg/kg/injection, and 1.0- and 1.8-fold for 60 and 40 mg/kg/injection. AUC1d to 18d 
further showed 2.0- and 1.5-fold tumour weight decrease on 60 and 40 mg/kg/inject ion 
doses levels as compared to controls (Table VI-1). 





Figure VI-6: Area under the curve of tumour growth inhibition from day 1 to day 9 (AUC1dto9d) 
and from day 1 until the end of the experiment (day 18) (AUC1dto18d).  
Panel (A): median and range of AUC1d to 9d of tumour weights following FY26 treatments. 
Panel (B): median and range of AUC1d to 18d of tumour weights following FY26 treatments. 
Non-parametric Kruskal-Wallis Test revealed statistically significant differences in 
both AUC1d to 9d (p=0.02) and AUC1d to 18d (p=0.008) (Figure VI-6). Post-hoc testing 
(Dunn’s Test) showed no difference between the treatment group for AUC1d to 9d but 
for AUC1d to 18d with a significant difference (p=0.021) was detected between the 
vehicle and 80 mg/kg FY26 group. As the survival of the 80 mg/kg treated group was 
0% after 5 treatments, Kruskal-Wallis Test was conducted on the same date but 
leaving the 80 mg/kg treated mice out. The test demonstrated with a p-value of 0.327 
that no difference in tumour growth inhibition of 40 and 60 mg/kg compared to the 
vehicle (control) group was detected. 
Table VI-1: AUC1d to 9d , AUC1d to 18d and the slope of tumour weights after repetitive treatments 
with the vehicle, 40 mg/kg, 60 mg/kg and 80 mg/kg FY26 (mean ± SEM, n=3-5). 











































251 ± 89 328 ± 91 137 ± 86 p=0.032 
 
The slope of the linear regression adjusted to tumour growth allowed to differentia te 
slow (low slope) and fast (high slope) tumour growth, according to FY26 dose level 
(Figure VI-7). The maximum slope was found in the untreated control group.  
Mice treated with 80 mg/kg showed a 4.5-fold decline in tumour growth slope. 
Treatment with 60 mg/kg and 40 mg/kg FY26 resulted in a 1.9- and 2.5-fold respective 
declines in tumour growth slope as compared to controls (ANOVA, p-value = 0.078). 
 
Figure VI-7: Slope of the linear regression of tumour growth under the treatment with 
40 mg/kg, 60 mg/kg and 80 mg/kg FY26.  
To summarise, FY26 did exert a modest antitumour efficacy in mice bearing 
hepatocarcinoma tumour. FY26 efficacy was largest following dosing with 
80 mg/kg/injection. However, this dose level was too toxic even though the drug was 
given at ZT06, i.e. the circadian time point of best FY26 tolerability. Minimal 
differences were found regarding the efficacy of 40 vs. 60 mg/kg/injection, with the 
latter schedule being more toxic than the former one. Based on these results, a dose of 




50 mg/kg/injection was chosen to further study time dependent effects of FY26 on 
tumour growth inhibition in male CD1-Foxn1nu mice bearing Hepa1-6 Per2-luc 
tumours.  
3 Relationship between chronotolerance and antitumour 
efficacy 
3.1 Body weight loss after repeated FY26 injections at ZT06 vs. ZT18 
On the injection day, mean ± SEM body weight was 30.5 ± 1.1 g in the vehicle group, 
29.2 ± 0.8 g in the mice to receive FY26 at ZT06 and 29.2 ± 1.0 g for those to be 
treated at ZT18 (ANOVA, p=0.536). (Figure VI-8).  
 
Figure VI-8: Body weight distribution before the start of 6 repeated treatments with 50 mg/kg 
FY26 every other day injected at ZT06 and ZT18.  
Figure VI-9 shows daily mean body weights expressed both as grams and as 
percentages of pretreatment body weight. Control mice data were pooled whatever the 
vehicle administration timing was. Mice on vehicle displayed a gradual increase in 
body weight (Figure VI-9). In contrast mice on FY26 lost weight. Those treated at 
ZT06, displayed a maximum body weight loss of 4.9 ± 1.2% on day 4 (after the 2nd 
dose). For those treated at ZT18, maximum body weight loss was 8.2 ± 1.6% on day 
10, i.e. after the 5th injection. ANOVA with repeated measurements showed a 
statistically significant difference between tumour growth inhibition according to 
FY26 dosing (non-normalised and normalised body weights with a p-value of 
<0.0001). Significant differences were detected between the vehicle group vs. ZT06 




(****) and vehicle vs. ZT18 (****) for the normalised and non-normalised body 
weights. A significant difference was further detected between the normalised body 
weights of mice injected at ZT06 and ZT18 (**). 
 
Figure VI-9: Development of body weight over time after the treatment with 6 repeated 
injections of 50 mg/kg FY26 at ZT06 and ZT18.  
Panel (A) shows the body weight loss in g and panel (B) presents the normalised body weight 
loss in percentage. 
3.2 Tumour growth inhibition after FY26 dosing at ZT06 and ZT18 
Large differences in individual tumour weights were found before treatment onset, 
with extreme values ranging from 13.0 to 84.6 mg. The average ± SEM tumour weight 
ranged from 29.2 ± 0.8 mg up to 30.5 ± 1.1 mg according to mouse group, yet the 
differences were not statistically significant (ANOVA, p=.536) (Figure VI-10). 





Figure VI-10: Distribution of tumour weight (mg) before the start of treatments with 50 mg/kg 
FY26 at ZT06 and ZT18 or vehicle (control). 
Tumour growth curves in the three groups are depicted in Figure VI-11. The right 
panel presents the non-normalised tumour weights (mg). The tumour weights were 
normalised to the mouse tumour weights before the start of treatment. Tumour growth 
was similar in controls and in mice receiving FY26 at ZT06. In contrast, tumour 
growth was delayed in the mice receiving FY26 at ZT18. ANOVA with repeated 
measurements showed a significant difference between the tumour weights in the 
vehicle, ZT06 and ZT18 group (non-normalised tumour weights (mg) with p=0.005 
and the normalised tumour weights (%) with p=0.009). Post-hoc testing (Tukey’s 
multiple comparison test) revealed a significant difference between the tumour 
weights in mg of the vehicle vs. ZT06 group and between the normalised tumour 
weights (%) of the vehicle vs. ZT18. 





Figure VI-11: Time dependent tumour growth inhibition af ter 6 repeated treatments with 
50 mg/kg FY26 given at ZT06 and ZT18.  
Panel (A) shows the tumour growth inhibition after the treatment with FY26 and the vehicle 
in mg. Panel (B) depicts the normalised tumour growth inhibition in percantage.  
The slope of the linear regression representing the tumour growth inhibition was 
significantly different between treatment time points (p-value from ANOVA with 
0.04). The slope from the linear regression of the tumour growth decreased 1.2-fold 
following the FY26 injection at ZT06. At ZT18, the tumour growth declined 2-fold as 
compared to the vehicle. Tukey’s multiple comparison test identified a statistica lly 
significant difference between the vehicle treatment vs. the treatment at ZT18 (*) 
(Figure VI-12 and Table VI-2).  
Table VI-2: AUC1d to 16d and the slope representing the tumour growth after FY26 treatment at 
ZT06 and ZT18. 




253 ± 32 205 ± 41 131 ± 19 p=0.04 
 
In summary, the experiment suggested maximum tumour growth inhibition following 
6 repeated injections of 50 mg/kg FY26 every other day at ZT18, during the mid-span 
of the active phase of mice. 





Figure VI-12: Slope of tumour growth after 6 treatments with the vehicle and 50 mg/kg FY26 
at ZT06 and ZT18.  
3.3 Survival of tumour-bearing mice treated with FY26 at ZT06 or 
ZT18 
No death was recorded due to the vehicle toxicity. However due to fast tumour 
progression, mice died as a consequence of too high tumour weights on day 9 and 15. 
The overall survival of mice treated at ZT06 or ZT18 was 33.3%. Similar numbers of 
deaths were due to large tumour weights and toxicity. A trend toward least toxicity in 
ZT06-dosed mice was apparent. However, log-rank test did not reveal any statistica lly 
significant difference between treatment groups for overall survival (p=0.481) as well 
as for toxicity-related or tumour progression-related survival (p=0.069 and p=0.592 
respectively).  





Figure VI-13: Time dependent survival of mice undergoing 6 repeated treatments every other 
day of either the vehicle or 50 mg/kg FY26 at ZT06 and ZT18.  
Panel (A) depicts the overall survival whereas panel (B) depicts the number of death due to a 
high tumour weight and panel (C) shows the number of death due to hight FY26 toxicity.   





The results presented in this chapter demonstrated that FY26 was modestly active 
against Hepa1-6 Per2-luc cells at palpable stage. The efficacy depended upon dose 
level and it was limited by the toxicity of the largest dose level tested (80 mg/kg/d). 
FY26 seemed to be more active following dosing at the most toxic timing, a finding 
that would need confirmation on a larger number of mice. Subsequent studies aimed 












VII Results – Time dependencies in 
pharmacokinetics and pharmacodynamics of 
FY26 
  





The experiments aimed to define both the circadian patterns in the in vitro cellula r 
pharmacokinetics and pharmacodynamics of FY26, and the influence of the molecula r 
circadian clock on FY26 pharmacodynamics. 
The first pharmacokinetics experiment primarily aimed to determine the time 
dependent changes of intracellular FY26 uptake. Synchronised Hepa1-6 Per2-luc cells 
were exposed to 1 µM FY26 at six time points 4 h apart (T02, T06, T10, T14, T18 or 
T22) until the experiment was completed. Osmium concentrations were measured 
with Inductively Coupled Plasma Mass Spectrometry (ICP-MS) in extracellular and 
intracellular fractions collected over a time course of 72 h, representing a total of 360 
[Os] determinations. Dosing-time dependent changes in FY26 pharmacokinetics and 
pharmacodynamics were assessed through the determination of maximum 
intracellular FY26 concentration (Cmax), time to reach Cmax (tmax), area under the curve 
(AUC) and cellular viability in each culture dish (counts of dead and living cells per 
1 mL cell suspension). 
Three subsequent experiments aimed to determine the induction of apoptosis, 
autophagy and cell cycle phase distribution after FY26 exposure of Hepa1-6 Per2-luc 
and Hepa1-6 Per2-luc shBmal1 for 24 h (for apoptosis, autophagy and cell cycle phase 
distribution) and for 72 h (autophagy). A fifth experiment assessed possible time 
dependent cell cycle phase distributions after FY26 exposure. As the different 
pharmacodynamics endpoints were determined at different time points during the 
experiment, the effect of FY26 on bioluminescence was assessed under continues 
FY26 exposure which was monitored from the start of drug administration until 4 to 
5 days after.  
  




2 Time dependent cellular pharmacokinetic of FY26  
2.1 Osmium concentration in Hepa1-6 Per2-luc cell culture media 
Dosing- time dependent changes in FY26 pharmacokinetics were assessed in Hepa1-6 
Per2-luc cells synchronised with temperature cycle D. After 2.5 days of 
synchronisation, 1 µM of FY26 was added into each of the 198 Petri dishes at circadian 
time points T02, T06, T10, T14, T18 or T22 (33 dishes per dosing time point) with T0 
marking change from 36 to 37°C of the temperature cycle. The extracellular (media) 
and intracellular osmium concentrations were measured at 0 h (just before drug 
administration), then at 1 h, 3 h, 6 h, 9 h, 12 h, 18 h, 24 h, 30 h, 48 h and 72 h after 
drug administration (triplicate samples for each individual sampling time per circadian 
time). Osmium concentrations were determined using ICP-MS. 
The extracellular osmium concentrations remained close to 1 µM, which was in 
accordance with the FY26 dose at all dosing times (Figure VII-1). However, a 
minimum of extracellular osmium concentration (Cmin) was detected for each time 
point which varied across the different sampling time points. Table VII-1 summarises 
the distribution of the average Cmin that did not differ significantly according to FY26 
timing. Declines in extracellular osmium concentrations likely resulted from FY26 
cellular uptake. Throughout the whole experimental duration, the extracellula r 
osmium concentrations ranged between 0.7 ± 0.1 µM and 1.2 ± 0.1 µM as a function 
of both dosing time and FY26 exposure duration. Overall, FY26 was abundantly 
supplied to ensure drug saturation in the media throughout the experiment. 
Table VII-1: Extracellular osmium concentration (µM) of synchronised Hepa1-6 Per2-luc 
cells incubated with 1 µM FY26 (n=3). 
Circadian 
time 
Time Cmin occurred Cmin (osmium)in µM 
Mean ± SEM 
T02 1 h 0.896 ± 0.036 
T06 18 h 0.862 ± 0.022 
T10 3 h 0.729 ± 0.141 
T14 6 h 0.898 ± 0.045 
T18 12 h 0.885 ± 0.01 




T22 6 h 0.932 ± 0.03 
 
No statistically significant difference between the minimum of the extracellula r 
osmium concentration according to the time of the start of drug administration was 
detected (p-value from ANOVA with 0.352).  
 
Figure VII-1:Osmium concentration of cell culture media subjected to Hepa1-6 Per2-luc cells.  
The extracellular osmium concentration was measured at 0 h (time point of the administration 
of 1 µM FY26 thus serving as an untreated control), then at 1 h, 3 h, 9 h, 12 h, 18 h, 24 h, 




30 h, 48 h and 72 h. The sampling time point “0 h” refers to the time when 1 µM FY26 was 
added. At the same time, media with drugs were taken and treated as blank controls. The 
osmium concentration in the media of  each sample was determined using ICP-MS (n=3).  
2.2 The cellular uptake of FY26 in Hepa1-6 Per2-luc is time 
dependent 
The intra-cellular osmium concentration was determined according to the same 
experimental set up as used for the extra-cellular osmium determination. Figure VII-2 
depicts the individual and averaged intracellular osmium concentrations over the 72 h 
following FY26 addition into the media at one of six circadian times.  
 
Figure VII-2: Time dependent changes of intracellular osmium concentrations in 
synchronised Hepa1-6 Per2-luc (n=3).  




Based on the pharmacokinetics curves, the maximum of osmium intracellula r 
concentration (Cmax), the time needed to reach Cmax (tmax) and the AUC until tmax 
(AUC0h-tmax) were determined. All three parameters were largest following FY26 
addition at T02, and least following drug addition at T14 or T10. More specifica lly, 
Tmax (mean ± SEM) was 30.0 ± 0 h for the T02 group, as compared to 19 ± 8.2 h for 
T14. Cmax (mean ± SEM) was 28.7 ± 4.6 ng /106 cells for the T02 group, and 12.7 ± 
2.1 ng/106 cells for the T14 group. AUC0h-tmax (mean ± SEM) was 341 ± 8 ng ∙ h/ 106 
cells for the T02 group and 156  ± 14 ng ∙ h/ 106 cells) for the T10 group (Figure VII-3).  
 
Figure VII-3: Time dependent intracellular osmium uptake.  
Panel (A) presents Cmax of intracellular osmium, panel (B) depicts tmax and panel (C) shows 
the AUC0h-tmax of the intracellular osmium uptake (mean ± SEM, n=3).  
Cosinor Analysis validated statistically significant 24-h rhythms for both Cmax and 
AUC0h-tmax, for which a 12-h harmonic period was also found. No circadian rhythm 
was validated for tmax. The acrophases of Cmax and AUC0h-tmax occurred both within the 
hour following temperature rise from 36 to 37°C, thus suggesting increased FY26 
uptake following FY26 addition near this circadian time (Table VII-2). ANOVA 
confirmed statistically significant differences in Cmax values according to circadian 




dosing time (p=0.026). Tukey’s multiple test of comparisons emphasised on the 
difference between T02 vs. T14 (*). The AUC0h-tmax values also differed significantly 
(p=0.006). Tukey’s multiple comparison test pointed out significant differences 
between T02 vs. T06 (*), T02 vs. T10 (**) and between T02 vs. T18 (*).  
Table VII-2: Results from Cosinor Analysis of FY26 cellular absorption (AUC0h-tmax) and 
maximum cellular concentration (Cmax) according to drug administration timing.  
The results for tmax are not shown as they did not exhibit a 24-h or 12-h rhythm. 
 24-h rhythm 12-h rhythm 
AUC0h-tmax 
Acrophase 
(time in h) 
0.5 ± 1.0 2.4 ± 0.4 
Amplitude  
(ng osmium per 106 
cells ∙ h) 
0.2 ± 0.1 0.3 ± 0.1 
p-Value 0.011 0.002 
Cmax 
Acrophase 
(time in h) 
1.8 ± 0.9 - 
Amplitude 
(ng osmium per 106 cells) 
0.3 ± 0.1 - 
p-value 0.006 NS 
 
In summary, a large amplitude circadian rhythm characterised FY26 uptake in 
temperature-synchronised Hepa1-6 Per2-luc cells. Drug uptake was about twice as 
large following drug addition at T02 as compared to T14 or T10, based on Cmax or 
AUC0h-tmax values respectively. Such chronopharmacokinetics mechanism partly 
accounted for the in vitro chronotoxicity of FY26. Indeed, the maximum FY26 uptake 
and the highest toxicity resulted from FY26 addition at T02 and T04 respectively, i.e. 
during the early hours of the higher temperature plateau in the 24-h synchroniser. In 
contrast, there was no apparent relation between the times corresponding to lowest 




FY26 uptake (T10 or T14), and that associated with best tolerability, thus calling for 
further chronopharmacodynamics investigations. 
3 Time dependent pharmacodynamics of FY26  
The first experiment determined the effect of 1 µM FY26 on the time dependent cell 
viability changes. This was followed by two experiments which investigated the 
pharmacodynamics effects of FY26 on apoptosis and autophagy. Two further 
experiments determined the dose and time dependent effects of FY26 on cell cycle 
phase distribution. 
3.1 FY26 displays time dependent inhibition of cell proliferation 
Viable cell counts were determined iteratively over the 72-h that followed FY26 
addition at one of 6 circadian times in synchronised Hepa1-6 Per2-luc cells. Cell 
counts increased steadily thereafter, yet with apparently different patterns according 
to dosing time (Figure VII-5). While an initial cell count of 50 000 cells had been 
seeded initially, the cell counts at 0 h (mean ± SEM), just prior to drug addition ranged, 
from 2.2 ∙ 105 ± 3 ∙ 104 to 4.3 ∙ 105 ± 4.2 ∙ 104 for a 1 mL cell suspension of an individua l 
Petri dish. Statistically significant differences between the cell counts at different 
circadian time of sampling were detected (p from ANOVA with 0.019) (Figure VII-4).  
 
Figure VII-4: Number of cell counts of Hepa1-6 Per2-luc cells at the first sampling time point 
"0 h" at T02, T06, T10, T14, T18 and T22. 
Tukey’s multiple comparison test further showed a significant difference between cell 
counts at T14 vs. T18 (*). Subsequent cell counts in each group were then normalised 




to the average corresponding cell count at “0 h”. The AUC from 0 h to 72 h (AUC0h-72h) 
and the slope of the cell counts from the linear regression were determined. The results 
are shown in Table VII-3. 
 
Figure VII-5: Normalised cell counts of Hepa1-6 Per2-luc cells.  
The figures show the average ± SEM normalised (to the FY26 free control at 0 h) cell counts 
of Hepa1-6 Per2-luc cells. After 2.5 days under temperature synchronisation, 1µM FY26 was 
added at 0 h referring to the circadian time T02, T06, T10, T14, T18 and T22. Cells were 
harvested and counted at each circadian time point 0 h, 3 h, 9 h, 12 h, 18 h, 24 h, 30 h, 48 h 
and 72 h. Cells per replicate of each condition (n=3) were counted.  




The highest AUC0h-72h was observed at T10 and the minimum at T18. Cosinor 
Analysis found no significant 24-h or 12-h rhythm. ANOVA was significant with a 
p-value of 0.0003. Tukey’s multiple comparison test showed significant differences 
between the time points T02 vs. T06 (*), T10 (***), T18 (**), T22 (**) and T06 vs. 
T14 (*), T10 vs. T14 (**) and T14 vs. T22 (**) (Figure VII-6).  
Table VII-3: Mean ± SEM  of the AUC0h-72h and slope0h-72h of normalised cell counts according 
to the time of FY26 addition. 
 T02 T06 T10 T14 T18 T22 
AUC0h-72h 
(cell counts/ 
















4.4 ± 0.5 5.0 ± 0.7 5.8 ± 0.8 5.2 ± 1.0 3.0 ± 0.5 3.2 ± 1.5 
 
The maximum and minimum of the slope0h-72h were observed at T10 and T18. Cosinor 
Analysis revealed a non-significant trend with a p-value of 0.053 for a 24-h rhythm. 
ANOVA did not detect significant differences in Slope0h-72h (Figure VII-6). 
 
Figure VII-6: Time dependent changes of the AUC0h-72h (panel A) and the Slope0h-72h (panel B) 
after the administration of 1 µM FY26.  
Based on the cell counts, the 24 h doubling rate under continues exposure of 1 µM 
FY26 was calculated (Figure VII-7). The fastest doubling rate (mean ± SEM) was 
observed at T10 and T14 with a doubling rate of 25.6 ± 2.2 h and 25.5 ± 1.8 h. 




Following the drug administration at T18, cells needed on average (± SEM) 42.4 ± 
1.9 h to double the number of cells. Thus, between T10/14 and T18 the doubling rate 
almost doubled. This was significant according to ANOVA with a p-value of <0.0001. 
Post-hoc testing (Tukey’s multiple comparison test) further showed significant 
differences between the doubling rate at the time points T02 vs. T18 (*), T06 vs. T18 
(**), T10 vs. T18 (****), T14 vs. T18 (****) and T18 vs. T22 (***). Cosinor Analys is 
demonstrated a significant 24-h (p=0.005) and 12-h (p<0.0001) rhythm of the 
doubling rate of Hepa1-6 Per2-luc cells under continues FY26 exposure. The mesor 
was obtained with 30.7 ± 0.9 h. The amplitude and acrophase for the 24-h rhythm were 
0.1 ± 0.01 doubling rate ∙ h and 20.9 ± 1.2 h. The amplitude and acrophase for the 12-h 
rhythm were accordingly calculated with 0.2 ± 0.03 doubling rate ∙ h and 5.6 ± 0.4 h. 
 
Figure VII-7: Time dependent doubling rate of Hepa1-6 Per2-luc cells under the continues 
exposure of 1 µM FY26. 
So far, least FY26 uptake was identified at T10 to T14. This is coherent with the 
doubling rate which was fastest at T10 to T14. However, cells proliferated fastest at 
T18 suggesting that under continuous FY26 exposure, the time point of best FY26 
tolerability was identified at T18 (T21 according to Cosinor Analysis). This was 
consistent with the respective time points identified for the IC50 as best FY26 
tolerability was detected at T22. To better understand the link between cell cycle 
proliferation and the IC50, the effect of FY26 on the cell cycle phase distribution was 
assessed next. 




3.2 FY26 dose dependent effects on the cell cycle  
Figure VII-8 depicts and Table VII-4 presents the results of the cell cycle phase 
distribution in Hepa1-6 Per2-luc and Hepa1-6 Per2-luc shBmal1 after the exposure to 
increasing FY26 concentrations.  
The number of Hepa1-6 Per2-luc cells distributed in G0 and G1-phase dropped after 
the incubation of 5 µM FY26 and increased thereafter with increasing FY26 
concentrations. Consistently, the cells in S-phase increased following the exposure of 
5 µM and remained high after the incubation with 7.5 and 10 µM FY26. A decline of 
the number of Hepa1-6 Per2-luc cells in G2/M-phase was observed after the exposure 
of 7.5 and 10 µM FY26. This suggest that Hepa1-6 Per2-luc cells were arrested in 
S-phase and that cells continued to cycle from G2/M-phase to G0/G1-phase. ANOVA 
was significant for the distribution of cells amongst the cell cycle phases with 
p<0.0001. No effect was observed for the FY26 concentration (p>0.999) but for the 
cell cycle phase and FY26 interaction (p<0.0001). Post-hoc testing (Tukey’s mult ip le 
comparison identified statistically significant differences between G0/G1- vs. S-phase 
(****), G0/G1- vs. G2/M-phase (****) and between S- vs. G2/M-phase (****). 
For the Bmal1-silenced cell clone Hepa1-6 Per2-luc shBmal1 the number of cells 
distributed in G0/G1-phase decreased after the incubation with 7.5 µM FY26. 
Consequently an increase of Hepa1-6 Per2-luc shBmal1 cells in S-phase was observed 
as well as a decrease of cells in G2/M-phase. Differently from Hepa1-6 Per2-luc cells, 
the Bmal1-silenced cell clones did not proceed to G0/G1-phase but entered apoptosis 
instead. ANOVA was significant for the distribution of cells in the cell cycle phases 
(p<0.0001) but not the FY26 treatment (p>0.999). The interaction between both 
factors was significant (p<0.0001). Tukey’s multiple comparison test detected 
significant differences between G0/G1- vs. S-phase (****), G0/G1- vs. G2/M-phase 
(****) and between S- vs. G2/M-phase (****). 





Figure VII-8: Dose depending cell cycle phase distribution in Hepa1-6 Per2-luc (blue) and 
Hepa1-6 Per2-luc shBmal1 (red).  
Table VII-4: Dose dependent cell cycle phase distribution in Hepa1-6 Per2-luc and Hepa1-6 
Per2-luc shBmal1. Shown is the mean (± SEM) of three replicates (n=3). 
G0/G1- Phase 
 Hepa1-6 Per2-luc Hepa1-6 Per2-luc shBmal1 
Control (cell number %) 53.9 ± 1.1 55.3 ± 1.9 
5 µM FY26 (cell number %) 49.2 ± 1.1 55.9 ± 0.5 
7.5 µM FY26 (cell number %) 53.8 ± 1.2 52.8 ± 0.7  
10 µM FY26 (cell number %) 56.7 ± 0.2 54.9 ± 1.1 
S-Phase 
 Hepa1-6 Per2-luc Hepa1-6 Per2-luc shBmal1 
Control (cell number %) 13.8 ± 0.0 13.8 ± 1.0 
5 µM FY26 (cell number %) 18.3 ± 0.6 10.9 ± 0.6 
7.5 µM FY26 (cell number %) 16.5 ± 0.5 13.5 ± 0.2 
10 µM FY26 (cell number %) 18.2 ± 0.9 20.6 ± 1.6 
G2/M- Phase 




 Hepa1-6 Per2-luc Hepa1-6 Per2-luc shBmal1 
Control (cell number %) 32.3 ± 1.2 30.9 ± 1.0 
5 µM FY26 (cell number %) 32.4 ± 0.8 33.2 ± 0.2 
7.5 µM FY26 (cell number %) 29.8 ± 1.5 33.7 ± 0.7 
10 µM FY26 (cell number %) 25.0 ± 1.0 24.5 ± 2.6 
 
The number of apoptotic cells (Figure VII-9 and Table VII-5) was determined after 
the exposure of the same FY26 concentrations. Exposing both cell clones, Hepa1-6 
Per2-luc and Hepa1-6 Per2-luc shBmal1, to an FY26 concentration which was twice 
as high as the IC50, only resulted in 23.9 ± 1.4% apoptotic cells for Hepa1-6 Per2-luc 
and in 35.5 ± 0.8% apoptotic Hepa1-6 Per2-luc shBmal1 cells. Interestingly, a higher 
number of apoptotic cells were detected for the Bmal1-silenced Hepa1-6 Per2-luc cell 
clone. Incubating both clones with 7.5 µM FY26 doubled the number of apoptotic 
Hepa1-6 Per2-luc shBmal1 cells as compared to Hepa1-6 Per2-luc. These data are 
coherent with the decline of Hepa1-6 Per2-luc shBmal1 cells in G0/G1- and 
G2/M-phase confirming that a higher number of Hepa1-6 Per2-luc shBmal1 cells enter 
apoptosis instead of transitioning to G0/G1-phase [ANOVA with p-value of p<0.001 
for FY26 effect, with p=0.036 for the clock effect and p=0.001 for the interact ion, 
Turkey’s multiple comparison test with significant differences between: controls of 
both Hepa1-6 clones (*), between the Hepa1-6 Per2-luc control and 10 µM FY26 of 
Hepa1-6 Per2-luc (**) and its clock altered clone (****), between 5 µM and 7.5 µM 
FY26 Hepa1-6 Per2-luc shBmal1 and 10 µM FY26 Hepa1-6 Per2-luc (**) and 
between 7.5 µM FY26 Hepa16 Per2-luc and 7.5 (*) and 10 µM FY26 (***) Hepa1-6 
Per2-luc shBmal1 and between the control vs. 7.5 µM FY26 (***), 5 µM FY26 vs. 
7.5 (**) and 10 µM FY26 (****) and between 7.5 µM and 10 µM FY26 (****)]. 
 





Figure VII-9:FY26 dose dependent induction of apoptosis.  
Table VII-5: Results of the normalised number (mean ± SEM of n=3) of viable and apoptotic 
cells according to the exposure of increasing FY26 concentrations.  
Hepa1-6 Per2-luc 
 Vehicle 5 µM FY26 7.5 µM FY26 10 µM FY26 
Viable cells (%) 88.5 ± 1.6 74.4 ± 7.9 78.1 ± 2.1 63.8 ± 1.4 
Apoptotic cells 
(%) 
7.2 ± 0.6 15.5 ± 5.4 13.5 ± 1.4 23.9 ± 1.4 
Hepa1-6 Per2-luc shBmal1 
 Vehicle 5 µM FY26 7.5 µM FY26 10 µM FY26 
Viable cells (%) 86.1 ± 1.1 83.9 ± 0.8 52.8 ± 10.3 41.5 ± 1.4 
Apoptotic cells 
(%) 
4.6 ± 1.5 7.6 ± 1.0 30.0 ± 6.9 35.5 ± 0.8 
 
As another cell death mechanism, the induction of autophagy under the exposure of 
2.5 µM, 5 µM and 10 µM FY26 was investigated. The Figure VII-10 and Table VII-6 
present the results of the LC3B mRNA expression immediately and 72 h after the end 
of the 24 h FY26 exposure in both Hepa1-6 Per2-luc clones (right panels). For both 
cell clones the LC3B expression was higher when measured immediately after the end 
of the 24 h drug exposure time as compared to a 72 h FY26 recovery time span. 
Moreover the LC3B expression showed a dose response with increasing LC3B levels 




following the incubation with increasing FY26 concentrations. Consistently with the 
apoptosis data, the LC3B levels in the Bmal1-silenced Hepa1-6 cell clone were higher 
immediately and 72 h after the end of the 24 h FY26 exposure. ANOVA did not reveal 
a significant effect of the clock (p=0.856) and time (p=0.843) on the LC3B expression, 
although a significant effect of the FY26 concentrations (p=0.003) was determined. 
Interactions were only significant for the FY26 concentrations and time with p-value 
of 0.016.  
 
Figure VII-10: LC3B expression following the in exposure of 2.5 µM, 5 µM and 10 µM FY26 
in Hepa1-6 Per2-luc (panel A) and Hepa1-6 Per2-luc shBmal1 (panel B). 
Table VII-6: LC3B expression in Hepa1-6 Per2-luc and Hepa1-6 Per2-luc shBmal1 after the 







Relative gene expression (RGE) of LC3B 
control 2.5 µM 5 µM 10 µM 
No 
 
24 h 0.3 ± 
0.1 
0.8 ± 0.5 0.5 ± 0.4 1.9 ± 0.5 
72 h 0.8 ± 
0.3 
0.2 ± 0.1 0.6 ± 0.2 1.1 ± 0.3 
Yes 24 h 0.3 ± 
0.2 
1.5 ± 0.2 0.03 ± 0.02 0.9 ± 0.5 




72 h 0.9 ± 
0.5 
0.5 ± 0.4 0.4 ± 0.2 2.1 ± 0.8 
 
The data showed that FY26 led to a cell cycle arrest of Hepa1-6 Per2-luc and Hepa1-6 
Per2-luc shBmal1 in S-phase. Whereas Hepa1-6 Per2-luc cells continued to transit ion 
from G2/M-phase to G0/G1-phase, a higher number of Bmal1-silenced Hepa1-6 clone 
entered apoptosis pointing towards a clock dependent effect. Moreover, it was 
observed that the induction of autophagy was upregulated immediately after the end 
of the FY26 exposure. The LC3B levels decreased after a 72 h recovery time when the 
time dependent FY26 IC50 was determined with the best tolerability at T22 based on 
the in vitro chronotoxicity. 
3.3 Time dependent effect of FY26 on the cell cycle phase distribution 
The time dependent effect of the cell cycle phase distribution after FY26 
administration was tested at T04 and at T16 in both Hepa1-6 cell clones after the 
exposure of 7.5 µM FY26. This concentration was chosen as it was a compromis ing 
concentration between 5 µM and 10 µM FY26 which caused a higher number of 
Hepa1-6 Per2-luc and Hepa1-6 Per2-luc shBmal1 cells distributed in G0/G1- and 
S-phase and a decline of cells in G2/M-phase. 
A time dependent distribution of temperature synchronised Hepa1-6 Per2-luc cells 
was seen after the administration of the vehicle. From T04 to T16, the number of cells 
in G0/G1-phase decreased by 18.2% whereas the number of cells in S- and G2/M-phase 
increased by 5.2% and 13.2%. Thus, a shift of cells from G0/G1 to G2/M-phase was 
observed. Following the administration of 7.5 µM FY26 at T04, led to an increase of 
cells distributed in G2/M-phase of 10.8% whilst the number of cells in G0/G1-phase 
decreased by 10.8%. At T16 however, the number of cells in G0/G1-phase increased 
by 9.5% whereas the number of cells distributed in S- and G2/M-phase decreased by 
2.2% and 7.3%. The results suggest that, a higher number of cells undergo apoptosis 
following FY26 administration at T04 as Hepa1-6 Per2-luc cells did not transit ion 
from G2/M-phase to G0/G1-phase. Thus, T04 constituted the time point at which a 
higher number of cells entered apoptosis under the exposure of 7.5 µM FY26. 
ANOVA showed that statistically significant differences between the distribution of 




cell amongst the different cell cycle phases (p<0.0001). Treatment (p>0.999) and time 
(p>0.999) did not affect the cell cycle phase distribution even though significant 
interactions were achieved between the cell cycle phases vs. time (***) and between 
all three factors (****). 
No time dependent distribution of the temperature synchronised Bmal1-silenced 
Hepa1-6 cell clone after the vehicle administration was observed. At both time points 
the highest number of cells were distributed in G0/G1-phase. Following the incubation 
with 7.5 µM FY26 at T04 and T16, no time dependent difference in the distribution 
of cells amongst the cell cycle phases was observed. However, at both time points, the 
number of cells in G0/G1-phase decreased but increased in G2/M-phase pointing 
towards the induction of apoptosis regardless of the time of drug administrat ion. 
ANOVA confirmed a significant difference between the cell cycle phase distribution 
(p<0.001). However, no significant effect of treatment (p>0.999) and time (p>0.999) 
was detected nor any significant interaction between the three factors. 
 
Figure VII-11: Time dependent effect of 7.5 µM FY26 on the cell cycle stages on synchronised 
and non-synchronised Hepa1-6 Per2-luc cells (n=3 for vehicle, n=4-5 for FY26). 




Table VII-7: Normalised number of cells in percentage (mean ± SEM) distributed in the cell 
cycle phases (n=3 for controls, n=6 for treated samples).  
Hepa1-6 Per2-luc 
 G0/G1-Phase S-Phase G2/M-Phase 
Synchronised 
Vehicle (cell umber %) 
T04 52.1 ± 0.9 17.9 ± 0.2 29.9 ± 0.7 
T16 33.8 ± 2.3 23.1 ± 1.2 43.1 ± 1.0 
Synchronised 
7.5 µM FY26 (cell 
number %) 
T04 41.3 ± 5.7 17.9 ± 1.1 40.7 ± 4.7 
T16 43.3 ± 3.4 20.9 ± 1.5 35.8 ± 2.2 
Hepa1-6 Per2-luc shBmal1 
 G0/G1-Phase S-Phase G2/M-Phase 
Synchronised 
Vehicle (cell umber %) 
T04 43.5 ± 1.0 30.3 ± 1.1 26.3 ± 0.1 
T16 40.1 ± 0.3 30.4 ± 0.8 29.6 ± 1.0 
Synchronised 
7.5 µM FY26 (cell 
number %) 
T04 34.7 ± 10.5 26.2 ± 2.2 39.2 ± 8.5 
T16 36.9 ± 4.5 30.9 ± 2.9 32.2 ± 4.3 
 
To conclude, the administration of FY26 caused an increase of apoptotic cells 
following the start of incubation at T04. This was not the case when FY26 was added 
at T16. Regarding the Bmal1-silenced Hepa1-6 cell clone, no time dependent effect 
was observed but therefore in increase of cells in G2/M-phase suggesting that cells 
enter apoptosis at T04 and at T16.  
4 Time dependent effect of FY26 on bioluminescence 
So far the in vitro chronotoxicity of FY26, as well as the effect of FY26 on cell growth, 
cell cycle phase distribution, induction of apoptosis and autophagy was determined. 
The determination of those endpoints took place either immediately or 72 h after the 
end of the 24 h FY26 incubation time. In order to combine this, the time dependent 
effect of FY26 on the bioluminescence was monitored 5 days after drug administrat ion 
in Hepa1-6 Per2-luc, Hepa1-6 Per2-luc shBmal1 and in HCT116 Per2-luc cells.  
 




4.1 Time dependent effects of 1 µM FY26 on Hepa1-6 Per2-luc 
bioluminescence  
The specific circadian patterns in the cytotoxicity of a 24 h exposure to 1 µM FY26 in 
Hepa1-6 Per2-luc cells are recalled in Figure VII-12. At this dose level, the rate of 
viable cells (mean ± SEM) was 88.9 ± 2.3% following FY26 exposure at T04 as 
compared to 94.7 ± 1.4% at T16 (ANOVA, p=0.111, Cosinor Analysis p=0.054). Such 
cytotoxicity was in the range of an IC10 (inhibitory concentration which caused 10% 
cell death or 90% cell survival), with highest and lowest values matching previously-
reported IC50 chronotoxicity data. 
 
Figure VII-12: Cell survival of Hepa1-6 Per2-luc after a 24-h exposure to 1 µM of FY26 
(n=30). 
This dose level transiently inhibited Per2-luc bioluminescence, as quantified by the 
emission of photon counts per second. The exposure to media, vehicle or 0.2 µM FY26 
did not alter the bioluminescence oscillation patterns (Figure VII-13). The 
bioluminescence curves of Hepa1-6 Per2-luc cells treated with media, vehicle and 0.2 
µM FY26 at all four time points, reached the maxima on day 4 and declined until day 
6. After day 6 a small increase in bioluminescence was observed. The largest and most 
sustained decline was observed after the administration of 1 µM of FY26 at T22 which 
lasted for up to 2 days. At T04, bioluminescence declined within 12 h then increased 
after day 4.  





Figure VII-13: Effect of FY26 on Per2-luc expression dynamics according to the time of drug 
administration.  
The upper left panel shows the bioluminescence of the Per2-luc reporter in Hepa1-6 Per2-luc 
followed the administration of 1 µM FY26. The time point of drug administration was marked 
with a red hatched, vertical line. The upper right panels shows the bioluminescence of the 
same cell line followed FY26 exposure at T10, the lower left at T16 and the lower right at T22.  
In order to analyse the time dependent differences of immediate FY26 effects on 
Per2-luc bioluminescence, the differences in the area under the bioluminescence 
curves were calculated from the time of drug administration until the bioluminescence 
curve of 1 µM of FY26 crossed the mean of the vehicle bioluminescence curves. The 
difference between the AUCvehicle and the AUC1µM was calculated and plotted as 
AUCDiff (Figure VII-14). Maximum AUCDiff occurred at T22 (1236 ± 244 photon 
counts per second ∙ h). It was 3-fold as high as the smallest AUCDiff that followed 
FY26 addition at T04 (414 ± 43 photon counts per second ∙ h). ANOVA was 
significant with a p-value of 0.047 with a significant difference between T04 vs. T22 




(*) according to Tukey’s multiple comparison test. Cosinor Analysis demonstrated no 
significant 24-h rhythm (p=0.076). 
 
Figure VII-14: Time depndent changes of the AUCDiff after the administartion of 1 µM FY26 
at T04, T10, T16 and T22.  
To summarise, AUCDiff represents the FY26 effect on Per2-luc bioluminescence 
immediately after the drug administration. The highest inhibition of bioluminescence 
was observed following the drug administration at T22, as the difference between the 
AUCVehicle and AUC1µMFY26 was highest. The lowest bioluminescence inhibit ion 
occurred at T04. Thus, both time points showed opposite toxicity pattern as compared 
to previously demonstrated IC50 chronotoxicity pattern (T22 best tolerated time point).  
4.2 Time dependent effect of 1 µM FY26 on the Per2-luc reporter 
construct in Hepa1-6 Per2-luc shBmal1 
A similar experimental set up comparing a single dose of 1 µM FY26 to vehicle was 
applied to Bmal1-silenced Hepa1-6 cells. Cell survival ranged from 99.6 ± 0.2% after 
FY26 exposure onset at T22 down to 99.0 ± 0.2% at T04 (ANOVA, p=0.194, Cosinor 
Analysis: p=0.313) (Figure VII-15). 





Figure VII-15: Time dependent cell toxicity of 1 µM FY26 on Hepa1-6 Per2-luc shBmal1 
cells.  
The graphs show the cell survival following a 24 h exposure of 1 µM FY26 on Hepa1-6 
Per2-luc shBmal1 cell according to different drug administration times. The total protein 
content was measured 72 h using the photo-colorimetric endpoint measurement SRB assay. 
The bioluminescence of the vehicle treated cells, declined 5 days after cell seeding 
and reached “0” at T16 and T22. Exposing the cells at T04, T10, T16 and T22 to 1 µM 
FY26 led to a depletion of Per2-luc oscillation approximately 24 h after the start of 
drug exposure. FY26 decreased Per2-luc bioluminescence (mean ± SEM) from 1812 
± 287 photon counts per second to 440 ± 68 photon counts per second following dosing 
at T22. Dosing at T04, reduced bioluminescence from 1030 ± 48 photon counts per 
second to 362 ± 62 photon counts per second (Figure VII-16). Comparing the 
bioluminescence pattern with the ones observed for Hepa1-6 Per2-luc cells, no 
increase of bioluminescence was observed 3 to 5 days after the start of drug 
administration. This further supports previous data that the shBmal1-silenced cell 
clone is characterised by a higher sensitivity towards FY26 then Hepa1-6 Per2-luc.  





Figure VII-16: Time dependent effect of FY26 on the Hepa1-6 Per2-luc shBmal1 
bioluminescence. 
The AUCDiff was calculated as described for the Hepa1-6 Per2-luc. The 
bioluminescence curves at T04 and T10 did not cross each other. In order to be 
consistent with the AUCDiff at T16 and T22, the AUCDiff at T04 and T10 were 
calculated from 3.4/3.8 days to 5.8 days.  
The maximum AUCDiff occurred at T04 was with 4507 ± 173 photon counts per second 
∙ h (mean ± SEM) 3 fold higher as the minimum AUCDiff at T22 (1517 ± 237 photon 
counts per second ∙ h) (Figure VII-17). ANOVA was statistically significant with 
p<0.0001 between the AUCDiff at T04 vs. T10 (***), TT22 (***), T10 vs. T16 (**) 
and between T10 vs. T22 (***). Cosinor Analysis showed a significant 24-h rhythm 
(p<0.0001) with a mesor (mean ± SEM) at 3037 ± 138 photon counts per second ∙ h  
with an amplitude of 1783 ± 210 photon counts per second ∙ h and an acrophase at 
T 7.1  ± 0.7 d. 





Figure VII-17:Time dependent changes of the AUCDiff according to the time of FY26 
administration (n=3). 
Thus, the maximum Per2-luc bioluminescence inhibition in Hepa1-6 Per2-luc 
shBmal1 cells was observed at T04 whereas the maximum inhibition in Hepa1-6 
Per2-luc cells occurred 6 h earlier at T22.  
4.3 Time dependent effect of 1 µM and 2.5 µM FY26 on the Per2-luc 
reporter construct in HCT116 Per2-luc 
The effect of 2.5 µM FY26 and 1 µM FY26 on the Per2-luc bioluminescence in 
HCT116 Per2-luc cells was assessed as described for the previous experiments. Time 
dependent changes of the cell survival was observed after the exposure to 0.8 µM 
FY26 (data taken from the IC50 chronotoxicity study) with the highest cell survival at 
T22 with 99.4 ± 0.2% and the lowest at T04 with 97.2 ± 0.3% [ANOVA with p<0.0001 
and TMCT: T04 vs. T22 (****), T22 vs. T10 and T16 (****)]. Cosinor Analysis for 
a 24-h rhythm (p<0.0001) detected a mesor with 98.8 ± 2.5%, amplitude with 11.5 ± 
3.7% and an acrophase at T19.9 ± 1.2 h.  





Figure VII-18: Time dependent cell survival of HCT116 Per2-luc cells after the exposure of 
0.8 µM FY26 at T04, T10, T16 and T22.  
Next, the effect of 1 µM or 2.5 µM FY26 at T04, T10, T16 and T22 was assessed on 
the bioluminescence of HCT116 Per2-luc cells (Figure VII-19 ). Vehicle exposure did 
not affect bioluminescence as an increase was observed until day 6 to 7. After day 6 
to 7 bioluminescence started to decline except at T16. The administration of 2.5 µM 
and 1 µM FY26 led to a sharp decline of bioluminescence without any subsequent 
recovery at all circadian time points except at T10. Here, the bioluminescence of 
HCT116 Per2-luc cells exposed to 1 µM FY26 recovered. A dose response was 
observed with a higher inhibition of bioluminescence after the administration o f 
2.5 µM FY26 as compared to 1 µM FY26. 





Figure VII-19: Effect of 1 µM FY26 and 2.5 µM FY26 on Per2-luc expression in HCT116 
Per2-luc according to the time of drug administration.  
In order to analysis the time dependent differences, the difference between the median 
AUCvehicle and the AUC of each bioluminescence curve after the administration of 
1 µM and 2.5 µM FY26 were calculated from the start of FY26 exposure until the end 
of bioluminescence recording (Figure VII-20).  
The maximum and minimum of the AUCDiff1µM occurred at T16 with 2732 ± 89 photon 
counts per second ∙ h and at T04 to T10 with 1843 ± 139 and 1582 ± 603 photon counts 
per second ∙ h (ANOVA with p=0.137, Cosinor Analysis 24-h rhythm with p=0.192). 
The maximum for the AUCDiff2.5µM occurred at T16 with 2838 ± 44 photon counts 
per second ∙ h. However, different form the minimum for the AUCDiff1µM, the 
minimum of the AUCDiff2.5µM was shifted for 6 h to T22 and T04 with 2219 ± 46 and 
2227 ± 11 photon counts per second ∙ h. ANOVA was statistically significant 
(p<0.0001) with differences between the time points T04 vs. T10 (***) and T16 
(****), between T10 vs. T16 (*) and T22 (***) and between T16 vs. T22 (****). A 
statistically significant 24-h rhythm (p<0.0001) was detected with a mesor of 2475 ± 




26 photon counts per second ∙ h, an amplitude of 364 ± 37 photon counts per second ∙ h 
and an acrophase at T13.8 ± 0.4 h. 
 
Figure VII-20: Results of the difference between the median AUC of the vehicle and each AUC 
after the administration of 1 µM FY26 and 2.5 µM FY26.  
Panel A depicts the results of the AUCDiff1µM and panel B shows the results of the AUCDiff2.5µM. 
To sum up, a dose dependent difference between of 1 µM FY26 and 2.5 µM FY26 on 
the bioluminescence curve was measured. A significant difference was obtained for 
the AUCDiff2.5µM with the maximum inhibition of bioluminescence at T16. This was 
consistent with the results of the IC50 chronotoxicity as T16 was identified as one of 
the time point of highest FY26 toxicity together with T04. 
  




5 Postamble  
The pharmacokinetics study demonstrated that maximum cellular uptake of FY26 
resulted from FY26 exposure starting at T02. Minimum uptake was found for FY26 
exposures starting at T10 or T14. Viable cells were also counted in the same dishes as 
those used for pharmacokinetics determinations. According to the AUC0h-72h and the 
Slope0h-72h the highest cell viability was observed at T10 and the least at T18. This was 
further confirmed by the doubling rate as the doubling time was prolonged at T18. 
Following the cell viability studies, the effect of FY26 on the cell cycle showed an 
accumulation of cells in S-phase which was dose dependent. The number of Hepa1-6 
Per2-luc cells in G2/M-phase decreased whilst the number of cells in G0/G1-phase 
increased. This progression was not observed in shBmal1-silenced Hepa1-6 Per2-luc 
cells as both the number of cells in G0/G1- and in G2/M-phase decreased. This suggests 
that cells undergo apoptosis rather as to enter G0/G1-phase. The determination of a 
higher number of apoptotic Hepa1-6 Per2-luc shBmal1 cells supported this 
observation. Besides apoptosis, the induction of autophagy pointed towards a dose 
dependent increase of LC3B levels with higher levels detected immediately instead of 
72 h after the end of the FY26 incubation time. Determining the time dependent cell 
cycle phase distribution at T04 and T16 for both cell lines, showed that for Hepa1-6 
Per2-luc a higher number of cells accumulated in G2/M-phase at T04. At T16 a higher 
cell distribution in G0/G1-phase was observed. No such effect was observed for the 
Bmal1-silenced clone. The highest inhibition of Per2-luc bioluminescence recordings 
occurred at T22 for Hepa1-6 Per2-luc and at T16 for HCT116 Per2-luc. The 













VIII Results – The effect of FY26 on the 
circadian clock and the CTS  




1 Preamble  
The last experiment of the previous chapter shows the time dependent inhibition of 
bioluminescence after the FY26 administration at different time point. So far, it is 
unclear whether the inhibition of bioluminescence is caused by an inhibition of cell 
proliferation of by the interaction of FY26 with the Per2 promoter of the Per2-luc 
reporter construct and thus with the circadian clock. 
Thus, the interaction of FY26 with the circadian clock on a transcriptional translationa l 
and on the CTS are presented in this chapter. 
  
  




2 Effect of FY26 on Per2-luc oscillation 
The administration of FY26 on Hepa1-6 Per2-luc cells at different time points did not 
disturb Per2-luc oscillations (Figure VIII-1) although an initial increase of the 
amplitude was observed. Nevertheless, Hepa1-6 Per2-luc oscillations were detected 
with a period (mean ± SEM) of 23.9 ± 0.1 h after vehicle exposure and with a period 
of 25.3 ± 0.8 h after the exposure of 1 µM FY26.  
 
Figure VIII-1: Detrended bioluminescence of Hepa1-6 Per2-luc after the exposure of media, 
vehicle, 0.2 µM and 1 µM FY26 at T04, T10, T16 and T22. 
The administration of the vehicle to the Hepa1-6 Per2-luc shBmal1 cells did not alter 
Per2-luc bioluminescence oscillations. However, the introduction of 1 µM FY26 
dampened the amplitude of Per2-luc bioluminescence at all 4 time points (Figure 
VIII-2). The mean ± SEM period after vehicle administration was 23.4 ± 0.9 h and 
after FY26 administration 22.5 ± 1.6 h thus confirming the dampened amplitude of 
Per2-luc oscillations after the exposure of 1 µM FY26. 





Figure VIII-2: Detrended bioluminescence of Hepa1-6 Per2-luc shBmal1 bioluminescence 
after the exposure of vehicle and 1 µM FY26 at T04, T10, T16 and T22. 
The bioluminescence of the Per2-luc reporter in HCT116 cells was not altered after 
vehicle administration. The mean ± SEM period was calculated as 24.4 ± 0.6 h under 
the vehicle exposure. However, after the administration of 1 and 2.5 µM FY26, 
amplitudes were dampened except at T16 and at T10 for 1 µM FY26. The mean ± 
SEM periods were determined with 21.9 ± 0.9 h for 1 µM FY26 and with 23.2 ± 0.4 h 
for 2.5 µM FY26. This suggests that FY26 effected cell proliferation rather than the 
Per2-luc reporter. 
To summarise, the administration of FY26 did not alter the Hepa1-6 Per2-luc 
oscillation but did effect the amplitudes of the shBmal1-silenced Hepa1-6 clone and 
of HCT116 Per2-luc. Whether this effect was caused by an interaction of FY26 with 
the circadian clock will be investigated in the following chapter using Hepa1-6 
Per2-luc cells. 





Figure VIII-3: Detrended bioluminescence curves of HCT116 Per2-luc after the exposure of 
vehicle, 1 µM and 2.5 µM FY26 at T04, T10, T16 and T22. 
3 Effect of FY26 on clock gene expression  
Circadian patterns in mRNA expression of clock genes Per2, Bmal1 and Rev-erbα 
were determined in temperature synchronised Hepa1-6 Per2-luc cells with or without 
exposure to 1 µM FY26. The drug was added at T04 and at T22 (Figure VIII-4).  
No difference between the Per2 gene expression after the vehicle administration at 
T04 and at T22 was observed. The relative gene expression (RGE) was identified with 
0.38 ± 0.09 RGE (mean ± SEM) for T04 and with 0.29 ± 0.03 RGE for T22. The 
acrophase of the Per2 gene expression at T04 and at T22 was determined at T 15.6 h 
(Cosinor, p<0.001) and at T 13.4 h (Cosinor, p=0.125). No changes were observed 
following the FY26 administration at T04 and at T22. The highest Per2 expression 
following FY26 administration occurred at T16 with 0.28 ± 0.13 RGE for T04 and 
with 0.18 ± 0.04 RGE for T22. The acrophase of the Per2 expression of with FY26 




incubated cells at T04 and T22 was calculated with T15.7 h (Cosinor, p=0.406) and 
with T 14.4 h (Cosinor, p=0.505) (Figure VIII-4 and Table VIII-1).  
Following the vehicle administration at T04 and at T22, Bmal1 peak occurred at T20 
with 1.27 ± 0.49 RGE (mean ± SEM) and T22 with 1.27 ± 0.49 RGE. The acrophase 
was calculated with T16.2 h (Cosinor, p=0.614) for T04 and with T17.8 h (Cosinor, 
p=0.757). The FY26 exposure did not alter the Bmal1 gene expression. The highest 
Bmal1 expression occurred at T20 with 1.29 ± 0.39 RGE following dosing at T04 and 
at T22 with 1.8 ± 1.5 RGE after FY26 exposure at T22. The acrophases were 
calculated with T21.9 (Cosinor, p=0.022) for T04 and with T18.7 (Cosinor, p=0.608) 
for T22 (Figure VIII-4 and Table VIII-1).  
The highest expression of the clock gene Rev-erbα under the vehicle exposure was 
observed at T22 with 0.52 ± 0.18 RGE for T04 and at T16 with 1.55 ± 0.29 RGE for 
cells exposed to the vehicle at T22. Cosinor Analysis was applied and identified with 
an acrophase for Rev-erbα expression at T16.9 h (p=0.016) and at T14.9 h (p=0.231) 
for the vehicle administration at T04 and at T22. However, dosing cells at T04 with 
FY26 altered the maximum of Rev-erbα expression from T22 to T12 with 0.82 ± 0.52 
RGE. No change of Rev-erbα expression was observed when FY26 was administe red 
at T22. The relative gene expression was thus highest at T16 with 2.12 ± 0.31 RGE. 
Nevertheless, Cosinor Analysis identified the acrophase at T15.2 h for T04 (p=0.339) 
and at T15.8 for T22 (p=0.088) (Figure VIII-4 and Table VIII-1). 
To conclude, exposing 1 µM FY26 to Hepa1-6 Per2-luc cells did not affect the 
expression of the clock genes Per2, Bmal1 and Rev-erbα 20 h to 24 h after FY26 
administration at T04 and T22 as their pattern was similar to the gene expression 
pattern after vehicle administration. This suggest that the decline of photon counts per 
second was not related to the suppression of gene expression by FY26 but rather to 
the cytostatic effect of FY26 on Hepa1-6 Per2-luc, Hepa1-6 Per2-luc shBmal1 and 
HCT116 Per2-luc. 
 





Figure VIII-4: Effect of 1 µM FY26 on the gene expression of the clock genes Per2, Bmal1 









Table VIII-1: Cosinor Analysis of the clock gene expression after the exposure of the vehicle 
and FY26 at T04 and T22.  
The statistically significant results are highlighted in bold. 
T04 





in time (h)  
p-value 
Per2 Vehicle 24-h 0.2 ± 
0.02 
0.1 ± 0.03 15.6 ± 1.0 0.001 
12-h 0.09 ± 0.03 4.2 ± 0.5 0.03 
FY26 24-h 0.1 ± 
0.02 
0.04 15.7 0.406 
12-h 0.07 4.1 0.087 
Bmal1 Vehicle 24-h 0.8 ± 0.1 0.2 16.2 0.614 
12-h 0.2 -1.0 0.644 
FY26 24-h 0.8 ± 0.1 0.5 ± 0.1 21.9 0.022 
12-h 0.3 -1.4 0.209 
Rev-
erbα 
Vehicle 24-h 0.3 ± 
0.04 
0.2 ± 0.05 16.9 ± 1.3 0.016 
12-h 0.06 5.2 0.465 
FY26 24-h 0.46 ± 
0.09 
0.17 15.2 0.339 
12-h 0.09 -10.6 0.734 
T22 
Per2 Vehicle 24-h 0.1 ± 
0.02 
0.04 13.4 0.125 
12-h 0.07 ± 0.03 3.1 ± 0.6 0.016 
FY26 24-h 0.1 ± 
0.01 
0.02 14.4 0.505 
12-h 0.04 3.6 0.074 
Bmal1 Vehicle 24-h 0.76 ± 
0.12 
0.2 17.8 0.757 
12-h 0.1 12.2 0.774 
FY26 24-h 0.79 ± 
0.16 
0.2 18.7 0.608 
12-h 0.1 8.2 0.872 
Rev-
erbα 
Vehicle 24-h 0.5 ± 0.1 0.2 14.9 0.231 
12-h 0.2 ± 0.1 3.4 ± 0.6 0.021 
FY26 24-h 0.6 ± 0.1 0.4 15.8 0.088 
12-h 0.05 3.0 0.105 




4 FY26 affects circadian timing system biomarkers in mice 
4.1 FY26 disrupts mouse core body temperature if dosed at ZT18 
Six C57Bl/6 mice were subjected to antiphasic LD12:12 synchronisation immediate ly 
after the implantation of the temperature sensor into the peritoneal cavity. Core body 
temperature was automatically recorded at 5-min intervals throughout the whole 
experiment. Up to 8 days were needed for the mice in the antiphasic LD schedule to 
adjust the core body temperature cycle to the new synchroniser. Thus, all the mice 
were well synchronised by their respective LD12:12 schedules after 3 weeks (data not 
shown). 
The mice in both groups were intraperitoneally injected at ZT06 or at ZT18 with 
vehicle, then with 50 mg/kg FY26 one week later. FY26 treatment induced up to 8% 
body weight loss 24 h after dosing in individual mice (Figure VIII-5).  
 
Figure VIII-5:Time dependent body weight loss after a single i.p. injection of the vehicle and 
FY26. 
Panel A: body weight loss after a single i.p. injection of the vehicle at ZT06 and ZT18. Panel 
B: Body weight loss after a single i.p. injection of 50 mg/kg FY26 at ZT06 and ZT18 (n=3 per 
circadian time point). 
Maximum body weight loss (mean ± SEM) was 3.6 ± 1.2% following drug dosing at 
ZT06, as compared to 5.3 ± 1.7% at ZT18 (two-sample t−test for equal mean with 




p-value 0.493). The lack of statistical significance presumably resulted from the low 
toxicity of the compound, and the limited number of mice. 
The effects of vehicle and FY26 on core body temperature were determined in the 
same mice as a function of dosing time (Figure VIII-6). Vehicle injections did not 
affect core body temperature circadian patterns. In contrast, an immediate and sharp 
decline was observed in the mice injected at ZT18, with temperature acutely dropping 
by 3.7°C (from 37.5 ± 0.2°C to 33.8 ± 0.3°C) at 6 h post injection. In mice treated at 
ZT06, temperature decreased only by 1°C (from 35.7 ± 0.7°C to 34.7 ± 0.5°C), and 
such nadir was reached 2 h after injection. The differences between the extents of 
temperature decline according to FY26 timing were statistically significant (t−test 
with p=0.006). 
 
Figure VIII-6: Effect of a single intraperitoneal injection of the vehicle and 50 mg/kg FY26 
on core body temperature in mice. 
The panel depicts the average of the hourly average core body temperature of three mice at 
ZT06, ZT18 and of 6 mice for the vehicle. 
To further analyse the effects of vehicle and FY26 on core body temperature patterns, 
hourly averages were computed from the 5-min temperature records. The period was 
estimated for three days before and after FY26 administration using spectrum 
resampling algorithm as shown in the appendices Figure XI-18 and Figure XI-19.  




Estimated periods in individual mice were averaged over the 24-h span after vehicle 
or FY26 administration (Figure VIII-7). The endogenous period of the temperature 
rhythm remained stable at 22.8 ± 0.3 h or 22.9 ± 0.2 h in the mice receiving vehicle at 
ZT06 or ZT18 respectively. FY26 administration significantly lengthened the 
circadian period by 0.7 ± 0.5 h following dosing at ZT06 (23.5 ± 0.4 h), but it shortened 
it by 2.4 ± 0.4 h in the mice treated at ZT18 (20.6 ± 0.6 h). ANOVA revealed a 
significant difference of the periods according to timing (p=0.01) but not between the 
difference treatments (p=0.06). However, the interaction between time and treatment 
was significant with 0.004. Tukey’s multiple comparison showed a significant 
difference between the periods of the vehicle treated mice at ZT18 vs. the FY26 treated 
at ZT18 (*) and between the period of the FY26 treated mice at ZT06 and ZT18 (**).  
 
Figure VIII-7: Period of mice core body temperature 24 h after the injection of the vehicle 
and 50 mg/kg FY26 at ZT06 and ZT18. 
The results thus demonstrated that FY26 treatment did not affect the core body 
temperature rhythm when treated at ZT06. However, a drop of core body temperature 
by 3.7°C and a shortening of the temperature period by 2.4 h was encountered 
following dosing at ZT18. The results suggested a pronounced time dependency of 
FY26 transient effects on the CTS, with largest rhythm alterations corresponding to 
FY26 dosing at ZT18, i.e. the timing yielding the worse systemic toxicity.  




4.2 The effect of FY26 on the PER2::LUC liver expression  
Nine C57Bl/6 mice were first synchronised with LD12:12, then had a temperature 
sensor implanted into the peritoneal cavity and the posterior back skin shaved. Each 
mouse was then singly housed in the RT-Bio with luciferin-containing bottles and kept 
in DD for 7 to 13 days. After 3 to 5 days of baseline recording, three mice received a 
single i.p. vehicle injection at CT06 or CT18, while three mice were injected with 50 
mg/kg FY26 at CT06. Three other mice received the same treatment at CT18. As mice 
were kept under constant darkness, the period advanced every 24 h by 1.5 h. Injections 
being times at CT06 and CT18 referred thus to CT22.5-CT01.5 and to CT10.5-CT13.5 
instead. 
No body weight loss was observed after vehicle administration. In contrast, body 
weight loss (mean ± SEM) was largest 24 h after FY26 treatment irrespective of drug 
timing, being 6.6 ± 1.6% and 5.8 ± 4.3% for FY26 dosing at CT06 or CT18 
respectively (p from ANOVA = 0.279) (Figure VIII-8).  
 
Figure VIII-8: Body weight changes after FY26 dosing. Vehicle or 50 mg/kg FY26 were 
injecetd in one single i.p. injection at CT06 and CT18 in 9 individual PER2::LUC mice. 
The effects of vehicle or FY26 on PER2::LUC expression time series were analysed 
using Spectrum Analysis for the data sets from each of the 9 mice. Individ ual profiles 
of hourly averaged normalised photon counts per min including the period, amplitude 
and acrophase are shown in Appendix Figure XI-20. Figure VIII-9 depicts the average 
PER2::LUC bioluminescence for the 2 days preceding and the 3 days following 
vehicle or FY26 dosing at putative CT06 or CT18 respectively, under the assumption 




of the persistence of 24-hour periodicities in DD. The vehicle injection at CT06 and 
at CT18 did not affect PER2::LUC bioluminescence. The administration of 50 mg/kg 
FY26 led to the ablation of PER2::LUC oscillations at CT06 and CT18 which 
recovered after 1.5 days for CT06 and 2 days for CT18. Interestingly, no disruption of 
PER2::LUC oscillations following FY26 dosing at CT06 and CT18 were observed for 
mouse 1 and 3.  
 
Figure VIII-9: Effect of a single injection of the vehicle and 50 mg/kg FY26 at CT06 and CT18 
on the PER2::LUC expression in PER2::LUC mice.  
The graph depicts the mean of the hourly average of the normalised photon counts per min 
that reflect PER2::LUC expression in 3 mice receiving i.p. vehicle at CT06 (panel A), vehicle 
at CT18 (panel B) or 50 mg/kg FY26 at intended CT06 (panel C) or at intended CT18 (panel 
D). 
The mean ± SEM period of PER2::LUC expression remained stable at 22.5 ± 0.3 h 
after vehicle administration. Following the administration of FY26 at intended CT06 
and CT18, PER2::LUC oscillating bioluminescence pattern were abolished . 




Differences in bioluminescence patterns were further explored through computing 
AUC’s over the 24 h timespan after injection. The mean ± SEM AUC’s, in hourly 
averaged photon counts/min ∙ h. were 10.0 ± 1.5 and 22.1 ± 1.2 following FY26 
injection at CT06 or CT18 respectively (p-value from t-test = 0.004) (Figure VIII-10). 
Thus, the injection of 50 mg/kg FY26 led to a larger decrease of PER2::LUC 
bioluminescence at intended CT06 as at CT18. 
 
Figure VIII-10: Period and AUC of the PER2::LUC bioluminescence pattern after vehcile 
and FY26 treatment at intended CT06 and CT18.  
Panel (A) shows the change of the period of the PER2::LUC bioluminescence pattern and 
panel (B) shows the AUC of the PER2::LUC bioluminescence pattern after FY26 
administration at intended CT06 and CT18. 
Core body temperature was measured simultaneously with PER2::LUC 
bioluminescence expression. A technical failure happened for the three first mice kept 
under DD. Thus Figure VIII-11 displays core body temperature rhythms for two mice 
per condition. Vehicle administration at intended CT06 and CT18 did not alter core 
body temperature rhythms as compared to baseline. In contrast, FY26 profoundly 
altered the temperature rhythm at least for 48 h, with a drop by 0.8°C within 12 h and 
5 h after the injection at intended CT06 or CT18 respectively. Core body temperature 
rhythms recovered 2 days after treatment (Appendix Figure XI-21) (Figure VIII-11). 





Figure VIII-11: Time dependent changes of body temperature circadian rhythm of 
PER2::LUC mice treated with 50 mg/kg FY26 or vehicle.  
Panel A shows the effect of the vehicle administration at CT06 and CT18 on core body 
temperature and panel B shows the FY26 effect on core body temperature following dosing at 
CT06 and panel C at CT18. 
The period (mean ± SEM) of the temperature rhythm after vehicle was 23.4 ± 0.3 h. 
FY26 administration led to the ablation of core body temperature rhythm, whose 
dominant mean (± SEM) periods were computed at 29.5 ± 3.2 h and 33.9 ± 4.1 h for 
treatment at intended CT06 and CT18 respectively (Figure VIII-12). 
To summarise, FY26 transiently suppressed the circadian rhythm in core body 
temperature following dosing at ZT18, but not at ZT06 in mice synchronised with 
LD12:12. The disruption of this circadian biomarker was observed following FY26 
dosing at intended at CT06 and CT18 in mice kept in DD for 3 to 5 days before 
treatment application. Since the average endogenous period of PER2::LUC expression 
(which variable) in the DD control mice ranged from 22.0 h to 23.0 h, rather than 
remaining close to 24 hours, intended CT06 thus corresponded to CT22.5 to CT01.5, 
while intended CT18 was effectively located between CT10.5 and CT13.5. Therefore, 
the largest reduction in the AUC of the hourly averaged photon counts per min resulted 
from FY26 dosing at endogenous CT22.5 to CT01.5. This was consistent with the in 




vivo chronotoxicity study, where ZT22 was identified as close to the time point of 
worst FY26 tolerability.  
 
Figure VIII-12: Period of the mice core body temperature after the administration of vehicle 
and 50 mg/kg FY26 at intended CT06 and CT18. 





The in vitro studies demonstrated that FY26 did not affect the clock gene expression 
suggesting that the time dependent decrease of Per2-luc bioluminescence is related to 
FY26 cytotoxic.  
Further in vivo studies showed that FY26 could alter biomarkers of the circadian 
timing system at whole organism and molecular levels. The third experiment revealed 
that a single injection of FY26 (50 mg/kg) led to a sharp decrease in core body 
temperature thus a transient circadian disruption following treatment at ZT18 but not 
at ZT06.  
The forth experiment showed that the same dose of FY26 disrupted the circadian 
rhythms in both PER2::LUC bioluminescence for 2 out of 3 mice injected at CT06 
and CT18. However, the impact of the disruption was less following dosing at CT18 
as the AUC of the PER2::LUC bioluminescence was still higher as compared to CT06. 
Core body temperature rhythm of mice kept in DD further showed disrupted rhythms 
which recovered 2 days post treatment.  
Taken together, the studies not only showed that FY26 could respect or disrupt 
biomarkers of the circadian timing system according to its dosing time in light-dark 
synchronised mice, but also revealed that entrainment by a 12:12 h photoperiod plays 
a crucial role in the effect of FY26 on the CTS. Comparing the effect of FY26 on core 
body temperature, demonstrated that FY26 did not affect core body temperature 
rhythms of mice entrained to LD 12:12 cycles whereas this effect was diminished in 


















1 Towards the translation of in vitro into in vivo FY26 
chronotoxicity through temperature cycles resetting of 
circadian clocks 
Here, I first discuss the relevance of temperature synchronisation for assessing the in 
vitro chronotoxicity, using the anticancer drug candidate FY26 as an example 
(chapter IV). 
For the in vitro model, a murine hepatocarcinoma cell line with and without silenced 
Bmal1 and a human colon cancer cell line were chosen. Temperature cycle starting 
with a 5°C temperature change after the first 12 h followed by alternating temperature 
changes of 1°C between 36 and 37°C every 12 h, was designed to simulate mouse core 
body temperature, thus imposing a quasi-physiological temperature rhythm on a cell 
population (Brown et al., 2002). This temperature cycle “D” synchronised Hepa1-6 
Per2-luc and HCT116 Per2-luc to a robust circadian period (~ 24 h), with phase and 
amplitude remaining stable for 6 to 7 days. It outperformed other temperature 
schedules that were assessed regarding period, acrophase and amplitude stabilit ies 
over 6 to 7 days. The synchronisation properties of temperature cycle D was further 
tested by exposing Hepa1-6 Per2-luc to T-cycles with 20-h or 26-h periods in order to 
assess the synchronisation properties. A synchronisation, leading to a stable Per2-luc 
bioluminescence period of ~ 20 h, was achieved with temperature alternating from 37 
to 36°C and the reverse every 10 h. Such adequate synchronisation likely reflected the 
fact that the imposed 20-h period of the synchroniser matched the endogenous 
circadian period of Hepa1-6 Per2-luc cells that was determined in cell cultures 
released at a constant temperature of 37°C, after an initial 24-h temperature 
synchronisation flash. Exposing Hepa1-6 Per2-luc shBmal1 cells to temperature cycle 
D, resulted in “pseudo-rhythmic” oscillations with a triangle shaped Per2-luc 
bioluminescence pattern. Once Hepa1-6 Per2-luc shBmal1 cells were released at a 
constant temperature of 37°C, no sustained oscillations were observed as compared to 
the clock-proficient cell clone Hepa1-6 Per2-luc. This might indicate that the 
bioluminescence oscillations of Hepa1-6 Per2-luc shBmal1 under temperature 
synchronisation could relate to some residual clock function, as 36% Bmal1 mRNA 





clock in Hepa1-6 Per2-luc shBmal1, temperature cycles might have driven other 
cellular proteins resulting in triangle shaped Per2-luc peaks. One possible protein 
could be the heat shock protein 1 (HSP1) as heat shock proteins are upregulated in 
response to elevated temperature and in response to oxidative stress especially in 
cancer cells (Oksala et al., 2014; Santos et al., 2017; Werner et al., 2007). The 
activation of the heat shock factor 1 (HSF1) is regulated by the HSF cycle (Morimoto 
& development, 1998). The HSF1 has been linked to the circadian clock as it induced 
the expression of heat shock proteins at the beginning of the active phase in mice. 
Thus, the expression of HSP followed a circadian pattern (Reinke et al., 2008; Tamaru 
et al., 2011). The acrophase of the Per2-luc expression in the Bmal1 silenced cell line 
Hepa1-6 Per2-luc shBmal1 occurred during the end of the 36°C temperature cycle 
before the temperature raised to 37°C. This timing corresponded to the beginning of 
the active phase in mice, when the endogenous temperature rises as a result of its 
circadian regulation by the SCN. This hypothesis was further supported by the 
induction of the heat shock protein response following a 1.5°C temperature rise from 
37 to 38.5°C. Such response was inhibited by the HSP1 antagonist KNK437 (Buhr et 
al., 2010). Interestingly, the expression of Hsp reportedly remain rhythmic after the 
disruption of the circadian clock. In LAP-tTA|TRE-Rev-ervα double transgenic mice 
the molecular clock was disrupted by inhibiting Bmal1 through the overexpression of 
REV-ERBα. This resulted in a circadian accumulation of Per2 and Hsp mRNA 
indicating these rhythms could arise independently from the genetic clock (Kornmann 
et al., 2007). These findings might well explain the triangle shaped Per2-luc patterns 
in Hepa1-6 Per2-luc shBmal1 cells, as those cells were exposed to rhythmic external 
temperature cues. Other proteins which responded to temperature changes are the cold 
induced proteins RNA-binding proteins CIRBP and RBM3. It has been reported that 
CIRBP was upregulated in response to cold temperatures (Nishiyama et al., 1997). In 
mice kept in constant darkness following the entrainment to LD 12:12 cycles, Hsps 
were upregulated at CT18, during the activity phase, and Rbps were highly expressed 
in response to lower temperature at CT06 (Liu et al., 2013). The depletion of Cirbp 
and Rbm3 in mouse fibroblast reduced the amplitude of the clock genes Per1, Dbp, 
Nr1d1 and Nr1d2, following temperature synchronisation. Further, the binding of 
genes to PAS were regulated by CIRBP and RBM3 in mouse liver. This resulted in 





by Cribp and Rbm3 under temperature synchronisation (Liu et al., 2013). Further it 
was reported that the expression of Cirbp was regulated by temperature dependent 
splicing, which was highest at low temperatures (Gotic et al., 2016). Taken together, 
these data suggest that synchronisation through temperature cycles might be 
independent from the circadian clock, thus accounting for the “pseudo-rhythmic ity” 
observed in temperature synchronised Hepa1-6 Per2-luc shBmal1.  
I have further demonstrated that the expression of core clock genes Per2, Bmal1 and 
Rev-erbα in clock-proficient Hepa1-6 Per2-luc cells were rhythmic. The sampling of 
the cell pellet for RNA extraction was done 2.5 days after the start of temperature 
synchronisation. This time window was chosen as stable period lengths, acrophases 
and amplitudes were achieved 2.5 days after the start of synchronisation (data not 
shown). The Bmal1 peak was determined at T0, when the temperature increased from 
36°C to 37°C. The Per2 peak occurred at T12 following the programmed temperature 
decrease from 37 to 36°C, whereas the acrophase of the Rev-erbα expression occurred 
at T16, i.e. 4 h after the Per2 peak and 8 h before the Bmal1 peak. The 
bioluminescence curves of the Per2-luc and Bmal1-luc reporters into the HCT116 
cells, showed antiphase oscillation patterns, whilst being subjected to the same 
temperature cycle D. Both oscillations persisted and remained in antiphase, once the 
cells were released at a constant temperature of 37°C, as it was reported for the 
Hepa1-6 Per2-luc cells. Thus, synchronising both cell lines with a 24-h temperature 
cycle has revealed autonomous and self-sustained circadian clock genes expression 
patterns, using bioluminescence reporter technology in line with other reports 
(Nagoshi et al., 2004).  
The implication of circadian clock coordination for cell cycling was then examined in 
synchronised Hepa1-6 cell populations, since a 1:1 coupling between both oscillato rs 
was demonstrated in fibroblasts (Bieler et al., 2014; Feillet et al., 2014). Alternat ing 
12:12 h temperature cycles synchronised S-phase, but neither G0/G1 nor G2/M phase 
cells, to a 24-h period in Hepa1-6 Per2-luc. Hepa1-6 Per2-luc shBmal1, however, 
showed a 24-h rhythm in G0/G1-phase and a 12-h rhythm for G0/G1- and S-phase. This 
suggested that the cell cycle was at least partly uncoupled from the circadian clock in 
this model. Several studies have investigated the relationship between the circadian 





coupling was lost in some cancerous cell lines as described in the doctoral thesis of 
Elham (Aida) Farshadi. She demonstrated that the cell cycle in mouse breast 
carcinoma cells MBC399 was uncoupled from the circadian clock which was 
free-running (Farshadi, 2018). In my studies, the cell cycle phases distributions were 
determined under 24-h temperature synchronisation of the circadian clock as indicated 
with stable ~ 24 h oscillations of the Per2-luc reporter. Yet, the data support a partial 
uncoupling of the cell cycle in this model that would need further exploration using 
simultaneous clock and cell cycle phase imaging reporters. 
Temperature schedule D was then used to assess any time dependent toxicity of FY26 
in synchronised cell populations (chapter III.2). Toward this goal, the in vitro 
chronotoxicity of FY26 was determined in Hepa1-6 Per2-luc, Hepa1-6 Per2-luc 
shBmal1 and HCT116 Per2-luc. The IC50 of FY26 in Hepa1-6 Per2-luc cells was 
significantly highest following drug exposure at T22, suggesting this to be the time 
point of least drug toxicity. Thus at T22, a higher FY26 concentration was required to 
achieve a cell survival of 50% as compared to other times of FY26 addition. Whereas 
the IC50 of Hepa1-6 Per2-luc increased following drug addition from T04 to T22, the 
IC50 of FY26 in Hepa1-6 Per2-luc shBmal1 depicted a bimodal pattern identifying 
T10 and T22 as time points with the least FY26 toxicity. In schedule D, T10 and T22 
are situated 2 h before the temperature decreases from 37 to 36°C and temperature 
increases from 36 to 37°C, respectively. The IC50 of FY26 in HCT116 Per2-luc cells 
also exhibited a bimodal pattern although being clock-proficient. As observed in 
Hepa1-6 Per2-luc shBmal1, the highest IC50 was determined at T22 and the second 
highest value at T10. This suggested that the bimodal FY26 toxicity pattern might not 
only be related to a genetically disrupted circadian clock, but also to tissue specific 
entrainment properties and/or to the clock regulation of FY26 detoxificat ion 
mechanisms. 
The relevance of in vitro chronotoxicity data to predict for in vivo chronotoxic ity 
patterns was investigated in chapter III.4, using two osmium complexes, FY26 and 
FY25. FY26 and its active metabolite FY25 (Peter Sadler, personal communicat ion) 
were administered intraperitoneally at one of six equally spaced dosing times over the 
24 hours to male C57Bl/6 mice synchronised with LD12:12, where ZT0 and ZT12 





statistically significant circadian toxicity profile, based on body weight changes 
following drug administration. Maximum body weight loss was highest following 
FY26 treatment during the second half of the active phase (ZT18-ZT22) and lowest in 
mice dosed at ZT02, near the beginning of the inactive phase. The time points of 
highest and lowest toxicity were further confirmed by the assessment of the AUC of 
body weight loss over the 7 days following drug administration (AUC0d-7d) and by the 
slope of body weight recovery to pretreatment body weight. The highest AUC0d-7d 
occurred at ZT02 and the lowest at ZT22. Mouse body weights recovered fastest 
following FY26 injection at ZT06 and slowest after receiving it at ZT18. Cosinor 
Analyses revealed significant circadian rhythms thus identified the acrophases of least 
body weight loss, and AUC0d-7d and that of fastest recovery slope (best tolerability). 
The acrophases of these three parameters occurred at ZT6.7, ZT6.1 and ZT6.2 
respectively. This indicated that FY26 was best tolerated if administered at ZT6, i.e. 
near the middle of the inactive rest phase of the rest-activity circadian cycle. 
So far no chronotoxic profile had been reported for any osmium compound. However, 
the chronotoxicity patterns of platinum anticancer complexes have been thoroughly 
researched since the initial fortuitous discovery of cisplatin antitumour activity by 
Barnett Rosenberg (1969). Cisplatin was best tolerated when given near ZT15 to ZT18 
to mice or rats (Boughattas et al., 1990; Hrushesky et al., 1982b). As demonstrated for 
cisplatin, carboplatin and oxaliplatin were also best tolerated following treatment at 
ZT15 to ZT16 in mice. Worse renal and hematologic dose limiting toxicities of 
cisplatin, and worse hematologic and intestinal dose limiting toxicities of carboplatin 
and oxaliplatin were achieved in rodents treated between ZT6 to ZT10 (Boughattas et 
al., 1994; Boughattas et al., 1990; Boughattas et al., 1989; Ron et al., 1998). 
However, following up to six i.p. injections of FY26 (subacute toxicity) did not result 
in any histopathological changes, although mortality was 12 to 17%. This questioned 
the mechanisms involved in the toxicity of this metallo-compound. One of the ligands 
of FY26 was iodide which was replaced by chloride after its cellular uptake, being 
activated to FY25. Based on an oral communication with Professor Peter Sadler, 1 mg 
FY26 releases 150 µg iodide. As mice were injected with 50 mg/kg FY26 
corresponding to 1.5 mg FY26 for a 30 g mouse, 225 µg iodide were thus 





be 1117 ± 30 and 136 ± 5 mg/kg respectively (Webster et al., 1957).This refers to 
33.5 mg iodide and 4.1 mg iodate for a 30 g mouse. Thus, repeated injections of FY26 
could result in iodate intoxication. FY26 also increases ROS, thus hydrogen peroxide 
(H2O2); H2O2 can reacts with excess iodide to iodate and exceed the iodate LD50 
(Schmitz, 2001). FY26 lethal toxicity in mice could hence result from acute iodide 
toxicity, which is known to involve necrosis as well as cytoplasmic fragments 
desquamation, ER vesiculation and accumulation of lipofuscin in secondary 
lysosomes in thyroid cells (Many et al., 1992).  
Our data revealed that FY26 was best tolerated following dosing in the middle of the 
rest phase (ZT6), i.e. nearly 12 h apart from the optimal timing of platinum complexes, 
as well as that of Cd or Hg salts (Cal. J. C., 1984; Miura et al., 2012). FY26 was hence 
the first metallo-compound whose best tolerability resulted from its delivery during 
the rest phase of rodents. Thus the results from chronotoxicology studies supported 
the occurrence of clearly different pharmacologic mechanisms between FY26 and 
most other metallo-compounds, one of which could be related to acute iodide release.  
The consistency of the in vitro and in vivo chronotoxicity patterns of FY26, was further 
shown using the 24-h rhythm in temperature exposure as a reference biomarker. Best 
tolerability of FY26 occurred following drug addition at T18 to T22 in temperature 
synchronised cell cultures, and at ZT06 in LD12:12 synchronised mice. The time 
points of best FY26 tolerability in vitro and in vivo thus referred to the acrophases of 
both temperature cycles as depicted in Figure IX-1. Taken together, the results 
demonstrated that the endogenous temperature rhythms was an adequate circadian 
biomarker for predicting FY26 treatment in vivo based on the in vitro experiments. 
Core body temperature in humans is in antiphase to that in mice (Morf & Schibler, 
2013). Thus, FY26 would hypothetically be best tolerated in humans when given near 
the middle of the night, whereas cisplatin and oxaliplatin were best tolerated whe n 






Figure IX-1: Schematic representation of the temporal relations between the circadian rhythm 
in temperature and FY26 chronotolerance in vitro and in vivo. Results from Cosinor Analysis 
of the endogenous (dotted blue line) temperature cycle and core body temperature rhythm 
(dotted red line).  
The graph presents the 24-h periodic cosine curves best fitting the temperature cycles 
measured in cell media-containing dishes exposed to exogenous temperature schedule D 
(blue), and in LD 12:12 synchronised mice (Chapter V). Both curves are aligned in phase.  
2 Anticancer properties of FY26 at the time points of highest 
and lowest tolerability 
The balance between antitumor efficacy and tolerability is a critical issue in cancer 
chemotherapy. FY26 displayed modest efficacy against Hepa1-6, in nude CD1 mice. 
Dose-response experiments conducted at ZT06 first revealed that doses of 40 or 60 
but not 80 mg/kg were in the therapeutic range. Mice dosed with 40 rather than 
60 mg/kg FY26 showed a higher tumour growth inhibition. This is striking as the 
opposite effect was expected. According to the data showing a higher tumour efficacy 
at 40 mg/kg as at 60 mg/kg FY26, FY26 efficacy could display a bell-shaped tumour 
efficacy profile. A bell-shaped efficacy profile has so far been reported for the opioid 
buprenorphine. At lower doses buprenorphine exhibited a high antinociceptive effect 





distinct pharmacological targets: it is both an agonist of the µ-receptor and a 
co-activator of the opioid-receptor like 1 (ORL-1) receptor (Lizasoain et al., 1991; 
Lutfy et al., 2003). Such unusual dose response relation for an anticancer agent needs 
confirmation on a larger sample size. Yet, the buprenorphine example indicates that a 
bell-shaped FY26 efficacy profile is possible if FY26 has two cellular targets with 
different susceptibility thresholds. A more frequent dose-response pattern for efficacy 
is of an exponential type, with a “ceiling” effect for efficacy. For instance, several 
studies reported that cisplatin did not exhibit differences in efficacy between “low” 
(40 to 50 mg/m2) and “high” (75 to 100 mg/m2) dose levels in patients with head and 
neck cancer (Szturz et al., 2017; Wong et al., 2015). A meta-analysis comparing low 
dose versus high dose chemotherapy reported that anticancer efficacy was not 
impaired at low doses, which significantly reduced toxicity (Xie et al., 2017). These 
studies pointed towards a possible ceiling-effect of anticancer agents whose dose 
reduction might lower side effects but not efficacy.  
Next, the time dependent tumour growth inhibition following dosing with 50 mg/kg 
FY26 at ZT06 and ZT18 was tested. The FY26 dose of 50 mg/kg was chosen based 
on the previous therapeutic dose selection study that did not detect any statistica lly 
significant difference in efficacy between 40 and 60 mg/kg FY26. ZT06 and ZT18 had 
been identified as the time point of best and worst tolerability respectively. Tumour 
growth delay was ~ 40% larger at ZT18 as compared to ZT06, suggesting timing could 
influence FY26 antitumor efficacy. For the platinum compounds cisplatin and 
oxaliplatin, tumour growth inhibition was highest following dosing at ZT15 (Granda 
et al., 2002; Li et al., 2005a; Sothern et al., 1989). Thus, either platinum compounds 
exhibited highest efficacy following dosing at their best tolerated time points. FY26 
on the contrary, seemed to inhibit tumour growth more following its administration at 
the time point of worst toxicity, under the alternate day schedule that was selected. 
The anticancer drugs are also best tolerated during the light/ (rest) span in male mice, 
like FY26. This is the case for both topoisomerase inhibitor irinotecan and the mitot ic 
spindle poison docetaxel for FY26. However, both drugs were also most effective 
following their administration near their respective circadian times of best tolerability. 





weekly dosing schedule, but at ZT11 on an alternate day dosing regimen (Tampellini 
et al. 1998).  
The results from both efficacy studies put FY26 in a special position compared to the 
above mentioned anticancer agents. As both studies involved a limited number of 
mice, additional studies testing different FY26 dosing schedules in different 
tumour-bearing models, with adequate statistical power, are needed to confirm the 
current results. Further investigations of the mechanisms of action of FY26 are also 
indispensable as this might explain the differences in time dependent toxicity and 
efficacy profiles.  
3 The circadian clock effects the pharmacokinetics and 
pharmacodynamics profile of FY26 
3.1 Chronopharmacokinetics of FY26  
FY26 exhibited a circadian toxicity profile with best tolerability in the middle of the 
rest phase when core body temperature was lowest. The interplay between the 
circadian clock and FY26 pharmacokinetics and toxicity is discussed here.  
The in vitro chronopharmacokinetics study revealed that maximum intracellula r 
osmium concentrations resulted from FY26 addition at T02 and minimum ones at T14. 
The area under the curve of the graph depicting the intracellular osmium concentration 
curve from the time of drug introduction to tmax (AUC0h-tmax) was highest at T02 and 
lowest at T10 with a 2-fold difference. Cosinor analysis further confirmed the time 
points of maximum FY26 uptake with acrophases of the three selected endpoints being 
located near T02. Thus FY26 uptake displayed a circadian pattern with highest value 
at T02 and lowest one at T14. These times corresponded to 2 h after temperature 
increase from 36 to 37°C and decrease from 37 to 36°C respectively. According to the 
in vitro chronotoxicity data using IC50 as an endpoint, T22 had been identified as the 
time point of lowest toxicity. Thus, there was an 8 h time lag between the times of 
least FY26 uptake at T14 and that of least toxicity at T22. Interestingly, the highest 
FY26 uptake at T02 was only 2 h apart from the time point of worst toxicity at T04 
suggesting FY26 to depict an asymmetry toxicity pattern. Overall the results indicated 





not overlap. Such differences between circadian pharmacokinetics and 
pharmacodynamics profiles had been emphasised for the β-blocker propranolol 
chronopharmacology in human subjects. Maximum and minimum plasma 
concentrations were detected following oral propranolol administration at 08:00 and 
at 02:00 respectively. In contrast, propranolol efficacy, as assessed with heart rate 
decrease, followed no circadian pattern, thus indicating the dissociation between 
chronopharmacokinetics and chronopharmacodynamics could indeed be sharp 
(Langner & Lemmer, 1988).  
No transporter mechanism has been identified so far for FY26. However, according to 
a first systems pharmacology study, FY26 uptake involved energy dependent transport 
(Doctor Annabelle Ballesta, personal communication and manuscript in preparation). 
The intracellular uptake of cisplatin, was reported to be mediated by active transporters 
such as the organic cation transporter 2 (OCT2) and the multidrug toxin extrusion 1 
(MATE1) transporter. Passive diffusion through the lipid membrane was further 
suggested to be crucial for cisplatin uptake but will not be discussed for FY26 as its 
uptake has been suggested to be mainly an active one (Eljack et al., 2014; Yokoo et 
al., 2007).  
The platinum compound cisplatin is up taken through OCT2. The intracellular uptake 
of oxaliplatin is mediated by OCT2 and OCT3 whereas carboplatin is not a substrate 
of the organic action transporters (Ciarimboli et al., 2010; Ciarimboli et al., 2005; 
Yokoo et al., 2007; Yonezawa & Inui, 2011; Yonezawa et al., 2006). The expression 
of the OCT2 protein levels was rhythmic in kidney with highest and lowest values at 
ZT06 to ZT10 and at ZT18 to ZT22, respectively. The renal expression of MATE1 
did not follow a circadian pattern (Oda et al., 2014). In addition to the role of OCT2, 
OCT3 and MATE1 for Pt complexes transport, the copper transporter CTR1 was 
shown to be involved in the intracellular uptake of cisplatin, oxaliplatin and 
carboplatin as well (Larson et al., 2008; Song et al., 2004). The copper transporter 
CTR1 is encoded by the gene Slc31a1 which was shown to be rhythmic with highest 
mRNA expression in rat and mouse liver during the middle of the active span (Almon 
et al., 2008; Zhang et al., 2014). Based on these data, copper transporter and organic 





However, the exposure of ovarian cancer cell line A2780 to 100 µM verapamil, an 
unspecific P-gp inhibitor, and FY26 led to a 1.5-fold accumulation of intracellula r 
concentration of osmium as compared to non-verapamil exposed cells (Coverdale et 
al., 2018).Thus, there may also be some further role for an active efflux of FY26 or 
FY25 that could be mediated by P-gp (MDR1 transporter in the ABC transporter 
family). These transporters also displayed circadian rhythms and were controlled by 
the molecular clock. The efflux transporter multidrug-resistance genes 1 and 2 (Abcb1 
and Abcb4) and the multidrug resistance-associated protein 2 (MRP2) exhibited a 
circadian rhythm in their mRNA expression in liver, kidney and intestine in male 
C57BL/6 mice (Ando et al., 2005; Okyar et al., 2012; Zhang et al., 2008). Whereas 
Abcb1 expression was highest in the middle of the active phase, those of Abcb4 and 
Mrp2 were in antiphase, with an acrophase in the middle of the inactive phase (Zhang 
et al., 2008). In a separate work, together with colleagues at Warwick, INSERM, and 
Istanbul University, I have shown that P-gp mRNA, and protein expressions, as well 
as function are controlled by the circadian clock both in vitro and in vivo, in mouse 
ileum, liver and whole organism (Alper Okyar1 et al., 2018a). Thus a circadian rhythm 
in Abcb1/4 and Mrp2 transporters could also contribute to the chronopharmacokinet ics 
of FY26. Indeed, both transporters were highly expressed near the middle of the 
inactive phase when mice core body temperature pattern was lowest. This could thus 
be relevant for FY26 chronopharmacokinetics and chronopharmacodynamics as well. 
Future experiments could thus aim at the determination of the circadian expression of 
Abcb1/4 in the time dependent efflux of FY26 in Hepa1-6 Per2-luc cells.  
3.2 Chronopharmacodynamics of FY26 
Once FY26 was taken up by the Hepa1-6 Per2-luc cells, cells doubling time showed 
a circadian pattern with the slowest proliferation rate following drug addition at T18. 
This was confirmed using Per2-luc bioluminescence inhibition as a biomarker. The 
highest FY26-induced bioluminescence inhibition was observed following drug 
addition at T22, using the differences between bioluminescence AUCs in drug-
exposed vs. controls as an endpoint (AUCDiff). I further investigated the role of the 
circadian clock on the cell cycle phase distribution following FY26 administratio n at 
T04 or T16. Exposing Hepa1-6 Per2-luc cells to 7.5 µM FY26 at T04, resulted in an 





phase was observed suggesting that cells did not re-enter the cell cycle, but rather 
underwent apoptosis. This was not the case for cells exposed at T16. Here, a higher 
number of cells accumulated in S-phase. A small increase in G2/M-phase cells was 
also observed, suggesting that fewer cells entered apoptosis at T16 as compared to 
T04. The induction of apoptosis has been linked to the circadian clock, with 
overexpression of clock protein PER1 accounting for an increase of apoptosis in 
radiations-exposed HCT116 cells (Gery et al., 2006). The findings further 
corroborated the fact that the proliferation of Hepa1-6 Per2-luc cells was slowed down 
following dosing at T16. Thus, T22 was not the only time point when FY26 addition 
resulted in best tolerability, using IC50 as an endpoint, but also close to that (T16) when 
the drug slowed cellular proliferation yet maintained their viability. This was in 
contrast to T04, when more cell deaths were encountered.  
The dose accumulation of Hepa1-6 Per2-luc cells in S-phase that we further found in 
non-synchronised cell cultures exposed to FY26 was in line with published data in 
FY26-exposed A549 cells (van Rijt et al., 2014). Such S-phase cells accumulation had 
also been reported for cisplatin (Velma et al., 2016; Wagner & Karnitz, 2009). On the 
other hand, following the oxaliplatin treatment of colon cancer (HCT29) or breast 
cancer cells (MCF7), most cells arrested in G0/G1-phase, whereas the counts of S-
phase cells declined (William‐Faltaos et al., 2007). Carboplatin produced mixed cell 
cycle effects pending upon duration of exposure in a bladder cancer cell model: an 
arrest in S-phase after a 24-h exposure time, as observed for cisplatin, and a decrease 
in G2/M phase after 48-h (Wang et al., 2010). The FY26-exposed shBmal1-silenced 
Hepa1-6 Per2-luc cells accumulated in G2/M-phase whilst the number of cells in 
G0/G1-phase decreased. Additionally, it was observed that the number apoptotic 
Hepa1-6 Per2-luc shBma1 was twice as high as compared to Hepa1-6 Per2-luc 
following the exposure of 7.5 µM FY26. Both observations collaborate the fact that 
the clock disruptive cell line is more sensitive towards FY26 leading to the 
determination of a higher number of apoptotic cells.  
Whilst the vehicle exposure did not initiate apoptosis, a low induction of apoptosis 
was observed after the 24 h exposure of IC50 FY26 to Hepa1-6 Per2-luc (15.5% 
apoptotic cells) and Hepa1-6 Per2-luc shBmal1 cells (7.5 % apoptotic cells). The same 





FY26 did not immediately result in the induction of apoptosis as observed for cisplatin 
(Henkels & Turchi, 1999; Matsumoto et al., 2016; Romero-Canelón et al., 2015). 
Besides apoptosis, the induction of autophagy following FY26 exposure showed a 
trend towards a dose dependent increase in LC3B levels which was higher in the 
Hepa1-6 Per2-luc shBmal1 cells and immediately after the end of the 24 h FY26 
exposure.  
Thus, the results suggest a clock dependent induction of FY26-induced cell death. 
Indeed, a trend towards the highest expression of the autophagy marker LC3B and a 
highest number of apoptotic Hepa1-6 Per2-luc shBmal1 cells were encountered as 
compared to clock-proficient cells. The results, combined with data from the literature, 
suggested that autophagy and apoptosis could be activated through elevated ROS 
levels, which has been known to first induce autophagy then apoptosis in case of 
failure to repair. The induction of apoptosis and autophagy are mediated by increased 
levels of reactive oxygen levels (ROS) through the inhibition of the autophagy protein 
Beclin 1 by the anti-apoptotic and protein Bcl-2, which follows a circadian expression 
with an acrophase at ZT03 to ZT04. (Granda et al., 2005; Higuchi et al., 1998; 
Pattingre et al., 2005; Redza-Dutordoir & Averill-Bates, 2016; Scherz‐Shouval et al., 
2007). The peroxide H2O2 inactivates Atg4 which promotes the lipidation of ATG8. 
This further initiates the formation of the autophagosome leading to the upregulat ion 
of LC3B (Barth et al., 2010; Gao et al., 2018; Gouzi et al., 2018; Scherz‐Shouval et 
al., 2007). Thus, circadian pharmacodynamics could be linked to energy metabolism 
and ROS production, although these were not determined in my thesis. For instance, 
mitochondrial respiration and electron carrier NAD biosynthesis were rhythmic and 
clock controlled in mouse liver (Jacobi et al., 2015; Peek et al., 2013; Schmitt et al., 
2018).        
Unlike the platinum compounds, which are detoxified by reduced glutathione (GSH) 
(Li et al., 1997), FY26 was reported to be bioactivated by GSH (Fu et al., 2010; 
Needham et al., 2017). GSH was highest expressed during the mid-active phase in 
mouse liver (Davies et al., 1983; Xu et al., 2012). High intracellular GSH levels would 
account for a higher bioactivation of FY26 into FY25. As the highest concentrat ions 
of GSH in mouse tissues occurred in liver, and the acrophase of this rhythm was 





to occur in the second half of the nocturnal activity span of mice. Additionally, a high 
bioactivation rate would thus account for a high efficacy at ZT18 which was confirmed 
by the chronoefficacy study as the highest tumour growth inhibition occurred at ZT18.  
Nevertheless, further experiments investigating the chronoefficacy will be needed, as 
this study was done involving a small number of mice. Moreover, the determination 
of circadian GSH levels together with ROS levels, following the exposure of FY26 in 
Hepa1-6 Per2-luc cells, are crucial because GSH is involved in the detoxification of 
ROS. GSH decreases ROS levels (Armstrong et al., 2002; Tan et al., 1998). As GSH 
expression is highest during the mid-active span in mice, low ROS levels would have 
been expected. In this context, the determination of circadian GSH and ROS levels 
following FY26 exposure will allow to track the pharmacokinet ics-
pharmacodynamics interactions in Hepa1-6 Per2-luc cells and connect this to in vivo 
chronotoxicity and chonoefficacy.  
Unfortunately, the measurement of ROS was not possible as FY26 interaction with 
ROS using the Seahorse instrument. This methods will be replaced in future 
experiments by trying alternative ROS measurements by using DCFDA (2’-7’-
diclorfluorescein). 
4 FY26 and its interaction with the circadian clock 
FY26 effects on the circadian clocks were assessed using circadian clock gene Per2 
reporter expression both in cell cultures and in mice, clock genes mRNA circadian 
expressions in cell cultures, and core body temperature circadian rhythm in mice.  
In temperature cycle synchronised Hepa1-6 Per2-luc cells, FY26 transiently reduced 
bioluminescence, yet circadian oscillations persisted. The amplitude of the circadian 
oscillations were largest following FY26 dosing at T22. The persistence of the 
Per2-luc circadian oscillations, despite FY26 exposure, suggested that the circadian 
clock could remain functional. This finding was further supported by the persistent 
oscillatory patterns in the mRNA expression of clock genes Per2, Bmal1 and 
Rev-erbα, as determined with RT-qPCR in similar experimental conditions. This 
suggest that the decreased amplitude in Per2-luc bioluminescence was not caused by 





In contrast to FY26, cisplatin increased the mRNA expression of both Per2 and clock 
controlled gene Dbp, whilst abolishing Cry2 and Rev-erbα rhythms in the liver of 
C57BL/6 mice (Cao et al., 2018). The cytokine interferon-α dampened the Per2 
rhythm in ICR mouse liver with the largest amplitude reduction following dosing at 
ZT14 (Ohdo et al., 2001; Shinohara et al., 2008). Topoisomerase I inhibitor irinotecan 
down regulated and suppressed circadian mRNA expressions of clock genes Rev-erbα, 
Per2 and Bmal1 in the liver of male or female B6D2F1 mice, with mild or severe clock 
disruption depending upon dosing time (Ahowesso et al., 2011). Antimetabo lite 
5-fluorouracil reduced the expression of Per1 and Per2 in mouse liver as well as in 
NIH3T3 fibroblast without affecting cell viability (Terazono et al., 2008). FY26 
effected the CTS at variance with a strong clock disruption induced by the above-
mentioned anticancer drugs. In the hepatocarcinoma model, FY26 did not affect the 
clock gene mRNA expression, but altered cell cycle and cell death mechanisms. Thus, 
the time dependent decrease in Per2-luc bioluminescence amplitude were considered 
as a reflection of FY26-induced transient arrest of cell proliferation, rather than drug 
interaction with the Per2 promoter in Hepa1-6 Per2-luc cells. However, FY26 
interacted with PER2 protein measured through PER2::LUC liver bioluminescence. 
Following a single i.p. injection of FY26 led to the ablation of PER2::LUC rhythmic ity 
which was highest at CT06, referring to CT22.5 to CT01.5, as the AUC of 
bioluminescence was lowest accounting for the highest bioluminescence inhibit ion. 
This was thus in alignment with the highest in vivo FY26 toxicity at ZT18. 
The effect of FY26 on core body temperature was simultaneously measured with that 
on PER2 protein expression. At both circadian time points, FY26 injection caused a 
drop in core body temperature. At the CT24, the FY26 injection led to an ablation of 
rhythmicity which recovered 2 days after the injection. However, injecting FY26 at 
CT12, led to an increase of the amplitude of core body temperature rhythms follo wed 
by a recovery 2 days after the injection. The same experiment was further conducted 
on mice kept under constant LD 12:12 entrainment. Here, the single i.p. injection of 
FY26 led to a sharp decrease of core body temperature at ZT18 whereas no such effec t 
was observed following the injection at ZT06. This further confirmed the previous ly 
identified time point of worst FY26 tolerability in male C57BL/6 mice. Several other 





core body temperature rhythm mostly following its administration at the least tolerated 
time point ZT03 in female mice. Less alterations of daily circadian body temperature 
rhythm was found for male mice receiving irinotecan (Ahowesso et al., 2011). 
Interferon administration at ZT12 dampened the amplitude of rectal temperature more 
as compared to ZT0 (Ohdo et al., 2001). A further drug which effects core body 
temperature when given at the time point of least tolerability, is the antimetabo lite 
gemcitabine (Li et al., 2005a). Thus, FY26 like other anticancer drugs altered the 
circadian rhythm in core body temperature predominantly following its administrat ion 
at the time point of least tolerability. 
Besides, the circadian disruption of core body temperature, the data further pointed 
towards the crucial role of circadian entrainment with regard to toxicity. FY26 affected 
core body temperature rhythm when injected at CT24 and CT12 in constant darkness. 
However, no such effect was observed when FY26 injected at ZT06 in LD 12:12 
synchronised mice. As mentioned in the first chapter of the discussion, the 
accumulation of Per2 and Hsp in clock disruptive mice can result in circadian rhythms 
independently from the clock (Kornmann et al., 2007). This might as well suggests 
that PER2 plays a crucial role in the maintenance of core body temperature rhythms 
as an interaction with PER2 could lead to disruptive core body temperature rhythms. 
The extent to which core body temperature rhythm was disrupted, appeared to depend 
on whether the mouse was kept under alternating LD 12:12 entrainment or constant 
darkness. As a reduced toxicity was observed in mice kept under LD 12:12 
entrainment, light-dark synchronisation appeared to be crucial to coordinate a 
circadian pattern together with lowering FY26 toxicity. Translating this to the 
chronotherapy of cancer patients, would mean that maintaining a stable daily routine 
is important as it could contribute to the reduction of the toxicity of chemotherapy. As 
mentioned in the introduction (chapter I.9), the disruption of the CTS was associated 
with a lower survival rate in metastatic breast and gastro-intestinal cancer patients 
(Ballesta et al., 2017; Sephton et al., 2000). This was further confirmed by the effect 
of FY26 on core body temperature. Thus, developing anticancer drugs which do not 
affect the CTS could indeed help increase survival and should thoroughly be 


















The in vitro and in vivo studies were designed to answer to the questions (i) whether 
FY26 displays a circadian variation in its pharmacokinetics and pharmacodynamics 
characteristics and (ii) whether endogenous temperature cycles can be used to transfer 
in vitro chronotoxicity into in vivo chronotoxicity. 
I have demonstrated that the tolerability of FY26 was best following dosing during the 
first half of the inactive phase (ZT06) in mice and near the nadir of rhythmic 
temperature exposure in cell cultures (T22). FY26 chronotolerance pattern in cell 
cultures was aligned with that in mice, using temperature cycle as a biomarker. Indeed, 
FY26 tolerability was best, both in vitro and in vivo, following its administration near 
the acrophase of temperature exposure in both experimental models. It is the first time 
that such link between in vitro and in vivo chronotoxicity is shown, to the best of my 
knowledge. I have further discussed that time dependent pharmacokinetics and 
pharmacodynamics, including detoxification, of FY26 might result in part from the 
circadian expression of efflux transporters Mdr1 or Mrp2. Interestingly intracellula r 
FY26 uptake was highest at T02 whereas the minimum toxicity occurred at T22. This 
was consistent as a higher number of cells entered apoptosis at T04 whereas at T16 a 
higher number of cells accumulates in S-phase thus decelerate cell proliferation and 
bioluminescence.  
FY26 did not seem to alter the molecular circadian clock, at the level of mRNA gene 
expression, but rather at protein expression levels in cell populations. In mice (whole 
organism), a marked alteration of the core body temperature rhythm was uncovered. 
The intensity of the effect of FY26 on the protein expression and on core body 
temperature varied as a function of whether the mice were kept in LD12:12 
synchronisation or under constant darkness. The administration of FY26 at CT24 and 
CT12 led to a disruption of PER2 protein expression at CT12 whereas at CT24 the 
amplitude of the oscillation was dampened 
Regarding core body temperature, FY26 disrupted the core body temperature 
circadian rhythm in 2 out of 3 mice at both time points tested that corresponded to 
endogenous mean circadian times CT24 and to CT12. Neither time points matched the 
expected CTs of best and worst tolerability because of the free-running conditions in 
DD. In mice, kept under LD 12:12 entrainment, core body temperature rhythm was 





3.7°C then recovered within 24 h following dosing at ZT18. Thus, FY26-induced 
circadian disruption was worse following dosing at ZT18, using both PER2::LUC 
bioluminescence and circadian temperature rhythms as endpoints, in agreement with 
the chronoxicity pattern of FY26.  
Contrary to other anticancer agents, FY26 tended to display the highest tumour 
inhibition properties at ZT18. However, as the tumour efficacy studies could not be 
repeated, further research is needed to delineate the chronoefficacy of FY26. 
Further limitation to our study involved the humane endpoints of the in vivo studies. 
Once a body weight loss of 20% of pre-treatment body weight was recognised, the 
mouse was euthanized regardless of any sign of pain. As body weight was chosen as 
an endpoint for most in vivo studies described in this thesis and those reported in the 
literature, a maximum allowance of 20% body weight loss only enabled the detection 
of larger variations of body weight loss after FY26 administration at different 
circadian time points. This led to the early exclusion from the study of mice losing 
weight despite being clinical well. Regarding the in vitro studies, the experiments 
highlight the need for a systematic mapping of the circadian mechanisms of action of 
FY26, including time dependent active uptake and possibly ABCB4 and MRP2-
mediated efflux, the implication of circadian changes in GSH levels for both 
bioactivation of FY26, and its detoxification, and the time dependent effect of FY26 
on ROS induction. Such mechanisms will lend support to the chronopharmacokinet ics 
and chronopharmacodymanics that have been demonstrated here in synchronised cell 
culture models.  
The investigation of the chronopharmacology of FY26 and the determination of the 
effect of FY26 on the circadian clock are crucial. Clock disruption results in the 
impairment of cancer therapy through the promotion of tumour development and 
growth. (Innominato et al., 2012; Mormont et al., 2000; Sulli et al., 2018). Therefore, 
developing a drug as FY26 which was shown to overcome cisplatin resistance, to 
exhibit a circadian toxicity and efficacy profile with minimal clock interaction when 
given at ZT06, lowers adverse effects of chemotherapy as well as it enhances tumour 
growth inhibition. So far, FY26 is understood as a novel, potential anticancer drug to 
overcome cisplatin resistance. The use of endogenous temperature cycles identified 





in vivo chronotoxicity of FY26. Thus, temperature cycles helped to unravel the FY26 
chronopharmacology whilst it has the potential to minimise the number of mice used 
in in vivo experiments.  
In order to put this into a larger context, the use of temperature cycles mimicking core 
body temperature rhythm as marker of the CTS may constitute a crucial new factor in 
drug development. CTS robustness has been linked to significant improvements in 
both patient’s survival and quality of life in cancer patients. We show that the 
information it conveys could also help reduce animal experiments, an idea which is in 
alignment with the 3R’s of animal research (replacement, reduction and refinement) 


















1 Appendices: In vitro chronotoxicity 
 
 
Figure XI-1: Dose response curve of Hepa1-6 Per2-luc and Hepa1-6 Per2-luc shBmal1 under 
the exposure of the concentration scale A.  
Four thousand Hepa1-6 Per2-luc and Hepa1-6 Per2-luc shBmal1 cells were seeded in each 
well of a 96-well NUNC plate. Two days after cell seeding, cells were exposed to different 
FY26 concentrations (0.001 µM, 0.01 µM, 0.1 µM, 1 µM, 10 µM, 100 µM FY26) of the 
concentration scale A. After 24 h of incubation, FY26 was removed and replaced by media. 
The total cellular protein content was measured using SRB-Assay (n=12) 72 h after FY26 
withdrawal. The cell survival was calculated. For Hepa1-6 Per2-luc the maximum cell 
survival was 98.0% ± 0.6% at 0.001 µM FY26 and the minimum was 6.9% ± 0.2% for 100 
µM FY26. The highest survival rate of Hepa1-6 Per2-luc shBmal1 was 109.5% ± 2.6% 






Figure XI-2: Optimisation of the concentration scales done in Hepa1-6 Per2-luc and Heap1-6 
Per2-luc shBmal1.  
Four thousand Hepa1-6 Per2-luc and Hepa1-6 Per2-luc shBmal1 cells were seeded per well 
of a 96-well NUNC plate and exposed to different FY26 concentrations after 2 days (n=12). 
Cells were exposed for 24 h to concentration scales B, C and D. Total cellular protein content 
was measured 72 h after FY26 removal. For both, Hepa1-6 Per2-luc and its shBmal1 clone, 
a maximum cell survival of 101.2 ± 1.2% and 101.2% ± 0.2% and a minimum cell survival of 
4.2% ± 0.2% and 4.2% ± 0.1% were achieved. Concentration scale C was used for exposing 
Hepa1-6 Per2-luc resulting in a survival rate ranging from 21.2% ± 1.5% to 97.5% ± 1.5%. 
Further, a minimum and maximum survival of 16.3% ± 2.1% to 100.8% ± 2.0% was observed 






Figure XI-3: Optimisation of the concentration scales in HCT116 Per2-luc.  
Eighty-thousand cells have been seeded and drugged with different concentrations of FY26. 
Experiment 1 and 2 were exposed to the concentration scale H and experiment 3 to the 
concentration scale I for 24 h. Total cellular protein content was measured 72 h after the drug 
removal. One-way ANOVA showed a significant difference between the IC50 values with 
p<0.0001. Tukey’ multiple comparison detected a direct significant difference between the 
IC50 of experiment 1 vs. C (****), experiment 2 vs. 3 (****) as well as between experiment 1 
vs. 2 (**). The cell survival for the 1st experiment ranged from 6.8% ± 0.5% to 89.9% ± 2.9%, 
for the 2nd experiment from 49.4% ± 9.1% to 97.2% ± 1.2% and for the third experiment from 









Figure XI-4: Dose response curves at T04, T10, T16 and T22 in Hepa1-6 Per2-luc after the 
exposure of the concentration scale E (Experiment A).  
Different concentrations of FY26 of the concentration scale E (16 µM, 12 µM, 10 µM, 8 µM, 
6 µM, 4 µM, 2 µM, 1 µM and 0.5 µM) were exposed at T04. T10, T16 and T22 after 2.5 days 
after the start of temperature synchronisation. After 24 h exposure time, the drug-media was 
replaced by fresh media. The total protein content was measures 72h after media change 
(n=18). Minimum and maximum cell survival rates (mean ± SEM) ranged from 3.9% ± 0.1% 
to 89.5% ± 2.2% for T04, from 3.5% ± 0.1% to 93.1 ± 1.6% for T10, from 3.6% ± 0.1% to 







Figure XI-5: Dose response curves at T04, T10, T16 and T22 in Hepa1-6 Per2-luc after the 
exposure of the concentration scale F (Experiment B).  
Different concentrations of FY26, concentration scale F, (30 µM, 15 µM, 10 µM, 8 µM, 6 µM, 
4 µM, 2 µM, 1 µM and 0.5 µM) were used for exposing synchronised cell cultures at T04. 
T10, T16 or T22 after 2.5 days after the start of temperature synchronisation. After 24 h 
exposure duration, the drug-containing media was replaced by fresh media. Total protein 
content was measured 72h after media change (n=12) using the SRB assay. The minimum and 
maximum survival rate of cells subjected to concentration scale F was 7.9% ± 0.4% to 99.9% 
± 0.2% for T04, 11.9% ± 0.5% to 99.9% ± 0.4% for T10, 7.6% ± 0.6% to 100.5% ± 0.15 for 






Figure XI-6: Dose response curve of Hepa1-6 Per2-luc shBmal1 at T04, T10, T16 and T22 
after the exposure of the concentration scale G.  
 After 2.5 days of synchronisation of Hepa1-6 Per2-luc shBmal1 cells were treated with 21 
µM, 14 µM. 7 µM, 6 µM, 5 µM, 4 µM, 2 µM, 1 µM and 0.5 µM. The media was changed after 
24 h drug exposure time. Protein content was determined 72 h after media change (n=12).  
The minimum survival ranged from 26.0% ± 2.3% to 99.5% ± 0.5% for T04, from 21.3% ± 
1.6% to 100.6% ± 0.3% for T10, from 19.3% ± 1.3% to 99.7% ± 0.3% for T16 and from 25.8% 






Figure XI-7: Dose response curve at T04, T10, T16 and T22 for Hepa1-6 Per2-luc shBmal1 
after the exposure of the concentration scale F.  
Hepa1-6 Per2-luc shBmal1 cells were incubated for 24 h at different FY26 concentrations (30 
µM, 15 µM, 10 µM, 8 µM. 6 µM, 4 µM, 2 µM, 1 µM and 0.5 µM). Media changed was done 
24 h after drug administration and protein content was determined 72 h after media change 
(n=12). A minimum to maximum survival was obtained ranging from 15.4% ± 1.2% to 99.6% 
± 0.1% for T04, from 13.0% ± 1.1% to 99.8% ± 0.1% for T10, from 11.9% ± 0.3% to 99.9% 






Figure XI-8: Dose response curves at T04, T10, T16 and T22 on synchronised HCT116 
Per2-luc cells after exposure of the concentration scale I.  
Eighty thousand HCT116 Per2-luc cells were seeded per well in a 96-well FALCON plate and 
subjected to temperature cycle D. Different concentrations of FY26 were added after 2.5 days 
of synchronisation at T04, T10, T16 or T22. FY26-containing media was removed and 
replaced with drug-free media after an exposure duration of 24 h. Cellular protein content 
was determined in each dish 72 h after completion of drug exposure (n=23). Solid and dotted 
lines link experimental dose-related survival rates in first and second experiment respectively. 
The minimum cell survival ranged from 7.9% ± 1.7% to 11.7% ± 2.2% and the maximum 






2 Appendices: In vivo Chronotoxicity 
 
Figure XI-9: Escalating dose selection study for FY25 and FY26.  
Panel A and B show the body weight development of non treated mice, mice treated with the 
vehicle, 20, 40, 80 and 160 mg/kg FY25 (panel A) and FY26 (panel B). Panel C depicts the 
survival of mice treated with FY25 (Log-rank test p=0.0002) and panel D shows the survival 






Figure XI-10: Histopathological slices of mouse stomach.  







Figure XI-11: Histopathological slices of mouse ileum.  








Figure XI-12: Histopathological slices of mouse colon.  








Figure XI-13: Histopathologic slices of mouse liver.  
Mouse 1 was injected with the vehicle (control) and mouse 2 to mouse 5 were injected with 







Figure XI-14: Histopathological slices of mouse kidney.  








Figure XI-15: Histopathological slices of mouse spleen.  








Figure XI-16: Histopathological slices of mouse bone marrow.  
Mouse 1 was injected with the vehicle (control) and mouse 2 to mouse 5 were injected with 










Figure XI-17: In vitro and in vivo temperature cycles recorded with the Anipill® .  
The figure depicts the temperature cycles measured by the Anipill® which were placed in 
three 35 mm NUNC Petri dishes put in the cell culture incubator and implanted in the 






3 Appendices: FY26 and the circadian timing system 
3.1 Result of Spectrum Analysis on mice core body temperature 















Figure XI-18: Changes of mice core body temperature after the injection of the vehicle at 




















Figure XI-19: Changes of mice core body temperature rhythm after the injection of 50 mg/kg 
FY26 at ZT06 and ZT18. The black marker represents the i.p. injection of 50 mg/kg FY26.  



































Figure XI-20: Results of the Spectrum Analysis showing the changes of the PER2::LUC 
expression and its period, acrophase and amplitude in 9 PER2::LUC mice after the treatment 
with the vehicle and 50 mg/kg FY26 at CT06 and CT18.  
The vertical line marked the injection time point. Mouse 1 to 3 were reallocated in the RT-Bio 
on the 11/12/17 (not shown in graph), mouse 4 to mouse 6 were reallocated on the 05/02/18 







3.3 Spectrum Analysis of mice core body temperature in without 















Figure XI-21: Results of the Spectrum Analysis on core body temperature of 9 PER2::LUC 
mice when injected with the vehicle and 50 mg/kg FY26 at CT06 and CT18.  
Mouse 1 to 3 were reallocated in the RT-Bio on the 11/12/17 (not shown in graph), mouse 4 
to mouse 6 were reallocated on the 05/02/18 and mouse 7 to mouse 9 on the 22/02/18.The 
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